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Abstract 
Unlike conventional biological samples (blood and urine), hair samples have a 
much wider detection period and can provide a retrospective timeline of an 
individual’s drug use. However, the most crucial issue facing hair analysis is the 
avoidance of false-positive results caused by passive exposure to the drug. Passive 
exposure could be a result of direct contact with the consumed material or its 
smoke. This issue is of great concern especially with the drugs that have a greater 
potential for external contamination. Common examples of these are cannabis 
and nicotine, two drugs that are by far the most used drugs worldwide. 
The work presented in this thesis describes the development and validation of 
three analytical methods for cannabis and nicotine in hair matrices. These 
methods were then employed to analyse authentic hair samples and their washes.  
The first method involved liquid-liquid extraction (LLE) of the cannabinoids, ∆9- 
tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN) and metabolite 
11-hydroxy-∆9-tetrahydrocannabinol (11-OH-THC) from hair followed by analysis 
using standard gas chromatography-mass spectrometry (GC-MS). Cyclohexane: 
EtOAc (3/1, v/v) was found be the best extracting solvent for THC, CBD, CBN and 
11-OH-THC. The percentage of extraction recovery for all four analytes ranged 
from 87.9% to 97.2%. 
The second method involved solid-phase extraction (SPE) of the main metabolite 
11-nor-∆9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) from hair followed 
by analysis using two-dimensional gas chromatography-mass spectrometry (2D GC-
MS). The SPE method provided a clean extract with an acceptable extraction 
recovery (approximately 50%). 
Authentic hair samples were then collected from 20 known cannabis users 
admitted to Al-Amal addiction hospital in Jeddah, Saudi Arabia. Cannabis users 
were interviewed at the time of sample collection and self-reported their cannabis 
use history. Concentrations of different cannabinoids were then measured using 
the validated methods. The aim of this project was to investigate the potential 
value of measuring cannabinoid concentrations in hair. The detected 
concentrations ranged from 0.11 to 0.34 ng/mg for THC, 0.2 to 4.42 ng/mg for 
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CBD, 0.31 to 1.02 for CBN, and 2.14 to 7.01 pg/mg for THC-COOH. Surprisingly, 
THC has a very low detection rate, whereas, CBD and THC-COOH had the highest 
detection rate of all cannabinoids. The relationship between measured 
concentrations and use history was then subject to statistical analysis. There was 
no significant correlation found between concentrations of cannabinoids in hair 
and the use history. 
The third method involved methanolic extraction of nicotine and cotinine from 
pet dogs’ fur followed by analysis by zwitterionic hydrophilic interaction liquid 
chromatography tandem mass spectrometry (ZICHILIC-MSMS). Further clean-up of 
the fur methanolic extract was found to be problematic. Centrifugation and direct 
analysis was found to be the best approach. The tandem MS allowed for low 
detection limits. The aim of this project was to investigate the association 
between dog fur nicotine and cotinine concentrations and owner-reported 
exposure to environmental tobacco smoke. 66 fur samples were collected from 41 
dogs at two time points. Total nicotine and total cotinine were quantified in 
unwashed fur samples using the validated method. Statistical analysis revealed a 
significant difference in the mean concentrations of nicotine and cotinine in 
different exposure groups. By providing information on dog’s exposure to 
environmental tobacco smoke (ETS) over time, fur analysis may be useful in 
assessing dogs and companion owner’s histories of exposure to ETS. 
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 Introduction 
 Forensic toxicology 
‘ALL SUBSTANCES ARE POISONS. THERE IS NONE WHICH IS NOT A POISON. THE 
RIGHT DOSE DIFFERENTIATES A POISON AND A REMEDY’ 
Paracelsus: 1493 - 1541 
The above quote was given to us in the sixteenth century by whom is nowadays 
known as the father of toxicology, Paracelsus. This quotation, which is sometimes 
condensed to “the dose makes the poison”, is often referred to as classic 
toxicology maxim. The word ‘toxin’, in toxicology, is derived from ancient Greek 
‘τοξικόν toxikon’. According to Dorland's Medical Dictionary, a toxin is a poisonous 
substance produced within living cells or organisms, while toxicology is the science 
or study of poisons. The above definition of toxins excludes synthetic toxins, such 
as some drugs of abuse, as they are made by artificial processes. A poison, 
according to the same dictionary, is defined as a substance that cause 
disturbances in organisms, usually by chemical reaction or other activity on the 
molecular scale, when an organism absorbs a sufficient quantity(1). Therefore, 
we can say that all toxins are poisons but not all poisons are toxins. Toxicology 
can be broken down into different disciplines based on the purpose of the 
measurement of a toxin and/or the toxicity and source of sample.  These 
disciplines deal primarily with analytical chemistry, bioassay, and applied 
mathematics.  
The five main toxicology disciplines are molecular, veterinary, environmental, 
clinical and forensic toxicology. Molecular Toxicology is the study of the effects 
of various chemical components on living organisms. Veterinary Toxicology 
focusses on the diagnosis and treatment of poisoning exclusively in animals. 
Environmental Toxicology is concerned with the study of chemicals that 
contaminate food, water, soil, or the atmosphere. Clinical and forensic toxicology 
are similar branches of toxicology and both are involved in the detection and 
identification of toxic chemicals and their metabolites in biological samples. The 
difference is that clinical toxicology is usually hospital-based, and therefore, the 
analysis request is received exclusively, from hospital physicians, while forensic 
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toxicology is often carried out for administrative and/or medico-legal purposes 
and has a wider range of customers including but not limited to; police officers, 
court employees, and defendants.  
Forensic toxicology has different applications and hence can be further classified 
into different sub-categories. The Forensic Toxicology Council (FTC) was formed 
in 2009 in the United States to represent the interests of the major professional 
organisations, to provide information to government and policy makers regarding 
the field, and promote the advancement and development of forensic toxicology. 
FTC classified forensic toxicology into four main disciplines; namely (1) Death 
Investigation (or post-mortem) Toxicology, (2) Human Performance Toxicology, 
(3) Doping Control and (4) Workplace Drug Testing (2). Death investigation 
toxicology is typically required to confirm or eliminate the possibility of a drug 
overdose and its potential contribution to death. Human performance toxicology 
deals with the effect of alcohol and drugs on human performance and behaviour, 
and the potential medico-legal consequences of drug and alcohol use. This 
category includes investigation of impaired driving and drug facilitated crime 
(DFC) which may require determination of possible exposure to a substance hour 
to weeks after an alleged offence. Doping control is a well-established activity in 
sport and is often required to monitor athletes for the use of list of prohibited 
substances both in and out of competition. Workplace drug testing is carried out 
usually, but not exclusively, in industries and professions of safety nature and 
security critical, such as transportation and the armed forces.   
Before toxicology testing can go forward, suitable samples need to be collected. 
Urine and blood or its component parts, that is, plasma or serum, are the most 
commonly employed matrices in forensic toxicology. Alternative matrices include 
hair, saliva and oral fluid, nail, meconium, sweat, amniotic fluid, breast milk, 
vitreous humour, bone and bone marrow, liver and brain (3). Most of the biological 
samples are complementary and each sample type has different advantages. The 
selection of the sample type is hugely influenced and dictated by the purpose of 
the analysis, the targeted substances and the time of sample collection. For 
instance, the typical matrix for workplace or court-ordered drug testing is urine. 
Blood is preferred and most frequently collected when the behaviour of an 
individual is to be the subject to an investigation. Interpretation of impairment 
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from drug levels in urine is not possible. Oral fluid is an excellent matrix to show 
recent drug use, however, it contains only the parent drug substance rather than 
drug metabolites for some drugs. For example, there is almost no carboxy 
metabolite of THC present in oral fluid (4). Conversely, hair is the best option to 
monitor long-term exposure or use but is not as suitable to assess recent exposure.  
Hair as a biological matrix for drug detection has increasingly received attention 
in recent years, and is utilised in the work presented in this thesis. The 
physiological and anatomical properties of hair, the potential and benefits of hair 
as a matrix for drug detection, as well as its associated limitations and challenges, 
will be discussed in this chapter. 
As mentioned earlier, results of forensic toxicology testing may be used for legal 
purposes and hence in court proceedings. Therefore, the first necessary 
component of the testing process is to guarantee the validity of test specimens. 
This is accomplished through chronological documentation of sample status from 
the time of collection until analysis. This process is called ‘chain of custody’ (5). 
Analyses in forensic toxicology are typically conducted in two phases; screening 
and confirmation. Screening tests are intended to provide an indication of whether 
a particular drug or drug class is present and, typically, involve using immunoassay 
techniques, which are usually designed to targets a class of drugs, such as opiates, 
or may be a broad-based screening test using more advanced techniques such as 
gas chromatography mass spectrometry (GC-MS).  
Screening assays usually produce either a negative or a presumptive positive result 
for one or more drugs or drug classes which are then subjected to a confirmation 
test. According to the SOFT/AAFS Forensic Laboratory Guidelines, the initial 
detection of drugs should be confirmed whenever possible by a second technique 
based on a different chemical principle (5). Typically, a mass spectra based 
technique is employed for confirmation.  
The type of sample, the chemical properties of targeted substances and the 
required sensitivity could dictate the selection of the appropriate analytical 
method either during screening or confirmation. The scope of analysis and list of 
targeted substances varies from one laboratory to another, and is usually 
determined based on many factors including, but not limited to, the purpose of 
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the analysis, the prevalence of a substance and availability of the required 
resources and instrumentation. 
 Hair 
Hair is a fine thread-like strand growing from underneath the skin with a root 
covering the mammals body. It is commonly dismissed as being of negligible 
importance, however, the hair follicle (HF) is, in fact, one of human biology’s 
most interesting structures (6). Hair is a mammalian quality that provides 
numerous important roles. These include; thermal insulation, social and sexual 
communication, sensory perception (e.g. whiskers), and protection against 
trauma, noxious insults, insects, etc. These features have very obvious benefits in 
animals, however it is not yet clear how these may have proved crucial for human 
survival (7). The primary difference between hair and fur is the word usage. The 
hair of non-human mammals is referred to as “fur,” while humans have hair. So, 
basically, hair is a characteristic of all mammals. Fur is a reference to the hair of 
animals. 
 Basic structure of mammalian hair 
Hair and fur are chemically indistinguishable, and have the same chemical 
composition (8). Hair consists of a shaft that protrudes above the skin and a root 
sunk in a pit called the follicle as shown in Figure 1-1. The hair shaft is composed 
of protein, lipids and contains other trace materials, and consists of three distinct 
morphological units, moving inwards from the outside of the fibre these are; the 
cuticle, the cortex and the medulla as shown in Figure 1-2. These three units and 
accompanying root sheath are formed by the metabolically active dividing cells 
above and around the papilla of the follicle.  
The cuticle is formed of flat overlapping cells separated by the cell membrane 
complex (CMC). It covers the hair from the root to the tip of the epidermis and 
acts as a a sheath to the hair, protecting it from the environment (9,10). The 
cortex, or shell of the hair shaft, surrounding the medulla, is composed of 
elongated, fusiform cells (spindle-shaped), keratinized filaments aligned parallel 
to the length of the hair as shown in Figure 1-3. It is the main component in hair 
33 
 
 
and represents an average of 90% of total hair mass (11). The cortex may contain 
acortical fusi, pigment granules, and/or ovoid bodies. 
 
Figure 1-1 Hair follicle (root) and hair shaft (12). 
 
 
Figure 1-2 Structure and constituents of the human hair shaft. Adapted with permission 
from ref (13)  
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Figure 1-3 Structure and constituents of the hair shaft cortex. from ref (14) with permission. 
 
The medulla is a group of high porosity cells in the central part of the hair, located 
usually in the large terminal hair fibres. It should be noted that the medulla is 
sometimes absent in human hair (15). Studies on incidence of medullation in 
human hair revealed a considerably lower presence of medulla in scalp hair in 
comparison with axillary and pubic hair (10). The medulla’s role is still not well 
understood and little research has been conducted on its chemistry and other 
properties (14). The root of a single hair is situated in an epidermal tube known 
as the hair follicle, sunken into either the dermis or the subcutaneous tissue. The 
components of the follicle are shown in Figure 1-4. It is surrounded by a rich blood 
capillary system that delivers necessary nutrients, elements and metabolic 
material to the growing hair (16). The germination centre around the hair bulb 
papilla is formed by keratinocytes and melanocytes present on the basement 
membrane, shown in Figure 1-5. 
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Figure 1-4 Formation of hair in a follicle from matrix cells on the basement membrane to the 
mature hair shaft. Adapted with permission from (13) 
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Figure 1-5 Melanocyte on the basement membrane of the cortex. Adapted with permission 
from (13) 
 
Melanin is synthesised in melanocytes and released into the keratinocytes in 
vesicles (melanosomes) by an exocytotic mechanism. In the keratinocytes, the 
membranes of the vesicles are digested and melanin pigments remain. Three 
glands, the sebaceous gland, the apocrine gland, and the eccrine (sweat) gland, 
are closely associated with hair follicles (17). Typically, the hair follicle and the 
sebaceous gland are merged both anatomically and functionally to form a 
pilosebaceous unit. The ducts of apocrine and sebaceous glands, only, empty their 
secretions into the hair follicle, while the eccrine glands do not (17). Sebaceous 
glands and eccrine glands are distributed nearly over the entire surface of the 
body, on the other hand, apocrine glands are present in the axilla, the ear canal, 
the eyelids, and the perineal region. Sebum is the name for sebaceous gland 
secretion and is reported to contain mainly triglycerides (41%), free fatty acids 
(16%), wax esters (25%) and squalene (12%) (11). Sebaceous glands and sweat 
glands are one of the proposed routes in which drugs and their metabolites are 
incorporated into hair. 
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 Chemical composition 
Human hair composition is influenced by its moisture content (up to 32% by 
weight) (18). It consists of approximately 65% to 95% proteins and other 
constituents such as water, lipids, pigment, and trace elements. Proteins are 
condensation polymers of amino acids. There are two groups of proteins that 
comprise a hair fibre; keratin and keratin associated proteins (KAPs). The keratin 
present in hair is helical and constructed into filaments and keratin intermediate 
filaments (KIFs) which are responsible for the fibrous structure of the hair. KIFs 
are part of a bigger family of molecules; the intermediate filament family (IF). IFs 
are measured to be 8-12 nm in diameter; KIFs are roughly 9 nm in diameter (19). 
Lipids are found within the hair fibre, some of which are in crystalline form, 
external lipids excreted from the sebaceous glands are found in the cuticle. Some 
trace elements such as the heavy metals, iron and lead, are also found in hair.  
 Hair growth cycle  
Hair growth starts in cells around the papilla in a germination centre. These cells 
are a collection of epithelial cells called the matrix cells and are responsible for 
the growth of hair. The matrix cell cycle is one of the most rapid of all human 
tissues. As a result of matrix cells mitosis, they become larger and move up the 
follicle into the keratogenous zone. Here the cells synthesise melanin pigment and 
begin to ‘keratinize’. Long fibers are formed through the cross-linking of the 
sulfhydryl groups in amino acids like cysteine. Gradually, the hair cells die and 
decompose by eliminating the cell nucleus and releasing water. Humans, unlike 
most other mammals, grow their hair in a mosaic pattern with noteworthy 
independence of growth and pigmentation resides in the individual hair follicle. 
Other mammals grow their hair synchronously or as a wave. The hair growth cycle 
describes the changing histological morphology of the shaft and of the follicle over 
time. Starting with the anagen phase, the follicle and its shaft progress through 
the catagen phase, and finally the telogen phase as shown is Figure 1-6. Each 
strand of hair on the human body is at its own stage of development. Once the 
cycle is complete, it restarts and a new strand of hair begins to form. In humans, 
the anagen phase lasts for three to five years, the catagen phase for a few weeks 
and the telogen phase for two months (20). The anagen phase is known as the 
growth phase. The longer the hair stays in the anagen phase, the longer it will 
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grow. About 85% of the hairs are in the anagen phase at any given time. It is 
thought that drugs and trace elements are incorporated into hair at this time of 
intense metabolic activity (17). The next phase is catagen which is also known as 
the transitional phase. The first sign of catagen phase is the cessation of melanin 
production in the hair bulb and apoptosis of follicular melanocytes (21). During 
this time, the hair follicle shrinks due to disintegration and the papilla detaches 
and cuts the hair strand off from its feeding blood supply. Ultimately, the follicle 
is a sixth of its original length, causing the hair shaft to be pushed upward causing 
an increase in length of the terminal fibres. During the telogen or resting phase 
the follicle remains dormant. Only 10% to 15% of the hairs are in this phase of 
growth at any given time. In this phase the epidermal cells lining the follicle 
channel continue to grow as normal and may accumulate around the base of the 
hair, temporarily anchoring it in place and preserving the hair for its natural 
purpose without demanding the body's resources needed during the growth phase. 
At some point, the follicle will begin to grow again, softening the anchor point of 
the shaft initially. The hair base will break free from the root and the hair will be 
shed. Within two weeks the new hair shaft will begin to emerge once the telogen 
phase is complete. 
 
 
Figure 1-6 Different phases of the hair cycle. Adapted with permission from (10) 
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 Rate of hair growth  
The duration of growth cycles is harmonized by many hormones and cytokines and 
influenced by many factors including; ethnicity, gender, the body site where the 
hair is growing, age, stage of development, dietary habits, environmental 
alterations like day-length, disease, or cosmetic use (22,23). There is little 
evidence to suggest that this rate can be increased by external factors such as 
grooming or shaving (6). Hair in the vertex region of the scalp is often selected as 
a test specimen because it has approximately 85% of hair follicles in the anagen 
phase (least variation) and has the fastest growth rate. Different studies were 
carried out to estimate growth rate of human scalp hair. Harkey (17) reported an 
average growth rate of 0.44 mm/day. Pötsch et al.  found a variation between 
0.07 and 0.78 mm/day, with 82% of the examined population between 0.32 and 
0.46 mm/day (24). For the purpose of interpretation, one centimetre per month 
(1 cm/month) is generally accepted in the scientific community as growth rate of 
scalp hair for an adult male or female (25,26). Therefore, a short length of hair 
(2-3 cm) from the scalp can theoretically represent the exposure to drugs over the 
past two to three months. 
 Hair pigmentation  
Melanins in mammals are formed in specialised cells called melanocytes, which 
enclose distinct cytoplasmic organelles known as melanosomes. The process of 
formation of melanin is called follicular melanogenesis and takes place in the hair 
bulb. The active melanocytes, which exist in the anagen hair follicle, transfer 
melanin mainly to the hair shaft cortex, to a lesser extent to the medulla, and 
only rarely to the hair cuticle (27). Hair color is genetically controlled and is 
among the most diverse of the pigmentation phenotypes. In the past, it was 
proposed that the variations in the proportion of two, chemically, different forms 
of melanin pigment, created from the same melanocyte, would determine the 
human hair and skin colour. Eumelanins are believed to be responsible for dark 
hair, while pheomelanins for yellow-to-red colours (28). In 2000, Prota critised 
these traditional concept and proposed a four-class system for defining hair color 
(29). According to Prota’s system, the diversity in hair colour is caused by four 
types of melanin. In addition to the known melanin pigments eumelanins and 
pheomelanins; their oxidative products oxyeumelanin and oxypheomelanin are 
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believed to have a role to play in determining hair colour. In Prota’s proposal, 
presence of the intact eumelanin pigment will result in black to dark brown hair, 
on the other hand, hair that contains more of an oxidative breakdown product of 
eumelanin, namely oxyeumelanin, tend to be lighter. Presence of large amounts 
of oxyeumelanin will result in blond hair.  
 Human scalp hair and dog’s fur 
Human hairs are divided into three basic types: vellus, intermediate and terminal 
hair. These hair types are distinguishable based on different characteristics 
including; length, colour, texture, shape and diameter and, also, based on their 
region of growth. The vellus hair is the very small colourless hair that covers 
almost the whole human body, clearly seen on the bald scalp or forehead. The 
intermediate hair is that found on the hands and legs of adults that has an 
intermediate size and length and intermediate cross sectional area. The terminal 
hair is usually coloured, long hair and has a wide cross sectional area which is 
mostly found in the scalp, beard, moustache, eyelashes, eyebrows, pubic hair and 
axilla. The main focus of this research is mostly on the terminal scalp hair as it is 
the chosen specimen for analysis. A human hair fibre is approximately 50 - 100 µm 
in diameter and can grow up to metres in length (30). The average human displays 
an estimated total number of 5 million hair follicles, of which 80,000–150,000 are 
located on the scalp (31). Domestic animals, such as pet dogs, are distinguished 
primarily through their medullary structure and pigmentation (32). In human hairs, 
the medulla is generally amorphous in appearance, whereas in animal hairs, its 
structure is frequently very regular and well defined. This core, in animals, allows 
for the coating of the hair to provide excellent thermal insulation, whereas human 
hair lacks this ability and does nothing to provide temperature regulation for the 
body. In humans, pigment granules are commonly distributed toward the cuticle 
as shown in Figure 1-7 (A). Animal hairs have the pigment granules commonly 
distributed toward the medulla, as shown in Figure 1-7 (B). 
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(A) 
 
(B) 
Figure 1-7 Photomicrograph of (A) human hair and (B) dog’s fur  
 
 Mechanism of drug incorporation  
The precise mechanisms involved in the incorporation of drugs into hair has not 
been clarified completely and more research is still necessary. However, the 
factors that influence incorporation of drugs into hair have been studied 
extensively in the literature (24,33–40). Three models have been suggested in the 
literature to explain incorporation of drugs into hair: drugs can enter the hair 
through (1) active or passive diffusion from the bloodstream nourishing the dermal 
papilla, (2) diffusion from sweat and sebaceous glands that release its secretions 
into the growing or mature hair fibre, or (3) diffusion into the mature hair fibre 
from smoke, vapours, powders or raw drug materials. A combination of these 
routes is likely to be the most realistic model to explain the drug profiles in hair 
(27). A schematic view of three proposed incorporation routes of drugs into hair 
is shown in Figure 1-8. So far, the contribution of the different routes is not fully 
understood and may vary greatly between substances and individuals.  
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Figure 1-8 Incorporation routes of drugs into the hair. Reproduced from (27). (© 2007 by 
Taylor & Francis Group, LLC) 
 
 Drug properties influencing incorporation  
The physiochemical properties of drugs are assumed to play a role in their 
incorporation into hair, the main ones being lipophilicity, basicity and melanin 
affinity. Due to the chemical nature of the cell membrane, non-polar, more 
lipophilic parent drugs are more likely to pass from the bloodstream to the hair 
forming cells than polar, more hydrophilic drug metabolites (34). Nakahara et al 
reported a positive correlation of 0.770 between lipophilicity and incorporation 
rate into rat hair for nineteen basic drugs of abuse (39).  
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Ionisation of drugs at physiological pH has a great impact on their incorporation 
into hair. Basic drugs exist as cationic molecules at physiological pH and should 
preferentially bind to melanin in pigmented hair. In a rat model and at 
physiological pH, Rollins et al reported a higher incorporation rate for the weak 
base, codeine, than the weak acid, phenobarbital (41). Nakahara et al came to 
similar conclusion after examining the incorporation rates of twenty acidic, basic 
and neutral drugs of abuse using the rat model (39). They observed a 3600-fold 
difference between the incorporation rates of cocaine (highest rate) and THC-
COOH (lowest rate). Borges et al reported a better incorporation rate for the 
amphetamine into both pigmented and non-pigmented hair than its non-basic 
analogue N-acetylamphetamine (40). 
As discussed earlier in section 1.2.5, melanin pigments have been proven to be 
responsible for hair colour and are thought to be the principal component for 
binding drugs. Melanin polymers possess many negatively charged carboxylic acid 
groups in their structure which attract positively charged basic drug molecules 
under physiological conditions, therefore, melanin affinity is associated with drug 
basicity. Several researchers have demonstrated that different hair colour and 
types incorporate different amounts of drugs when exposed under identical 
conditions. These studies have suggested that coarse, dark hair may incorporate 
more drug than fine brown or blond hair. Henderson et al. studied incorporation 
of isotopically labelled cocaine (COC) into human hair. Despite the small sample 
size, the authors reported 2.7 times more COC-d5 in the non-caucasian group (42). 
Kronstrand et al. examined the concentration of codeine after controlled dose 
administration versus hair melanin content. The authors reported a linear 
relationship between codeine concentrations and total melanin (r2=0.86) and 
eumelanin (r2=0.90) and suggested normalizing concentrations for melanin 
content (43). Rollins et al published their findings for a similar study confirming 
Kronstrand’s conclusion (34). These findings contrast with more neutral and acidic 
drugs such as THC-COOH and N-acetylamphetamine where a lack of correlation 
between concentrations of these drugs in hair to hair melanin content has been 
reported (39,40). 
44 
 
 
 Hair analysis  
 Chronology  
In 1858, the first case of the determination of poison in human hair was published 
in the ‘Practical Guide to Legal Medicine’ by Hoppe (44). Hoppe succeeded in 
determination of arsenic in the hair of a body exhumed after 11 years. Almost a 
century later, in 1954 Goldblum determined barbiturates in the hair of a guinea-
pig (45). This was followed in the next two decades by metals and trace element 
analysis in hair (46–48). At that time, hair was proposed as a promising specimen 
for assessing dietary status of people. However, Sorenson et al soon doubted its 
validity due to the  difficulties in establishing normal ranges due to the variations 
among laboratories and potentials of external contamination from cosmetic 
products, air or water (49). In 1979, detection of drugs of abuse in hair was 
initiated in an important publication by Baumgartner (50). He had investigated 
opiate addiction by extracting opiates from hair using methanol and 2 hours 
heating. A number of studies followed during the eighties on detection of other 
drugs of abuse. One of the keystone papers was published in Germany by Klug in 
1980 (44). For the first time, the solid hair matrix was converted into a liquid 
phase using sodium hydroxide in Klug’s work. The common logical expectation at 
that time was that only what is detected in urine could be seen in hair. This way 
of thinking continued until the end of the 1980s, when cocaine and 
benzoylecgonine were quantified and the cocaine concentration was always higher 
than that of benzoylecgonine. The first determination of cocaine in human hair 
was carried out by Valente in 1980 (51). Since the nineties, the attention to hair 
analysis has amplified substantially as a result of the advances in detection 
technologies offering increased sensitivity. Immunoassays, chromatographic 
techniques coupled with mass spectrometry (MS) and tandem mass spectrometry  
(MSMS) (GC-MS, GC-MSMS, LC-MS and LC-MSMS) enabled the detection of even a 
single dose or presence of drugs in a single hair strand. (27) 
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 Pros and cons of hair analysis  
Hair analysis for drugs has passed through different stages over the years. It has 
been sometimes glorified, sometimes condemned, sometimes accepted, 
sometimes rejected. Knowing its benefits and drawbacks will, certainly, guide 
concerned authorities when deciding whether or not it is a suitable drug testing 
method for their purpose. In 1995, the Society of Hair Testing (SoHT) was 
established to encourage consistency of analytical procedures and results 
interpretation, and to help to prevent or minimise sample mix-up, wrong sample 
treatment, analytical errors and wrong interpretation of correct results. Since 
then, the SoHT has published some recommendations and quality control 
guidelines about hair sample collection and handling procedures, washing, cut-
offs for obtaining positive results, metabolites to be assayed and metabolite-to 
parent drug ratios (26,52,53). The main advantages of hair drug testing include; 
(1) a wide window of detection allowing retrospective detection of exposure to 
illegal drugs, (2) easy and non-invasive sample collection, (3) easy to store and 
handle hair samples, (4) difficult to dilute or adulterate hair matrices. Despite the 
above advantages, hair drug testing has also some drawbacks. The main 
disadvantages of hair testing for drugs is that; (1) it does not provide information 
relating to recent drug use (previous 7 to 10 days), (2) the detection period usually 
relies on the length of the subject’s hair, (3) there are still disagreements on many 
factors that may lead to bias or wrong interpretation of the results, particularly 
concerning external contamination, cosmetic treatments, ethnic and genetic 
variation and a lack of understanding of drug incorporation mechanisms. To sum 
up, hair is a useful alternative to blood or urine and a complementary matrix 
providing important information in drug-related investigations. Interpretation of 
hair testing results are sometimes challenging due to many factors that may bias 
the result and must be considered carefully.  
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 General aims and objectives 
From the literature it is obvious that there are many variables that must be 
considered when interpreting the presence of drugs in hair matrices. Cannabis and 
nicotine are the most widely used drugs. Despite the fact that they have different 
physiochemical properties, they both share the same challenge in forensic hair 
testing due to their presence in smoke and hence the potential for external sample 
contamination. A better understanding of the analytical procedure and 
concentrations of these compounds in hair samples collected from human active 
users (cannabis) or passively exposed companion dogs (nicotine) will greatly aid 
interpretation. The aims of this study and how they will be achieved are listed 
below:  
1.  To optimise an analytical procedure for cannabinoids in human hair and 
explore the detection rate of different cannabinoids in hair samples collected 
from Arab users. 
 To develop GC-MS and 2D-GC-MS methods for the determination of THC, 
CBD, CBN, 11—OH-THC and THC-COOH in hair, which will include the 
optimisation of sample preparation and extraction procedures.  
 To validate the developed methods in accordance with SWGTOX 
guidelines. 
 To analyse authentic hair samples collected from Middle Eastern 
cannabis users admitted for treatment at Al-Amal addiction Hospital, 
Jeddah, Saudi Arabia.  
 To statistically analyse quantified concentrations against the reported 
use history. 
2. To investigate the value of nicotine and cotinine determination in hair to 
establish the degree of exposure to environmental tobacco smoke (ETS): 
 To develop and validate an LC-MS-MS method for the determination of 
nicotine and its metabolites in dog fur. 
  To analyse fur samples collected from dogs exposed to various degrees 
of ETS.  
 To statistically analyse concentrations of nicotine and cotinine against 
their exposure parameters. 
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 Outline of thesis 
The content of the thesis is outlined as follows. Chapter 2 provides an introduction 
to cannabinoids and their pharmacological, physical and chemical properties of 
different compounds. It also reviews the current and past literature for analysis 
of cannabinoids in hair matrices. Chapter 3 discusses the details of the 
optimisation of extraction methods for the three parent cannabinoids (THC, CBD, 
and CBN) and the two main metabolites (11-OH-THC and THC-COOH) from hair 
samples using different techniques including LLE, SPE and SALL. This chapter also 
reports experiments of different derivatising reagent combinations for 
identification of THC-COOH in mass spectrometry equipped with a negative 
chemical ionisation source (NCI). Chapter 4 describes the two instruments 
acquisition parameters, principles of keys components in the 2D GC-NCI-MS and 
validation methods and results for both GC-MS and 2D-GC-MS methods. Chapter 5 
provides the empirical findings of the application the developed and validated 
methods on authentic hair samples collected from cannabis user. This chapter also 
studies the relationship and correlation of cannabinoids concentrations with the 
reported use pattern. Chapter 6 provides an introduction to environmental 
tobacco smoke (ETS) and its essential biomarker nicotine and cotinine. It also 
provides an overview of the pharmacological, physical and chemical properties of 
nicotine and cotinine, and summary on their analytical methods in hair in the 
literature. Chapter 7 reports the method development and validation using LC-
MSMS. Chapter 8 report an application of the validated method on fur specimens 
collected from dogs exposed to ETS for total nicotine and cotinine quantitation. 
This chapters also reports a brief explanation of the statistical techniques. Finally, 
Chapter 9 provides a brief summary, general discussion, contributions and 
limitations of the study. In addition, this chapter also includes suggestions for 
future research. 
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 Cannabis 
 Introduction 
The cannabis plant is believed to originate from either Central Asia or near the 
Altai or the Tian Shan Mountains (54). Although all taxonomists recognize the 
species cannabis sativa (55),  the cannabis plant is subdivided by some into three 
species: cannabis sativa, cannabis indica, and cannabis ruderalis (56) based on 
typology and morphology of the plants (see Figure 2-1). All three species have no 
differences in genetics or chemical composition. 
 
 
Figure 2-1 Cannabis Species. 
SOURCE: Anonymous / Wikimedia Commons / Public Domain 
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 Components of cannabis 
The cannabis plant and its products are composed of a wide range of chemicals. 
Of these, 483 compounds are believed to be present exclusively in cannabis. Yet, 
approximately 66 cannabinoids have been identified (57). In the past, the term 
“cannabinoids” was often used to refer to a group of C21 terpenophenolic 
compounds that are found exclusively in cannabis sativa L (Linnaeus) and which 
activate cannabinoid receptors. However, recent discoveries of synthetic 
cannabinoids and the endogenous cannabinoids have caused some confusion over 
the use of this term. Therefore, cannabinoids can be classified in three main 
categories according to their origin, endocannabinoids to refer to cannabinoids of 
human origin, phytocannabinoids refer to cannabinoids of plants origin and 
synthetic cannabinoids refer to those synthesized in laboratories. In this work, 
phytocannabinoids are of interest and the term “cannabinoid” will be used 
throughout to represent this category only. The 66 cannabinoids are divided into 
10 subclasses (57). From an analytical point of view, cannabinoids of greater 
abundance are usually of interest. The main cannabinoids include the primary 
psychoactive compound ∆9-tetrahydrocannabinol (THC), and the degradative 
product of the cannabis plant, cannabidiol (CBD), and the oxidation artifact of 
THC, cannabinol (CBN). From 1980 to 1997, a total of 35,213 samples of seized 
cannabis products in the United States were analyzed by gas chromatography (GC) 
(58). The mean THC concentration increased from less than 1.5% in 1980 to 4.2% 
in 1997. The maximum levels found were 29.9 and 33.1% in marijuana and 
sinsemilla cannabis, respectively. The main pharmacological characteristics of 
these compounds and other less abundant cannabinoids are shown in Table 2-1. 
Of these, the main cannabinoids that are usually targeted in biological samples 
are THC, CBD, and CBN. CBN was first named a cannabinoid in 1896 by Wood et al 
(59) and its structure was elucidated in 1940 (60). CBD was isolated in 1940 (61), 
but its correct structure was first explained in 1963 by Mechoulam and Shvo (62). 
The main active ingredient, THC, was first isolated by Wollner et al in 1942 (63), 
but the correct structure was illustrated 22 years later by Gaoni and Mechoulam 
in 1964 (64). 
In addition to the above three cannabinoids, tetrahydrocannabinol acid A (THCA-
A) is one of the cannabinoids that has recently gained increasing recognition in 
forensic toxicology laboratories. THCA-A is the non-psychoactive precursor of THC 
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in cannabis plants. The presence of this cannabinoid exclusively in the cannabis 
plant may serve as a marker for differentiating between the legal intake of THC 
medication and external exposure to cannabis products (65). Chemical structures 
of pharmacologically active cannabinoids and THCA-A are shown in Figure 2-2. 
Table 2-1 Pharmacological actions of the main cannabinoids found in the cannabis plant 
(57) 
Cannabinoids Main pharmacological characteristics 
Delta-9-tetrahydrocannabinol 
(∆9-THC) 
Primary psychoactive effects  
Cannabidiol (CBD) 
Anxiolytic, anti-psychotic, analgesic, anti-
inflammatory, anti-oxidant, anti-spasmodic 
Cannabinol (CBN) 
Anti-inflammatory, sedative, antibiotic, 
anticonvulsant 
Delta-8-tetrahydrocannabinol 
(∆8-THC) 
Some psychoactive effects  
Cannabigerolic acid (CBGA) Antibiotic  
Cannabigerol (CBG) 
 Analgesic, anti-inflammatory, antibiotic, 
antifungal  
Cannabichromene (CBC) 
Analgesic, anti-inflammatory, antibiotic, 
antifungal 
Cannabidioloic acid (CBDA) Antibiotic  
Delta-9-tetrahydrocannabivarin 
(∆9-THCV) 
Euphoriant, analgesic  
 
Although cannabis plants have similar composition, they can be cultivated to 
provide different strains. The main cannabinoid types that are usually detected in 
all strains are THC, CBD, CBN, CBG and CBC. However, there can be significant 
variation in their quantitative ratios (66). The traditional cannabis gene pools 
originate either from cannabis sativa, which comprises the vast majority of 
naturally occurring hemp and drug land races, or from cannabis indica (AKA 
Cannabis afghanica) from Afghanistan and Pakistan, and has become a component 
in many modern drug cultivars. The majority of the varieties from these regions, 
shown in Figure 2-3, are high in psychoactive THC with a widely varying CBD 
content. 
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Figure 2-2 Chemical structure of cannabinoids.  
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Δ9-tetrahydrocannabinol acid A (Δ9-THCA-A), Δ9-tetrahydocannabinol (Δ9-THC), Δ9-
tetrahydrocannabivarin (THCV), Δ8-tetrahydrocannabinol (Δ8-THC), Cannabigerolic acid 
(CBGA) cannabigerol (CBG), cannabichromene (CBC), cannabinol (CBN), cannabidioloic 
acid (CBDA) and cannabidiol (CBD). 
 
 
Figure 2-3 The four major cannabis gene pools. Adapted from (54) 
 
 Prevalence of cannabis use 
The first archaeological evidence of cannabis use by humans was found in China 
roughly 4000 years B.C. (67). According to the 2016 World Drug Report by the 
United Nations Office on Drugs and Crime (UNODC), cannabis remains the most 
widely consumed drug worldwide by an estimated 183 million users (68). The 
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) reported in 
their latest publication on drugs trends that the prevalence of cannabis use is 
estimated to be five times that of other substances with cannabis being the most 
commonly used drug by approximately 84 million users. In Scotland, cannabis was 
reported by 20% of the 8,692 individuals providing information on recent ‘illicit’ 
drug use and seeking treatment (69). 
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 Legal status of cannabis in the UK and KSA 
In the UK, four main statutes regulate the availability of drugs: the Medicines Act 
1968, the Misuse of Drugs Act 1971, the Misuse of Drugs Regulations 2001, and the 
most recent Psychoactive Substances Act which came into force on 26 May 2016 
as complementary to the 1971 act. The Misuse of Drugs Act 1971 is intended to 
prevent the non-medical use of certain drugs including cannabis (70), whereas the 
Misuse of Drugs Regulations 2001 intended to allow for the lawful possession and 
supply of controlled (illegal) drugs for legitimate purposes. Under the Misuse of 
Drugs Act 1971, illegal drugs are divided into Classes A, B and C, while in the 
Misuse of Drugs Regulations 2001, drugs are divided into five schedules. At the 
moment, cannabis is a class B, schedule 1 drug according to the UK legislations. It 
is illegal to possess, supply or produce this drug. Cannabis possession carries a 
maximum sentence of 5 years’ imprisonment and a fine. Cannabis trafficking 
offences carry a maximum sentence of 14 years’ imprisonment and a fine. It is 
noteworthy that based on the advice from the advisory council on the misuse of 
drugs, which was established to keep the drug situation under review, cannabis 
was downgraded from class B to class C in 2004 and was then upgraded back to 
class B in 2009 (70–72). 
In the Kingdom of Saudi Arabia (KSA), narcotics control law differentiates between 
narcotics smugglers, dealers and users. For the first time offender, punishment is 
imprisonment, lashing or financial fine or all. For the repeat offenders, 
punishment is increased and the involved person may be sentenced to death. 
Narcotics users are jailed for two years and punished according to the judge's 
decision. If the offender is a foreigner, he is deported from the Kingdom. A 
narcotics user who enrols in a treatment program is not questioned, but admitted 
into a specialized hospital (73). 
 Modes of ingestion of cannabis  
Cannabis is available mainly in the form of herbal plant material or dried resin. 
According to the UNODC 2016 World Drug Report, Europe, North Africa and the 
Near and Middle East are the main markets for cannabis resin and is produced 
mainly in Morocco, Afghanistan and, to a lesser extent, Lebanon (68). In Saudi 
Arabia, official reports indicated that Yemen is an important source of cannabis 
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resin (74). Cannabis products have various street names including; hashish, bango, 
hemp, marijuana, pot, gandia, grass, chanvre and many more. The most potent 
form of cannabis is known as sinsemilla and is prepared from dried parts of mostly 
indoor-grown female plants. Typically, cannabis resin is smoked in combination 
with tobacco as joints. Smoking the joint involves burning the flowers and inhaling 
the active components of the plant that are released. Heat will lead to 
decarboxylation of the non-psychoactive precursor THCA-A to the primary active 
ingredient THC. Smoking is the dominant route of administration for illicit 
cannabis. 
 Cannabinoids pharmacology in humans 
According to Dorland's Medical Dictionary, pharmacology can be defined as the 
science that deals with the origin, nature, chemistry, effects, and uses of drugs 
(1). The two main aspects of pharmacology are pharmacokinetics and 
pharmacodynamics. Pharmacokinetics describes what the body does to a drug 
following administration. Currently, it is defined as the study of the time course 
of drug absorption, distribution, metabolism, and excretion. Pharmacodynamics 
describes what a drug does to the body. It refers to the relationship between drug 
concentration at the site of action and the resulting effect, including the time 
course and intensity of therapeutic and adverse effects and involves receptor 
binding, post-receptor effects, and chemical interactions.   
 Pharmacokinetic of cannabinoids 
The pharmacokinetic study of cannabinoids is known to be a challenging task due 
to several factors. Those contributing significantly to the problem are low analyte 
concentrations and rapid and extensive metabolism. Moreover, the 
physicochemical characteristics of cannabinoids restrain their separation from the 
biological matrices and from each other, and minimize drug recovery due to their 
adsorption into multiple body organs. 
Absorption can occur through different sites in the body depending on the route 
of administration. Drugs that are inhaled or smoked, such as cannabis resin, are 
absorbed into the bloodstream through the lungs. Δ9-THC becomes detectable in 
plasma after just a few seconds following inhalation and reaches peak 
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concentrations in 0.08 to 0.17 hour. After smoking, plasma concentrations for 
THC, 11-OH-THC and THC-COOH were found to peak in the range of 6–10 minutes, 
9–23 minutes and 32–133 minutes, respectively (75,76). The maximal THC plasma 
concentration was found to be approximately 3-fold the maximal concentration of 
THC-COOH and 20-fold the maximal concentration of 11-OH-THC (76). However, 
after oral administration, the THC peak concentration in plasma is reached after 
1 to 6 hours (77), which is a significant delay. The relatively long half-life is caused 
by the lipophilic nature of THC which enhances its distribution to adipose tissue 
and different body organs, then causes it to be slowly released back into the blood 
and metabolized (78,79). THC bioavailability was found to vary significantly 
according to inhalation behaviour during smoking and frequency of use. It was 
reported to range from 2-56% (80). Within 72 h after smoking, approximately 50% 
of the inhaled THC will be excreted as the metabolite, and the remaining 50% 
distributed throughout fatty tissue in the body.  
Following absorption, several factors affect the degree to which drugs are 
distributed into body fat and tissues. These factors include the drug lipophilicity, 
protein binding, and the size of the drug. Higher volumes of distribution are 
reported for drugs which are more likely to be distributed widely into body fat or 
tissues. In blood, due to the low partition coefficient of the drug into red blood 
cells (RBCs), only 10% of Δ9-THC is distributed in the erythrocytes and about 90% 
is distributed into the plasma. More than 95% of THC in plasma is bound to plasma 
lipoproteins which complicates the THC initial disposition. The initial volume of 
distribution of THC was reported to be 2.55±1.93 L in drug-free users and 6.38±4.1 
L in regular users, and 10 L/kg at steady-state (81). 
Drug metabolism is the biochemical alteration of compounds through specialized 
enzymatic systems. The main purpose of metabolism is to prepare the drugs for 
excretion from the body, usually by making the drug more polar or converting the 
lipophilic compounds into more readily excreted hydrophilic products. Metabolism 
of some drugs will add some pharmacological activity by the formation of 
pharmacologically active metabolites or it may even be responsible for producing 
all the pharmacological activity following ingestion of a pro-drug. The liver is the 
primary organ responsible for metabolism but other sites including the kidneys are 
also involved. The ∆9-THC biotransformation takes place mainly in the liver and is 
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catalysed by enzymes of the cytochrome P450 (CYP) complex. In humans, more 
than 20 metabolites can be identified from Δ9-THC metabolism. In forensic 
toxicology, Δ9-THC metabolism leads to formation of two dominating metabolites 
of analytical interest. The first is 11-hydroxy-Δ9-tetrahydrocannabinol (11-OH-
THC), a product of microsomal hydroxylation of Δ9-THC. This metabolite is 
psychoactive and is further oxidized to 11-nor-9-carboxy-delta-9-
tetrahydrocannabinol (THC-COOH), the primary inactive metabolite (see Figure 
2-4).  It is noteworthy that there are several shortcuts used interchangeably 
throughout the literature to refer to this metabolite such as; 9-Carboxy-THC, THC-
COOH, c-THC or THCA, however, THC-COOH only will be used in this work to refer 
to this metabolite.  
Elimination is the process by which drugs are removed from the body. This occurs 
mainly by excretion through the kidneys, but some drugs may be eliminated in the 
bile, or via the lungs. The rate at which drugs are excreted from the kidneys will 
vary depending on the drug's properties, e.g. whether it is acidic (low pH) or basic 
(high pH), and on the pH of the urine. All aspects of the pharmacology of drugs 
should be taken into consideration when interpreting toxicological data (8). More 
than 65% of smoked THC is excreted in the faeces and about 20% in the urine 
(82,83). Usually THC−COOH is found in the urine as glucuronide conjugates while 
11-OH-THC predominates in the faeces (84).  
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Figure 2-4 The main metabolic route for Δ9-THC 
 
 Cannabis mechanism of action  
Due to the THC activity at many sites, scientists have encountered some 
difficulties in illustrating its mechanism of action. Over the years, two hypotheses 
were proposed for THC’s mechanism of action. One hypothesis suggested that THC 
exerted its effects through non-specific interactions of the drug with cellular and 
organelle membranes (85,86). The other hypothesis suggested that THC interacted 
with specific cannabinoid receptors  (87,88). However, our understanding of 
cannabinoid pharmacology has increased enormously over the last 25 years by 
several important discoveries. Central (CB1) (89,90) and peripheral (CB2) (90) 
cannabinoid receptors have been characterized, endogenous ligands 
(endocannabinoids); anandamide (91) and 2-arachidonyl glycerol (92), have been 
identified, and specific CB1 (93) and CB2 receptor antagonists (94) have been 
synthesized. The psychological and physiological effects of cannabis are 
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attributed, mainly, to the activation of these two main cannabinoid receptors by 
THC (95). CB1 receptors are found mainly on neurons in the brain, spinal cord and 
peripheral nervous system, whereas CB2 receptors occur principally in immune 
cells (95). The absence of cannabinoid receptors in the brain stem, which controls 
the body's vital functions may explain the low toxicity of cannabinoids. The 
activation of CB receptors on presynaptic cells by THC reduces the amount of 
neurotransmitter that gets released, which in turn affects how messages are sent, 
received, and processed by the cell. 
 Effects of cannabis 
Many factors contribute to the severity of cannabis use consequences. These 
factors include, but are not limited to, the dose and THC and CBD content in the 
plant, administration method, user’s history, expectations and mood state (96). 
Effects of cannabis have been studied and reviewed extensively in the literature 
(96–100). Main cannabis effects include; euphoria, anxiety, altered time 
perception, loss of concentration, and panic attacks. The most commonly 
researched ones are feelings of well-being, euphoria, and relaxation. THC 
produces an increase in heart rate, blood pressure, and body temperature. It is 
also possible to experience dry mouth, increased hunger, and pain reduction. Very 
high doses of cannabis can cause anxiety, panic, or result in long-term impairment 
of memory and learning ability and psychotic episodes. 
 Analysis of cannabinoids in hair matrices 
The vast majority of studies have concentrated on identifying the most abundant 
cannabinoid analyte in hair, the more neutral and lipophilic parent compound, 
THC and its main metabolite THC-COOH, which is present in much lower 
concentrations in the hair. The main benefit of measuring THCCOOH in hair is that 
cannabis use can be more effectively documented than with detection of the 
parent THC which could be deposited in hair following environmental exposure to 
cannabis smoke. Analysis of cannabinoids in hair has challenged the sensitivity 
limits of immunoassay and confirmation assays; advanced instrumentations have 
been required in most cases to increase the confirmation rate of presumptive 
positive results.  
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In the latest version of guidelines of the Society of Hair Testing (SoHT) (26), the 
European Workplace Drug Testing Society (EWDTS) (101), the German Society of 
Toxicological and Forensic Chemistry (GTFCh) (102) and the Substance Abuse and 
Mental Health Services Administration (SAMHSA) (103), the following cut-off 
concentrations in Table 2-2 are recommended for detecting cannabis use in hair: 
Table 2-2 Recommended cut-offs for THC and THC-COOH in hair to identify use. 
 Drug Screening  
cut-off (ng/mg) 
Confirmation 
 cut-off (ng/mg) 
SoHT & 
EWDTS 
THC  ≤ 0.1 0.05 
THC-COOH - 0.0002 
GTFCh THC  ≤ 0.02 - 
THC-COOH - - 
SAMHSA THC - - 
THC-COOH ≤ 0.001 0.00005 
 
Despite the fact that a rapid, and simple gas chromatography mass spectrometry 
(GC/MS) method could be developed and employed to serve as a screening tool, 
the low cost of immunoassays makes it more preferable and widely utilized to 
screen for drugs of abuse to efficiently exclude negative samples and limit further 
confirmatory testing to presumptive positive samples.   
 Immunoassays  
The term immunoassay is generally used to describe antibody-mediated analytical 
procedures. In these type of assays, the power of detection of antibody-antigen 
(Ab-Ag) reactions is exploited to develop assay technologies for detecting drug 
compounds and their metabolites in a variety of matrices. There are two main 
types of antibodies employed in immunoassays. The first type is polyclonal 
antibodies which are produced in-vivo inside different animals (such as sheep, 
goats) and contain a mixture of antibodies that have the capability to bind to 
different antigen binding sites (epitopes). The second type is monoclonal 
antibodies which are generated from a single cell line using hybridoma1 technology 
                                         
1 Hybridomas are produced by injecting a specific antigen into a mouse, collecting an antibody-
producing cell from the mouse's spleen, and fusing it with a tumor cell called a myeloma cell. 
The hybridoma cells multiply indefinitely in the laboratory and can be used to produce a 
specific antibody indefinitely 
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and mouse myeloma cell lines. These antibodies are known to be more specific 
for a single epitope on a multivalent antigen. 
Immunoassays come in many different formats and variations, competitive and 
non-competitive, heterogeneous and homogeneous. In competitive formats, the 
analyte of interest (unlabeled antigen) in the test sample is measured by its ability 
to compete with the labeled antigen in the immunoassay. Immunoassays that 
require separation of bound and free labelled antigen are referred to as being 
heterogeneous immunoassays. Those that do not require separation are referred 
to as homogeneous immunoassays. Homogeneous methods have generally been 
applied to the measurement of small analytes such as drugs of abuse and 
therapeutic drugs. Examples of the most commonly reported immunoassays 
include radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), 
enzyme-multiplied immunoassay technique (EMIT), fluorescence polarization 
immunoassay (FPIA), cloned enzyme donor immunoassay (CEDIA) and kinetic 
interaction of microparticles in solution (KIMS). These tests have mainly been 
reported for screening drugs of abuse in urine samples and their principles usually 
implied in names.  
 Immunoassays as a screening tool for hair matrices 
One of the concerns with regards to immunoassay screening for hair matrices is 
the incompatibility of immunoassay kits designed for biological fluids, such as 
urine, blood and oral fluid, with hair. This incompatibility arises either from 
sample pre-treatment variations or due to targeting different parent drugs or 
metabolites (104). The traditional method for extraction of incorporated drug 
from the hair matrix is overnight incubation at a certain temperature with organic 
solvent such as methanol (MeOH). This method has been proven to cause 
degradation in the performance of the immunoassay even with evaporation of 
methanol and reconstitution with buffer. Coulter et al have reported a successful 
method to overcome this by adaption of the sample pre-treatment step to make 
it more suitable for ELISA (105). In their work, an aqueous incubation, to extract 
drugs from the hair matrix, was used and the hair extract was directly placed into 
the ELISA microplate well (105). In addition to the improved sensitivity, less 
extraction time, elimination of evaporation and reconstitution steps were 
advantages from the new extraction protocol. Referring to this proposed 
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extraction method, Moore stated that ‘the method should expand the menu of 
immunoassay screening kits for drugs in hair matrices as the major obstacle no 
longer exists’ (106). In the same year, 2010, Comedical Laboratories marketed a 
(VMA-T) reagent purposely designed to treat hair samples for compatibility with 
immunological methods currently used in urinalysis. Its assays convert 6-
monoacetylmorphine (6-MAM) and cocaine (which may be present in hair) to their 
metabolites which are detected in urine, specifically morphine and 
benzoylecgonine (107). Although cannabinoids immunological methods are not 
benefited directly from this reagent, a complementary reagent (M3), which has 
been more recently proposed from the same provider, was employed successfully 
for extraction of 11-nor-D9-tetrahydrocannabinol-9-carboxylic acid glucuronide 
(THC-COOH-glu) in hair for the first time by Pichini et al (108). Many laboratories 
are currently using ELISA tests, not specifically designed for hair testing but 
compatible with this matrix if the sample is prepared suitably (109–111). 
Alternatively, there are purposely designed immunoassays for hair testing analysis 
(112).  
 Evaluation of immunoassay kits for the detection of cannabis using 
hair matrices 
Most commercially available cannabinoid immunoassay kits are calibrated with the 
major metabolite THC-COOH, as the presence of this metabolite is believed to 
prove consumption and excludes the possibility of external contamination which 
is always present when targeting only THC. The full validation of an immunoassay 
method is looked at as a very complex task. Many factors contribute to this 
complexity including; (1) nonlinearity of the calibration curves and the decisive 
consequences of that on the validity of the results at the cut-off value, and (2) 
the potential presence of unwanted cross-reactivities and unspecific binding to 
matrix components. The validation and cut-off value determination is generally 
carried out by the manufacturers. Therefore, the cut-off value decision is 
extremely important and has a direct impact on the detection time window and 
the positive rate. There are many methods reported in the literature for 
evaluating immunoassay performance. The most common one is achieved by 
measuring the following four parameters; true-positive (TP), true-negative (TN), 
false-positive (FP) and false-negative (FN) of the assay. Usually these can be 
obtained by comparing results of immunoassay screening and a confirmatory 
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technique such as GC/MS. Results are then used to calculate the specificity [TN / 
(TN + FP)] × 100%, sensitivity [TP / (TP + FN)] × 100%, and efficiency [(TP + TN) / 
(TN + FP + TP + FN)] × 100%. Knowledge of the sensitivity and specificity of 
cannabinoid immunoassays for different cannabinoid analytes is essential for their 
proper use, since these assay characteristics differ and affect detection times.  
The performance characteristic of two immunoassay kits, one from NeoGen for 
THC-COOH and the other one obtained from Immunalysis for THC, were carried 
out. Both kits have shown good performance, however, the Immunalysis kit was 
found to be better for targeting THC while the NeoGen kit had the superiority with 
THC-COOH. A copy of two posters presenting the work and results are shown in 
Appendix I and Appendix II. 
 Confirmatory Testing 
It is a common practice in forensic toxicology laboratories to carry out the 
confirmation technique by a chemical technique that is based on a different 
scientific principle from the chemical technique used in the initial test. Typically, 
chromatographic techniques coupled with mass spectrometry are used for 
confirmation due to their high specificity. Analysis of hair samples using these kind 
of techniques usually involve several steps including; extraction of drugs from 
inside the hair matrix, cleaning the hair extract, derivatisation (if required), and 
analysis using one of the following techniques; GC-MS, GC-MSMS, LC-MS, LC-MSMS. 
A review of sample preparation methods, instrumentations employed, commonly 
targeted analytes for cannabinoids and range of concentrations detected in hair 
is included in the following three sections. 
 Sample preparation 
The importance of sample preparation in analytical methods lies in its huge impact 
on sensitivity, through concentration of the target analyte and exclusion of 
unwanted interferences in the sample. In hair analysis, differentiation between 
external contamination and incorporated analyte in hair is another function of 
sample preparation, giving it an even more crucial role. Methods for the 
determination of cannabinoids in hair usually include the following basic steps: 1. 
washing hair with a solvent to remove any cannabinoids adsorbed to external 
surfaces of the hair; 2. digestion or dissolution of the keratinic matrix to extract 
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cannabinoids and metabolites from inside hair, this step is carried out usually 
using strong alkaline hydrolysis; 3. further cleaning or extraction of the digested 
hair; 4. derivatization of the extracted cannabinoids; and 5. analysis using gas or 
liquid chromatographic coupled with mass spectrometry. 
So far, it is an acknowledged fact that no standardised washing procedures can 
effectively remove all external contaminants with no loss from the targeted 
analyte (113,114). Cannabinoids are present in cannabis smoke and passive 
exposure to this smoke can result in external adsorption of cannabinoids into the 
hair shaft. Therefore, determination of THC-COOH, the main metabolite for 
cannabis, in hair continues to be the main frequently used indicator to prove 
cannabis consumption.  
Despite the fact that alkaline hydrolysis is the most favoured and dominated 
method for extraction of cannabinoids incorporated into hair, other methods have 
been reported in the literature, such as enzymatic hydrolysis (115,116), methanol 
(117,118), and acidic aqueous buffer (119), diatomaceous followed by pressurised 
liquid extraction (PLE) (120) and acetonitrile (121). Dissolving hair using alkaline 
hydrolysis involves using a strong base such as sodium hydroxide (NaOH), (122–
127), or potassium hydroxide (KOH) (128,129). Alkaline hydrolysis is generally 
preferred over the other methods due to its efficiency, simplicity, and can be 
carried out very rapidly. However, the method is not suitable for all analyte and 
other methods must be used to extract these from hair. For instance, the ester-
linked glucuronide conjugate (THC-COOH glucuronides) will be cleaved and 
converted back to THC-COOH when alkaline hydrolysis used. Also, heating is 
essential to accelerate the hydrolysis, and an analyte such as 
tetrahydrocannabinolic acid A (THCA-A) will decarboxylate to form THC when 
heated.  
After extraction of analytes from within the hair, the resulting digest is not 
suitable for injection and needs further cleaning. One of the main challenges in 
cannabinoids analysis is the differences in chemical properties for the main 
cannabinoids THC, CBD and CBN and the main metabolite THC-COOH. This 
variation makes it difficult to, effectively and simultaneously, extract all 
compounds in one universal procedure. Therefore, it is important to adjust the pH 
of the hair digest prior to extraction of THC-COOH. Early methods for the 
64 
 
 
determination of cannabinoids in hair used liquid-liquid extraction (LLE) (115,130–
133), solid-phase extraction (SPE) (114,120,134), solid-phase microextraction 
(SPME) (124,135,136), and solid-phase dynamic extraction (SPDE) (125). A two-
step liquid/liquid extraction procedure seems to be the most used and reported 
cleaning method. An extraction solvent is added to the hair digest without prior 
manipulation to extract the main cannabinoids (THC, CBD, CBN) and the 
metabolite 11-OH-THC, the aqueous layer is then separated, acidified or 
neutralised, and re-extracted with the same solvent or different extraction 
method, such as SPE. Varying volumes of acetic acid are most often reported for 
this purpose (137–139), other acids have been reported as well, such as acetate 
buffer with acetic acid (140,141), hydrochloric acid (129), formic acid (142) and 
maleic acid (138). The two organic extracts are then either combined or prepared 
separately for derivatisation or straight analysis. Different extraction solvents 
were reported for extraction of cannabinoids using LLE; n-hexane-Ethyl acetate 
(EtOAc) (90:10, v/v) (130,131,138,140,143), hexane-EtOAc (3:1, v/v) (133), Ethyl 
Acetate (EtOAc) (142), pentane (116), chloroform / isopropyl alcohol (97:3, v/v) 
(115).  
A common method to analyse cannabinoids involves gas chromatography-mass 
spectrometry (GC-MS). In most cases, derivatisation is often utilised to make the 
analytes volatile and improve chromatographic and mass spectrometric (MS) 
identification. Following review of the literature for cannabinoids analysis in hair, 
it was found that the developed analytical methods either do not include a 
derivatisation step (116,124,132,136,144), or use a silylation derivatisation agent 
(such as BSTFA or MSTFA) (65,114,125,130,133–135,145), or acylation reagents 
(usually a mixture of a perfluorinated anhydride (TFAA, PFPA, or HFBA) and a 
perfluorinated alkyl alcohol (HFIP or PFPOH) (114,115,134,137,138,140,146,147). 
 
 Analysis  
Cannabinoids are not incorporated into hair as efficiently as most other drugs. As 
a result, concentrations of cannabinoids in hair after smoking or ingestion of 
cannabis are very low and can only be detected with extremely sensitive analytical 
methods. Several methods for hair analysis of cannabinoids have been developed 
using gas chromatography mass spectrometry operating in electron impact mode 
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(GC-EI-MS) (65,115,116,125,132,133,135,145,148,149), gas chromatography mass 
spectrometry in negative chemical ionization mode (GC-NCI-MS) (123,138,150–
152), gas chromatography tandem mass spectrometry in negative chemical 
ionization mode (GC-NCI-MSMS) (134,139,140,143,147,149,153–156), gas 
chromatography tandem mass spectrometry in positive chemical ionisation mode 
(GC-PCI-MSMS) (134), two-dimensional gas chromatography time-of-flight mass 
spectrometry in electron impact mode (157), two-dimensional gas 
chromatography mass spectrometry in negative chemical ionization mode (2D GC-
NCI-MS) (141), or two-dimensional gas chromatography tandem mass spectrometry 
in EI mode (2D GC-EI-MS) (158). The analytical procedures described in the 
literature for the analysis of cannabinoids in human hair are mainly targeted for 
the simultaneous detection of parent cannabinoids THC, CBD and CBN  
(107,119,124–127,132,133,135,136,144,145,148,159), the main metabolite THC-
COOH only (123,139,141,143,151,152,154,158,160–163) or, both, one or more of 
parent cannabinoids (THC, CBD and CBN) and the main metabolite (THC-COOH) 
(115,120,130,131,164). Simultaneous detection of both parent cannabinoids and 
the main metabolite from hair is a very challenging task. The differences in 
chemical properties of the metabolites make it difficult to use one universal 
extraction procedure to extract all cannabinoids efficiently in one single elution. 
Usually, the pH of the hair digest with sodium hydroxide needs to be adjusted 
after extraction of the parent cannabinoids (THC, CBD and CBN) and prior to the 
extraction of THC-COOH. This process ends up in two fractions. Combining the two 
fractions makes derivatisation more complicated. Due to the extremely low 
concentrations of THC-COOH in hair, perfluorinated agents are often preferred 
due to the superior sensitivity that can be achieved when this derivative is 
analysed using MS operated in NCI mode. However, derivatisation of THC and CBD 
with perfluorinated agents will produce identical retention times and identical 
mass spectra, and hence will result in inaccurate quantitation results. This 
problem was highlighted previously in the literature for PFPOH-PFPA (115) and  
HFIP-TFAA (165). Derivatisation of all cannabinoids with silylation agents such as 
BSTFA or MSTFA will solve this problem and produce derivatives that can be 
separated when analysed on standard GC-MS instrumentation in EI mode. 
However, the problem exists that although the concentrations of THC, CBD and 
CBN are present in hair in the nanogram range and GC-EI-MS may provide sufficient 
sensitivity to detect them, the concentrations of THC-COOH are present in hair in 
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the picogram range which cannot be detected on standard GC-EI-MS. It would 
appear that there is no GC-based method in the literature allowing the 
simultaneous determination of THC, CBD, CBN and THC-COOH in one sample 
preparation and injection. Recently, Dulaurent et al reported a liquid 
chromatography tandem mass spectrometry (LC-MSMS) method for the 
determination of the four compounds in one sample preparation and injection for 
the first time(131). The other methods describing the determination of the 4 
compounds used 2 sample preparations and 2 injections  (114,115) or 1 sample 
preparation and 2 injections (134). Tandem MS operated in NCI is often employed 
to target THC-COOH in hair and is known to provide good sensitivity. However, 
due to the high cost of such instrumentation, 2D GC-NCI-MS is proposed as a 
cheaper alternative.  
 Concentrations of cannabinoids in hair 
In general, there is an accepted consensus that concentrations of THC, CBD and 
CBN are in the high picogram to low nanogram per milligram of hair range, while 
concentrations of THC-COOH are in the high femtogram to low picogram per 
milligram of hair range. There have been several studies investigating the 
concentrations of different cannabinoids in hair. The range of concentrations 
detected in these studies is compared against the concentrations obtained in this 
thesis and shown in detail in section 5.8.3. 
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 Hair sample preparation and extraction 
methods for THC, CBD, CBN, 11-OH-THC, and 
THC-COOH 
 Introduction 
In this project, only the main cannabinoids (THC, CBD, CBN) and phase-one main 
metabolites (11-OH-THC and THC-COOH) were targeted, therefore, NaOH was 
employed to extract analytes of interest from the hair. Despite the fact that the 
n-hexane/ethyl acetate mixture is the most frequently reported extraction 
solvent in the literature, for health and safety reasons, n-hexane use is restricted 
for routine analysis in the Forensic Medicine and Science laboratory (FMS), 
University of Glasgow due to its potential carcinogenicity and chronic toxicity 
effect. As an alternative to n-hexane and aiming at optimisation of the extraction 
method, the extraction power of five solvents for cannabinoids from hair; 
cyclohexane, cyclohexane-EtOAc (90:10, v/v), methyl tert-butyl ether (MTBE), 
ethyl acetate (EtOAc), and dichloromethane (DCM) was investigated. Acidification 
of the hair digest is another area that was subject to further investigation. With 
exception of maleic acid, which was not readily available, a series of experiments 
were carried out to evaluate the effect of all the acids reported in the literature 
for pH adjustment on the recovery of THC-COOH. In addition to LLE of hair for 
THC-COOH, two different extraction methods were evaluated; supported-assisted 
liquid-liquid extraction (SALL) and solid-phase extraction (SPE). SALL evaluation 
was carried out following a protocol proposed by the manufacturer. The initial 
method for SPE was based on previously published work by Moore et al (141). Due 
to an issue during extraction, the SPE method was subject to further optimisation. 
The extraction comparison will be discussed further in sections  3.5 and 3.6. 
Traditionally, the most common derivatising reagents used for analysis of THC-
COOH on GC-MS with negative chemical ionisation (NCI) are the fluorinated 
anhydrides. The need for derivatisation becomes important especially when 
targeting the main metabolite (THC-COOH), which is more polar and has a high 
boiling point and will degrade at high temperatures. The chemical structure of 
THC-COOH provides two possible sites for derivatisation; carboxyl and hydroxyl 
groups. With the aim of optimising the detection sensitivity, both groups were 
subject to different combinations of derivatisation.  
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 Aims 
The purpose of the work presented in this chapter was to optimise extraction 
methods for the three parent cannabinoids (THC, CBD, and CBN) and the two 
metabolites (11-OH-THC and THC-COOH) in hair samples. In addition, the outcome 
of different derivatisation reagent combination for THC-COOH was investigated. 
Five extraction solvents including; EtOAc, cyclohexane, methyl tert-butyl ether 
and dichloromethane, were tested as alternative extracting solvents to n-hexane 
for liquid-liquid extraction (LLE). The optimised method giving the highest 
recoveries would then be selected to analyse these drugs in hair. Different 
methods for the purpose of acidifying the alkaline hair digest sample were 
compared for the extraction of THC-COOH using LLE. Moreover, SALL and SPE 
extraction methods were compared for the extraction of THC-COOH.  
 Materials and methods 
 Materials 
∆9-Tetrahydrocannabinol (THC) at 100 µg/mL, Cannabidiol (CBD) at 1 mg/mL, 
Cannabinol (CBN) at 1 mg/mL, 11-Hydroxy-Δ9-tetrahydrocannabinol (11-OH-THC) 
at 100 µg/mL, and 11-nor-9-carboxy-∆9-tetrahydrocannabinol (THC-COOH) at 100 
µg/ml were purchased from Sigma Aldrich (Basingstoke, UK). All of these drugs 
were purchased dissolved in 1 mL methanol. Deuterated internal standards (ISTD); 
∆9-Tetrahydrocannabinol-d3 (THC-d3), 11-Hydroxy-Δ9-tetrahydrocannabinol-d3 
(11-OH-THC-d3) and 11-nor-9-carboxy-∆9-tetrahydrocannabinol- d3 (THC-COOH-
d3) (100 µg/mL), each at 100 µg/mL, were obtained from Sigma Aldrich 
(Basingstoke, UK). The following derivatisation reagents; N,O-bis-(trimethylsilyl)-
trifluoroacetamide (BSTFA) with 1% trimethylchlorosilane (TMCS), 1,1,1,3,3,3-
Hexafluoro-2-propanol (HFIP), trifluoroacetic anhydride (TFAA), 
pentafluoropropionic anhydride (PFPA),  2,2,3,3,3-Pentafluoro-1-propanol 
(PFPOH), Heptafluorobutyric anhydride (HFBA), and Methyl iodide were purchased 
from Sigma Aldrich (Basingstoke, UK). The following chemicals; acetonitrile (ACN), 
glacial acetic acid, methanol (MeOH), ethyl acetate (EtOAc), dichloromethane 
(DCM), hexane, cyclohexane, methyl-t-butyl ether (MTBE), and hydrochloric acid 
37% (HCl) were supplied by VWR International Ltd, (Lutterworth, UK). Deionised 
water was obtained from the in-house Millipore® system. ChemElut–1mL 
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unbuffered supported-assisted liquid-liquid extraction (SALL) extraction 
cartridges was obtained from Agilent, UK  
 Preparation of chemical solutions  
 0.1M sodium acetate buffer 
2.93g of sodium acetate trihydrate was weighed in a weighing boat, transferred 
into a beaker and then dissolved in 400 mL deionised water. 1.62 mL glacial acetic 
acid was then added.  The buffer was pH adjusted to pH 4, 5 or 6 with 0.1M acetic 
acid (to lower pH) or 0.1M sodium acetate (to raise pH).  After adjusting the pH, 
the solution was then transferred into a 500 mL volumetric flask, and made up to 
the mark with deionised water.  This was mixed well and stored at approx. 5oC 
and discarded after 30 days. 
 0.1 M hydrochloric acid 
4.2 mL of concentrated hydrochloric acid (37.5% concentrated HCl) was added 
slowly to a 500 mL volumetric that was already filled with about 400 mL of 
deionised water (DI H2O). The volume was then made up to the mark with 
deionised water and stored at room temperature. 
 1 M Acetic Acid 
28.6 mL of glacial acetic acid was added into a 500 mL volumetric flask that was 
approximately half filled with DI H2O and mixed. The total volume was then 
brought up to 500 mL with DI H2O. The solution was stored at room temperature 
and discard after two months.   
 1 M Sodium hydroxide 
One mole of NaOH (40 g) was added slowly, with constant stirring and monitoring 
the temperature of the solution, to about 750 ml of deionized water in a 1 litre 
beaker. After all the NaOH has been added, the solution was transferred to a 1 L 
volumetric flask and made up to the mark with deionized water. The solution was 
then stored in a plastic container with plastic stopper at room temperature and 
discarded after two months.   
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 Cyclohexane (or n-hexane) / EtOAc (9:1, v/v) 
A ratio of 9:1 (cyclohexane (or n-hexane): ethyl acetate) was used. The volume of 
extracting solvent was prepared dependent on the number of samples to be 
extracted at the time of analysis. 
 Cyclohexane / EtOAc (3:1, v/v) 
A ratio of 3:1 (cyclohexane:ethyl acetate) was used. The volume of extracting 
solvent was prepared dependent on the number of samples to be extracted at the 
time of analysis. 
 0.1M HCl / ACN (70:30, v/v) 
A ratio of 7:3 (0.1M HCl:ACN) was used. The volume of SPE washing solution was 
prepared dependent on the number of samples to be extracted at the time of 
analysis. 
 Preparation of cannabinoid working solution mix 
Individual stock solutions of THC, 11-OH-THC and THC-COOH were prepared at a 
concentration of 10 µg/mL from purchased reference materials at 100 µg/mL by 
1:10 dilution with methanol. Stock solutions of CBD and CBN were prepared at a 
concentration of 10 µg/mL by 1:100 dilutions with methanol from 1 mg/mL 
reference standards. A working solution mixture at 1 µg/mL for analytes including 
(THC, CBD, CBN, 11-OH, and THC-COOH) was prepared by 1:10 dilution of stock 
solutions at 10 µg/mL.  
 Preparation of cannabinoid internal standard mix 
Individual stock solutions of internal standards THC-d3, 11-OH-THC-d3 and THC-
COOH-d3 were prepared at a concentration of 10 µg/mL from purchased reference 
materials at 100 µg/mL by 1:10 dilution with methanol. One Internal standards 
mixture at 1 µg/mL containing THC-d3, 11-OH-THC-d3, and THC-COOH-d3 was 
then prepared by 1:10 dilution of stock solutions at 10 µg/mL. 
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 Instrumentation 
The instrument parameters employed to carry out extraction recovery studies and 
derivatisation are briefly described in this chapter. The method development 
process, initial methods testing and the analytical principles will be covered in 
extensively in the following chapter. The two analytical systems used are gas 
chromatography mass spectrometry (GC-MS) (system1) and two-dimensional gas 
chromatography mass spectrometry (2D GC-MS) (system2). GC-MS (system1) was 
used for analysis of TMS derivatives of THC, CBD, CBN, 11-OH-THC and THC-COOH. 
Analysis was carried out using an Agilent gas chromatograph (6890) equipped with 
single quadrupole mass spectrometry (5795). Chromatographic separation was 
performed using a DB-5MS DG (30 m x 0.25 mm ID, 0.25 µm film thickness) column 
(Agilent J&W). The mass spectrometer was operated in the selected ion 
monitoring (SIM) mode with electron impact ionisation at an electron energy of 70 
eV. This instrument was employed to carry out most of the recovery studies. 2D 
GC-MS (system2) was employed to analyse the fluorinated derivative of THC-
COOH. Analysis was carried out using an Agilent gas chromatograph (6890) 
equipped with single quadrupole mass spectrometry (5795). Chromatographic 
separation was achieved using two capillary columns: a DB-5MS ultra inset (30 m 
x 0.25 mm ID, 0.25 µm film thickness) column as primary column and a HP-17MS 
(15 m x 0.320 mm ID, 0.25 µm film thickness). The mass spectrometer was 
operated in the negative ion chemical ionization mode using high purity ammonia 
as the reagent gas. MS identification was carried out using SIM mode. This 
instrument was employed to carry out the recovery studies from Supported-
Assisted liquid-liquid extraction (SALL), monitor drug loss experiment, and to test 
different derivatisation reagent combination for the THC-COOH. 
 Blank hair 
Blank hair was obtained from two sources known to be drug free; (1) volunteers 
within Forensic Medicine and Science (FMS), University of Glasgow, (2) friends and 
family members. Hair was first washed according to the wash protocol of FMS. 
Hair was then screened separately for the presence of interferences by the GC-MS 
method. No signals were observed at the retention times of targeted ions. Hair 
that screened negative and had no interferences was pooled together and mixed 
before weighing out 40-50 mg aliquots for extraction recovery studies. 
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 Digestion (Alkaline hydrolysis) 
40-50 mg of blank hair was spiked with different volumes of analytes depending 
on the purpose of the experiment. The exact volumes are detailed in the 
experimental sections. 1N NaOH sodium hydroxide (1 mL) was added, and the hair 
was heated at 70°C for 30-60 min. The sample was allowed to cool down to room 
temperature before carrying out further clean-up steps. 
 Extraction recovery calculations 
Recovery is defined as ‘the extraction efficiency of an analytical process, reported 
as percentages of the known amount of analytes of interest which are extracted 
and analysed by an optimised method’ (166) . The loss of analyte during extraction 
should be investigated with at least three replicates at two quality control (QC) 
levels. Internal standard is added after extraction to allow direct comparison with 
neat un-extracted standards. In order to calculate the recovery percentage, a non-
extracted standard at the same concentration was also prepared at the same time 
in triplicate. Internal standard solution was added after the extraction to all 
extracted and non-extracted standards. The peak area ratios of the analyte to its 
respective deuterated ISTD were calculated. The absolute recovery was 
determined for each analyte by dividing the extracted STD/ISTD ratio by that of 
the non-extracted STD/ISTD ratio at the same concentration and multiplying by 
100. This method was applied to all experiments. Ions that were used to calculate 
extraction recoveries are shown in tables Table 3-1and Table 3-2. 
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Table 3-1 Ions acquired in the Selected Ion Monitoring (SIM) mode using system1 
SIM group Analyte m/z Internal standard m/z 
1 CBD -2-TMS 390 THC-d3-TMS 374 
2 THC-TMS 371 
3 CBN-TMS 367 
4 11-OH-THC-2-TMS 371 11-OH-THC-d3-2-TMS 374 
5 THC-COOH-2-TMS 371 THC-COOH-d3-2-TMS 374 
 
Table 3-2 Ions acquired in the Selected Ion Monitoring (SIM) mode using system2 
SIM group Analyte m/z Internal standard m/z 
1 
THC-COOH-TFAA-
HFIP 
422 
THC-COOH-d3-TFAA-
HFIP 
425 
 
 Liquid-Liquid extraction  
 Rationale for LLE 
Liquid-liquid extraction (LLE) is an extraction of a substance from one liquid into 
another liquid phase. It consists in transferring one (or more) solute(s) contained 
in an aqueous solution to another immiscible organic liquid (solvent). It is also 
known as solvent extraction and partitioning, as the method to separate 
compounds is based on their relative solubility in the two immiscible liquids. One 
of the factors that determine drugs solubility is their ionisation status. As a rule 
of thumb, drugs are more hydrophilic when present in its ionised forms than the 
unionized forms because of the hydration of the ions, therefore the ionized drugs 
are difficulty to extract into organic solvents whereas the unionized forms will 
dissolve in the organic solvents which can be extracted into organic solvents. For 
hair analysis, all cannabinoids are extracted from the hair into alkaline solution 
after addition of 1M sodium hydroxide (NaOH) during sample preparation prior to 
LLE. The pH of hair alkaline solution is about 13-14. 
According to Henderson-Hasselbach Equation, any drug will be either in its 100% 
ionised or 100% unionized state when two pH units away from its pKa, higher pH 
than pKa promotes ionisation.  The pH of aqueous solutions in which a drug is 
dissolved determines the form in which the drug is present. For example, THC-
COOH has a pKa value of 4.2. When present in a hair digest solution with pH 14, 
it will be 100% ionized. All five cannabinoids, which are targeted for isolation by 
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LLE, are believed to be in their ionised forms under these very basic conditions. 
However, it has been reported frequently in the literature that direct extraction 
of the hair digest solution into a n-hexane:ethyl acetate mixture results in moving  
THC, CBD, CBN and 11-OH-THC from the digested hair solution into the organic 
solvent layer ‘Fraction (A)’. The carboxylated metabolite THC-COOH is generally 
extracted separately after acidifying the hair digest solution ‘Fraction (B)’. Based 
on the fact that the ionised status of THC, CBD, CBN and 11-OH-THC did not 
prevent them from being more soluble in the organic solvent, there must be 
another reason that THC-COOH is retained in the aqueous layer.  
The carboxylic acid group present on the THC-COOH structure is considered to be 
a highly polar organic functional group. This polarity results from the presence of 
a strongly polarized carbonyl (C=O) group and hydroxyl (O-H) group. The O-H group 
here is even more strongly polarized than the O-H group of alcohols due to the 
presence of the adjacent carbonyl moiety. These structural features not only 
enhance dipole strength, but also are responsible for the acidity of THC-COOH. 
Also, as a result of the ability to form "solubilizing" H-bonding interactions with 
like molecules and water as shown in Figure 3-1 and Figure 3-2, THC-COOH displays 
relatively high water solubility compared to the other cannabinoids.  
 
 
Figure 3-1 Intermolecular H-Bonding 
 
 
 
Figure 3-2 H-Bonding with Water 
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For LLE ‘Fraction (A), three main areas, as shown in Figure 3-3, were subject to 
investigation. Firstly, selection of the extraction solvent. Properties of proposed 
alternative solvents are shown in Table 3-3. In addition, DCM and a mixture of 
cyclohexane/ethylacetate (9:1, v/v) was prepared and included in the 
comparison. The choice of dissolving agent may become an issue in the process of 
refining a method. A range of solvents were assessed in order to determine which 
one extracted the most cannabinoids. Several factors must be considered while 
choosing a solvent to extract a drug from the matrix in addition to its powder to 
dissolve the required compounds which include selectivity, density, toxicity, 
volatility, reactivity, physical hazards and miscibility with aqueous media. Five 
solvents were examined as potential alternatives to n-hexane due to health and 
safety concerns related to it. Percentage of recovery and cleanness of extract 
were the main criteria of selection. Secondly, optimisation of selected solvent 
composition. As the selected solvent was a mixture of two solvents, the selected 
solvent composition was subject to further optimisation. Thirdly, the effect of 
centrifugation duration on extract cleanness. 
Table 3-3 Solvents properties 
Solvent Formula 
Density 
(g/mL) 
Sol. in H2O 
(% at 20 °C) 
Relative 
polarity 
cyclohexane C6H12 0.779 0.005 0.006 
ethyl acetate C4H8O2 0.894 8.7 0.228 
methyl t-butyl ether (MTBE) C5H12O 0.741 4.8 0.124 
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Figure 3-3 A diagram showing areas of optimisation for LLE ‘Fraction (A). (A) selection of 
extraction solvent, (B) optimisation of selected solvent composition, and (C) optimisation of 
sample centrifugation duration after LLE. 
 
For LLE ‘Fraction ‘B’, the THC-COOH is isolated into organic solvent by converting 
it from its water soluble form to the insoluble non-ionic acid form by acidification. 
As different acidification methods were proposed in the literature, the most 
frequently reported methods were used and compared in this study.  
 
 THC, CBN, CBD,11-OH-THC (Fraction ‘A’) 
 Experimental - Selection of extraction solvent  
Selection of extraction solvent was carried out in two stages. Firstly, extraction 
recoveries of drugs of interest from the spiked aqueous digestion solution (1mL 
1M NaOH) without involving hair matrices were calculated. Later, 40-50 mg of hair 
was weighed out and spiked with the same concentrations of analytes. For both 
recovery experiments, four sets of the following two levels were prepared; 200 
and 400 ng of THC, CBD, CBN and 11-OH-THC. Alkaline hydrolysis was carried out 
according to the conditions described in section3.3.7. Hair digest solution was first 
left to cool at room temperature and then centrifuged for 10 min at 2500 rpm and 
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supernatant was then transferred to clean glass vial. 1.5 mL of the extracting 
organic solvent, methyl-t-butyl ether, ethyl acetate, cyclohexane, 
cyclohexane:ethylacetate (9/1, v/v), DCM were added. To standardise the 
process, the sample was then placed on a rotator for 5 min at speed 25 rpm instead 
of manual shaking (see Figure 3-4). The mixture was then centrifuged for 10 min 
at 2500 rpm to allow the two layers to separate. The organic phase was removed 
using a pasteur pipette to a clean 7 mL vial. Prior to evaporation, 200 ng of 
internal standards, THC-d3 and 11-OH-THC-d3, were added and evaporated to 
dryness under a gentle stream of nitrogen.at room temperature. Derivatisation 
was achieved with 30 µl of BSTFA + 1%TMCS at 80 oC for 20 mins. Vials were then 
left to cool down at RT for 5 minutes and transferred to GC vial for injection. 
 
Figure 3-4 Rotator 
 
 Experimental - Optimisation of solvent composition 
The solvent composition is important to simultaneously extract THC, CBD, CBN 
and 11-OH-THC from hair. For selection of the optimal solvent composition, 
extraction recoveries of cyclohexane: EtOAc at two compositions (9:1, v/v) and 
(3:1, v/v) were calculated in triplicate at two different levels; 200 and 400 ng. 
LLE was carried out according to the procedure described in section 3.4.2.1 
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 Experimental - Effect of centrifuge duration 
The centrifuge Is used to separate components of a mixture on the basis of particle 
size or density. In LLE, centrifugation is employed to separate the two immiscible 
layers and precipitate any unwanted particles suspended in the organic layer.  
Since the organic layer will contain interferences, increasing the centrifugation 
time to obtain cleaner extracts, was proposed. Two different centrifugation 
durations, 10 and 30 minutes, were assessed. Visual observation of the extract, 
chromatographic baseline and noise, and extraction recoveries were the 
assessment criteria. Analyses were carried out in triplicate at two levels, 200 and 
400 ng, and the average calculated. LLE was carried out according to the 
procedure described in Section 3.4.2.1 using the optimal solvent composition 
(cyclohexane: EtOAc (3:1, v/v)). 
 THC-COOH (Fraction ‘B’) 
 Experimental - Selection of sample acidification methods  
After optimisation of the LLE procedure for analytes extracted in fraction ‘A’, the 
remaining cannabinoid THC-COOH had to be extracted from fraction ‘B’. As it was 
necessary to adjust the pH prior to carrying out the second cycle of LLE, the 
literature was reviewed for the reported acidification methods. Different volumes 
of the following four acids were the most frequently reported:  
A. Acetic acid (114,115,131,137,138) 
B. Acetate buffer with Acetic acid (140,141,147) 
C. Formic acid (142,164) 
D. Hydrochloric acid (HCl) (150,167) 
 
Following a review of the literature, it was found that the influence of 
acidification of the basic hair digest on the THC-COOH extraction recovery has 
never been reported. 120 µl acetic acid, 500 µl acetic acid, 1000 µl acetic acid, 
1mL of 0.1M sodium acetate buffer (pH 4.5) and 200 µl acetic acid, 50 µl formic 
acid, and 100 µl HCl were used for acidification and compared against each other. 
Three sets of 40-50 mg fortified hair matrix with 200 and 400 ng of THC-COOH 
were prepared for each acidification method. Firstly, the prepared samples were 
subject to LLE using cyclohexane:EtOAc (3/1, v/v)as described in section 3.4.2.1. 
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The, remaining aqueous layer was acidified using the acids described above. A 
second cycle of LLE using 1.5 mL of cyclohexane:EtOAc (3/1, v/v) was carried out. 
The sample was then placed on a rotator for 5 min at speed 25 rpm and centrifuged 
for 10 min at 2500 rpm. The organic layer was transferred to a clean 7 mL vial. 
Prior to evaporation, 200 ng (200 µl of 1 µg/mL) of internal standard, THC-COOH-
d3, was added and evaporated to dryness under gentle stream of nitrogen.  
Derivatisation was achieved with 30 µl of BSTFA with 1%TMCS at 80 oC for 20 mins. 
The vial was cooled down to RT for 5 minutes and transferred to GC vial for 
injection. 
 Simultaneous extraction of all cannabinoids using LLE  
 Rationale 
The extraction method that will, simultaneously, extract all cannabinoids is 
preferable when an advanced analytical instrument has the capabilities to achieve 
the required sensitivity for all analytes. The ionisation status of THC-COOH is 
important for analyte solubility, therefore, it was investigated whether an early 
acidification of the basic hair digest solution would be a suitable method for 
simultaneous extraction of all cannabinoids in a single fraction. Mercolini et al 
and Shah et al reported an early acidification of the basic hair digest solution, 
with formic acid and HCl, respectively, to extract THC and THC-COOH 
simultaneously in one fraction using LLE (142,167). 
 Experimental 
The basic hair digest solution was acidified using 100 µl HCl in three sets of hair 
samples spiked with 200 and 400 ng. The mixture was then extracted using 
cyclohexane: ethyl acetate (3/1, v/v) and derivatised according to the procedure 
described in the section 3.4.2.1. 
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 LLE versus SALL for THC-COOH extraction 
 Rationale for SALL 
Due to the low concentrations targeted for THC-COOH in hair, an extraction 
method with an extremely clean output and high recovery is required. The 
conventional LLE does not provide the desired extract cleanness. A SALL method 
was proposed as an efficient alternative to traditional LLE for extraction of THC-
COOH in fraction (B). This method is claimed to provide high analyte recoveries, 
cleaner extracts, no emulsion formation, and significant reduction in sample 
preparation time. SALL utilizes the same water immiscible solvent systems for 
analyte extraction. In SALL, the aqueous sample is immobilised on an inert 
support, and the organic phase flows through the support instead of shaking the 
two immiscible phases together. A general SALL protocol is shown in Figure 3-5. 
Unlike SPE, the entire loaded sample is absorbed onto the extraction bed and does 
not go to waste. Therefore, the capacity of the SALL is critical and the sample 
volume to be loaded should not exceed the recommended limit to be able to 
absorb the whole sample. 
 
Figure 3-5 Extraction procedure for THC-COOH using SALL cartridges. 
 
 Experimental 
Two sets of 40-50 mg hair were prepared to compare a traditional LLE method 
against SALL. Each set was composed of triplicate samples for three levels at 1, 
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10 and 100 ng of THC-COOH. The hair was then digested with 800 µl of 1M NaOH. 
As the SALL sorbent was unbuffered, the pH of pre-treated hair digest was 
adjusted by adding 200 µl of acetic acid. Sample was loaded onto the column (and 
a pulse of vacuum was applied for 3–5 seconds to initiate the flow. The sample 
was then allowed to completely absorb for 5 minutes. Cyclohexane/EtOAc (3:1 
v/v, 2x0.75mL) was then added and allowed to flow under gravity for 5 minutes. 
Organic solvent extract was collected and 10 ng of internal standard THC-COOH-
d3 was added prior to allowing it to dry under gentle stream of nitrogen. 
Traditional LLE extraction was carried out according to the procedure described 
in section 3.4.2.1 using 1.5 mL of cyclohexane:EtOAc (3:1, v/v). Extract was then 
derivatised by adding 30 µl TFAA-HFIP and incubating in heating block at 80 °C for 
30 minutes. 
 Solid-Phase extraction for THC-COOH 
 Rationale for SPE 
Solid-phase extraction uses siliceous or other materials with specific particle size 
(usually from 15 to 100 µm) in disposable plastic syringe barrels permitting 
sequential extraction, clean-up, and finally reproducible elution of THC-COOH at 
relatively low pressures. The employed SPE cartridge (CleanScreen® ZSTHC020) is 
copolymerized on a rigid, purified silica gel support. The two functional groups 
include a reverse phase, and an ion exchanger, primary amine. In anion-exchange 
SPE, the retention mechanism is the interaction of charged, anionic groups on the 
THC-COOH and charged, cationic functional groups on the sorbent, via ionic 
interactions as illustrated in Figure 3-6. SPE was proposed as an alternative 
extraction method to LLE and SALL for the remaining aqueous part (fraction ‘B’) 
of sample (A) or sample (B). Initially, the SPE method was investigated using a 
protocol based on previously published work for THC-COOH extraction from hair 
by Moore et al (141).  
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Figure 3-6 Mechanism of THC-COOH retention in the anion-exchange SPE columns 
 
 Experimental -SPE 
After acidification of the basic hair digest solution, the steps described in Figure 
3-7 was applied to the extraction of hair samples. 
 
Figure 3-7 Schematic diagram of a solid-phase extraction procedure.  
 
After hair digestion, as described in section 3.3.7, the solution was centrifuged 
for 10 mins at 2500 rpm. The supernatant was then poured into tubes containing 
acetic acid (1 mL), 1M acetic acid (3 mL), and 0.1M sodium acetate buffer (pH 
4.5, 2 mL). The tubes were capped, vortex mixed for 30 seconds and loaded onto 
the already conditioned SPE column (Figure 3-8 ‘A’). However, as soon as the 
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acidification solution was added to the supernatant, the solution turned turbid 
and produced a foul smell which is due to the sulphur containing amino acid, 
cysteine which is present in the hair structure. The formed particulates were 
found to either completely impede the sample flow through the column, even 
under full vacuum; or, impractically, increase the sample flow time. Authors of 
the published work were contacted for consultation. The response received 
doubted the completeness of the hair digestion. Therefore, to roll out this 
possibility, incubation time of hair with NaOH was increased to 2 hours. However, 
this did not solve the problem. To overcome this problem two amendments were 
proposed as follow: 
1. Method (B): addition of a 2nd centrifugation step after pouring the 
supernatant into the acidification mixture (Figure 3-8 ‘B’). 
2. Method (C): Elimination of the 1st centrifugation step, acidification of the 
sample and then centrifugation of the mixture prior to pouring the 
supernatant onto the extraction columns (Figure 3-8‘C’). 
 
Figure 3-8 Hair sample pre-treatment approaches prior to SPE.  
(A) One centrifugation takes place after hair hydrolysis, prior to acidification, (B) Two 
centrifugations takes place after hair hydrolysis and after acidification, (C) One 
centrifugation takes place after acidification  
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The effect of these changes on extraction recovery was then assessed by carrying 
out an extraction recovery study for both methods. Three sets of hair samples 
were prepared by weighing out 40-50 mg of hair. Each set consisted of two levels, 
200 and 400 ng, analysed in triplicate. 
 Experimental - Drug loss monitoring 
Since only picogram/femtogram amounts of THC-COOH are incorporated into hair, 
any minor drug loss during sample preparation is significant. Recovery of THC-
COOH from the standard derivatisation 3.5 mL vials was monitored. A calibration 
of eight concentrations (50, 100, 200, 500, 1, 2.5, 5 and 10 pg/50 mg) was 
derivatised by adding 30 µl TFAA-HFIP and incubating in heating block at 80 °C for 
30 minutes. The tube was then left to cool down at room temperature and then 
dried under a stream of nitrogen. Three sequential reconstitutions with 25 µl 
toluene from each vial was transferred to labelled auto sampler vials and injected.  
 Derivatisation 
 Rationale for derivatisation 
Derivatization is a technique commonly employed in forensic toxicology to 
enhance chromatographic separation and mass spectrometric identification. It is 
used to make polar drugs and metabolites less polar and thermally stable for GC- 
MS analysis. This process increases the molecular weights of the molecule and 
hence improves chromatography and selectivity. The advantageous use of a 
derivatising agent could extend beyond the chromatography to the ionization 
efficiency and producing more characteristic mass spectra. For analysis of 
cannabinoids in hair, two complementary instruments are usually employed; 
standard GC-MS with electron ionisation (EI) and GC-MS with negative chemical 
ionisation (NCI). Detection of THC-COOH in hair matrices needs superior sensitivity 
due to its extremely low concentrations. For this purpose, an MS equipped with a 
NCI source is frequently reported in the literature. Introducing functional groups 
that contain more halogen atoms, which have high electron affinity (e.g. fluorine), 
is believed to improve the detectability of a compound with NCI by making it more 
electronegative (168). As THC-COOH contains free carboxylic acids as well as 
hydroxyl groups, combinations of derivatising reagents were used to introduce 
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fluorine atoms on both the carboxyl and hydroxyl groups and hence enhance 
ionisation efficiency and maximise sensitivity. In addition, the selective 
methylation of the carboxyl group is claimed to improve the sensitivity in a 
recently published work carried out using liquid chromatography- negative 
electrospray MS (LC-ESI-MS) (163). The carboxyl group on THC-COOH was 
esterified using methyl iodide, PFPOH, and HFIP, while the hydroxyl group was 
perfluorinated using PFPA, TFAA and HFBA. The chemical properties of 
derivatising agents employed are shown in Table 3-4. 
Table 3-4 The chemical Properties of the employed derivatisation reagents 
Reagent Chemical structure 
Chemical 
Formula 
Molecular 
weight 
HFBA 
 
C6F14O3 410.06 
PFPA 
 
C6F10O3 310.05 
TFAA 
 
C4F6O3 210.03 
HFIP 
 
C3H2F6O 168.04 
PFPOH 
 
C3H3F5O 150.05 
Methyl iodide 
 
CH3I 141.94 
 
 Experimental 
Initial testing of all derivatisation reagents was carried out using unextracted 
standards. 100 µL of 1µg/mL individual working solutions with the same 
concentration of internal standard were transferred to 7 mL vials and dried under 
a stream of nitrogen before adding the derivatisation reagent. Derivatisation of 
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cannabinoids for GC-EI-MS analysis was achieved using 50 µl BSTFA with 1% TCMS. 
The vial was then capped and heated at 80 °C for 30 minutes.  
For the purpose of comparing the derivatisation reagents for NCI, experimental 
work was carried out in three stages; firstly, determination of reaction conditions 
for all reagent combinations, secondly, assessment of the chromatographic 
behaviour and MS characteristics of all derivatives, thirdly, further comparison of 
sensitivity in SIM-MS mode for derivatives with satisfactory results. 
 Conditions of derivatisation reactions  
According to the previous works in the literature, an incubation at 70-90 °C for 
10-30 minutes would usually provide satisfactory reaction conditions for the 
following combinations; PFPOH-PFPA, PFPOH-TFAA, PFPOH-HFBA, HFIP-PFPA, 
HFIP-TFAA, HFIP-HFBA. Therefore, 30 µl of PFPOH and HFIP and 50 µL of TFAA, 
PFPA, and HFBA was added, each separately, to the reaction medium after drying 
the standard. The mixture was then incubated for 20 minutes at 80 °C. When the 
derivatisation reaction involved selective methylation of a carboxyl group, the 
reaction was carried out in two steps. First, alkylation of the carboxyl group while 
maintaining the phenolic hydroxyl group unchanged by addition of 100 μL 
acetonitrile, an excess of a few crystals of solid sodium carbonate and 20 μL 
methyl iodide. This mixture was incubated for 1.5 h at 70 °C. Secondly, to 
derivatise the hydroxyl group, the mixture was dried and either 50 µL of TFAA, 
PFPA, or HFBA was added and incubated for 20 minutes at 80 °C.   
 Chromatographic behaviour and MS characteristics using full-scan 
mode 
Chromatographic separation and MS characteristics were assessed by 
derivatisation of 100 µl of THC-COOH working solution at 1µg/mL and an 
equivalent concentration of its deuterated ISTD THC-COOH-d3. Each derivative 
was injected separately using NCI mode with full-scan covering the range from 
100-700 atomic mass units (amu). 
 Sensitivity comparison of selected derivatives using SIM mode. 
Using GC-NCI-MS operated in SIM mode, two levels of unextracted standards at 
100 and 1000 pg were derivatised and analysed in triplicate. 
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 Results – LLE 
 THC, CBN, CBD,11-OH-THC (Fraction ‘A’) 
 Selection of extraction solvent  
A range of solvents were assessed in order to determine which one extracted the 
most cannabinoids. The extract using DCM was excluded from the beginning as it 
was found to form white crystals that cannot be injected into the GC system. 
EtOAc and cyclohexane/EtOAc (9:1 v/v) were found to extract the most 
compounds. The mean percentage recoveries of THC, CBD, CBN and 11-OH-THC 
from digestion alkaline solution (1mL 1M NaOH) without hair using different 
solvents is shown in Table 3-5. All solvents achieved good recovery for THC ranging 
from 86.4% to 91.5%. MTBE gave good recoveries (>80.5%) with all analytes except 
CBD (mean=12.3%). The efficiency of pure cyclohexane for extracting all 
cannabinoids in fraction (a) simultaneously was found to be poor. Despite the good 
percentage recoveries of THC and, to lesser extent, CBD with cyclohexane, mean 
%recoveries 91.5 and 80.1, respectively, the percentage recoveries of the other 
two cannabinoids were much lower, 48.8% and 16.5%, for CBN and 11-OH-THC, 
respectively. Cyclohexane/EtOAc (9:1 v/v) and ethyl acetate were found to 
extract the most compounds with extraction recoveries ranging from 76.4% to 
96.6%. Therefore, an extraction recovery of spiked blank hair matrices was carried 
out using cyclohexane/EtOAc (9:1 v/v) and ethyl acetate. Despite the fact that 
the percentage recoveries of most analytes dropped by 10-30%, both solvents gave 
reasonable percentage recoveries with the exception of CBD as shown in Table 
3-6. It should, however, be noted that the solvent mixture cyclohexane/EtOAc, of 
high non-polar solvent content, gave a relatively clean extract.  
Table 3-5 Mean extraction recoveries of cannabinoids from 1 mL 1M NaOH without hair  
Solvent THC CBD CBN 11-OH-THC 
Cyclohexane/EtOAc (9:1 v/v) 89.3 96.6 76.4 78.9 
Cyclohexane 91.5 80.1 48.8 16.5 
EtOAc 91.3 94.9 76.7 90.8 
MTBE 86.4 12.3 80.5 88.1 
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Table 3-6 Mean extraction recoveries of cannabinoids from 50 mg of hair digested with 1 mL 
1M NaOH using the solvent that achieved the recovery without hair. 
Solvent THC CBD CBN 11-OH-THC 
Cyclohexane/EtOAc (9:1 v/v) 70.3 28.7 53.6 68.6 
EtOAc 82.1 14.8 38.3 85.9 
 
 Optimisation of solvent composition 
Although 9 to 1 solvent composition of cyclohexane to EtOAc was found to be the 
best in the previous experiment, the percentage recoveries of CBD, CBN and 11-
OH-THC were found to vary significantly between days. Cyclohexane/EtOAc (3:1, 
v/v) instead of (9:1, v/v) was proposed and assessed. This new solvent composition 
(3:1, v/v) gave a better extraction percentage recovery for 11-OH-THC. The other 
cannabinoids, THC, CBN and CBD, gave similar percentage recoveries at the two 
solvent compositions as shown in Table 3-7  
Table 3-7 Mean extraction recoveries of cannabinoids from hair digested with 1 mL NaOH 
using cyclohexane/EtOAc mixture with two different compositions. 
Solvent THC CBD CBN OH-THC 
Cyclohexane/EtOAc (9:1 v/v) 86.4 105.1 107.5 37.6 
Cyclohexane/EtOAc (3:1 v/v) 97.2 95.9 94.2 87.9 
 
 Effect of centrifuge duration 
Centrifuge duration was assessed at 10 and 30 minutes. The results of extraction 
recovery and a visual examination of the chromatogram shows that centrifuge 
duration does not have a significant effect on the extraction yield or cleanliness 
of the extract. Extraction recoveries were similar to the values reported 
previously for Cyclohexane/EtOAc (3:1 v/v) in Table 3-7. 
 THC-COOH (Fraction ‘B’) 
Extraction recovery results with different acidification mixtures are shown in 
Table 3-8. Acetic acid seems to be the most appropriate acidification method. The 
lowest volume of acetic acid (120 µl) resulted in the best recovery with good 
reproducibility. It was not possible to calculate the percentage recovery of THC-
COOH from after acidification using the other three methods. No response for 
THC-COOH was recorded. 
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Table 3-8 Mean extraction recoveries of THC-COOH from hair digested with 1 mL NaOH 
using cyclohexane/EtOAc mixture with two different acidification methods. 
Acidification method THCA s CV 
120 µl Acetic acid 71.8 4.5 6.2 
500 µl Acetic acid 65.3 6.6 10.1 
1000 µl Acetic acid 61.2 10.8 17.7 
 
 Simultaneous extraction of all cannabinoids using LLE  
The early acidification of hair digest with 100 µl HCl resulted in acceptable 
recovery for THC and 11-OH-THC and poor recovery for THC-COOH as shown in 
Table 3-9. It was not possible to calculate the percentage recovery of CBD and 
CBN as no peaks were recorded for the monitored ions. 
Table 3-9 Mean extraction recoveries of cannabinoids from hair digested with 1 mL NaOH 
and acidified with 100 µl HCl prior to LLE with cyclohexane/EtOAc mixture.  
THC 11-OH-THC THC-COOH 
mean 86.74 80.41 14.76 
s 9.34 7.77 2.23 
cv 10.77 9.66 15.13 
 
 LLE versus SALL for THC-COOH 
Table 3-10 shows the percentage extraction recoveries of THC-COOH using LLE 
and SALL. It can be clearly concluded that LLE provided a better recovery. No 
significant improvement in extract cleanness was noticed. Therefore, SPE method 
was tested. 
Table 3-10 Mean, standard deviation and coefficient of variation of THC-COOH percentage 
recovery using LLE and SALL  
mean s CV 
LLE 98.16 16.22 16.52 
SALL 57.23 6.99 12.21 
 
 SPE for THC-COOH 
Table 3-11 shows the percentage extraction recoveries of THC-COOH from hair 
matrices using SPE. Three different approaches were compared. Despite the 
superior recovery that was noticed with approach (A), it was excluded due to the 
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reasons discussed earlier is section 3.11.2. Approaches (B) and (C) were found to 
have similar extraction efficiencies with slight superiority for approach (C). 
Therefore, approach (C), which involves one centrifugation step conducted after 
sample acidification, was employed for method validation and case sample 
analysis. 
Table 3-11 Mean, standard deviation and coefficient of variation of THC-COOH percentage 
recovery using SPE after three approaches for hair sample pre-treatment 
 Mean s CV 
Approach (A) 58.4 10.8 18.5 
Approach (B) 40.3 18.1 44.9 
Approach (C) 48.9 21.1 43.1 
 
 Drug loss monitoring 
As shown in Figure 3-9, the first reconstitution from the 50, 125, 250 and 500 pg 
vials and second reconstitution of the highest level were found to show a response 
which means some of the drug was left over in the reaction medium. The signal 
from the first reconstitution was calculated and ranged from 14.9% to 22.4% of 
the original signal. To improve detection sensitivity, the step of transferring the 
organic layer to a 7 mL vial for derivatisation and then to an auto sampler vial for 
injection was shortened. Instead, the LLE organic layer was transferred straight 
into a silanised high recovery vial (See Figure 3-10) which was used as a 
derivatisation medium and an auto-sampler vial for injection.  
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Figure 3-9 Comparison of detector response for the original, first and second reconstitutions 
of 4 levels of unextracted standards 
 
 
 
Figure 3-10 Silanised High Recovery (HR) vial 
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 Results – Derivatisation 
 Derivatisation of THC, CBD, CBN, 11-OH-THC and THC-
COOH for GC-EI-MS analysis 
Derivatisation with trimethylsilyl (TMS) is most commonly used when GC-MS with 
EI detection is the employed analytical technique (system 1). TMS derivatives are 
formed by attaching to the hydroxyl and/or carboxyl groups present on the THC, 
CBD, CBN, 11-OH-THC, and THC-COOH structures. Structures of formed 
cannabinoids TMS derivatives are shown in Figure 3-11. 
 
THC-TMS 
MW = 386 
 
11-OH-THC-2-TMS 
MW = 474 
 
CBD-2-TMS 
MW = 458 
 
THC-COOH-2-TMS 
MW = 488 
 
 
 
 
CBN-TMS 
MW= 382 
Figure 3-11 Chemical structure of cannabinoids TMS derivatives 
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The extracted ion chromatograms and full scan electron ionisation mass spectra 
for THC, CBD, CBN, 11-OH-THC, THC-COOH, their deuterated ISTD THC-d3, 11-
OH-THC-d3 and THC-COOH-d3 and standard TMS derivatives are shown in Figure 
3-12 to Figure 3-19.  
(A) 
 
(B) 
 
Figure 3-12 Extracted ion chromatograms for THC-TMS [m/z 371, 386, 303] (A), and its full 
scan electron ionisation (EI) mass spectra (B). 
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(A) 
 
(B) 
 
Figure 3-13 Extracted ion chromatograms for CBD-2-TMS [m/z 390, 337, 458] (A), and its full 
scan electron ionisation (EI) mass spectra (B). 
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(A) 
 
(B) 
 
Figure 3-14 Extracted ion chromatograms for CBN-TMS [m/z 367, 368, 382] and its full scan 
electron ionisation (EI) mass spectra (B). 
  
96 
 
 
(A) 
 
(B) 
 
Figure 3-15 Extracted ion chromatograms for THC-COOH-2-TMS [m/z 371, 373, 488] (A), and 
its full scan electron ionisation (EI) mass spectra (B). 
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(A) 
 
(B) 
 
Figure 3-16 Extracted ion chromatograms for 11-OH-THC-2-TMS [m/z 371, 474, 459] (A), and 
its full scan electron ionisation (EI) mass spectra (B). 
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(A) 
 
(B) 
 
Figure 3-17 Extracted ion chromatograms for THC-d3-TMS [m/z 374, 389] (A), and its full 
scan electron ionisation (EI) mass spectra (B). 
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(A) 
 
(B) 
 
Figure 3-18 Extracted ion chromatograms for 11-OH-THC-d3-2-TMS [m/z 374, 477] (A), and 
its full scan electron ionisation (EI) mass spectra (B). 
  
100 
 
 
 
(A) 
 
(B) 
 
Figure 3-19 Extracted ion chromatograms for THC-COOH-d3-2-TMS [m/z 374, 476] (A), and 
its full scan electron ionisation (EI) mass spectra (B). 
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THC and CBD have the same molecular mass prior to derivatisation. As there are 
two hydroxyl groups on the CBD structure and only one hydroxyl group present on 
the THC structure, different retention times and mass spectra are elucidated after 
derivatisation with silylation reagent. This is not achievable with some other 
derivatisation reagents such as perfluorinated anhydrides. The use of 
perfluorinated anhydrides alone or coupled with perfluoroalcohols, such as 
HFIP/TFAA or PFPOH/PFPA, will result in identical retention times and mass 
spectra. If analysis of one of the two only is of interest, consideration must be 
given to the possibility of the presence of the other in a sample when choosing 
the method of derivatization. Otherwise, a false positive or high concentration 
will be reported for THC. 
 Derivatisation of THC-COOH for 2D GC-NCI-MS 
analysis 
 Conditions of derivatisation reactions  
Determination of optimal reaction conditions for all reagent combinations was 
achieved by reviewing the literature for frequently reported conditions. As the 
primary aim was to select the combination that provides satisfactory 
chromatography and mass spectra characteristics, no further optimisation was 
carried out. Chemical structures of all combinations are shown in Figure 3-20, 
Figure 3-21and Figure 3-22.  
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Figure 3-20 Chemical structures of THC-COOH derivatives by esterification of carboxyl 
group with iodomethane and acylation of hydroxyl group with three perfluorinated 
anhydrides; TFAA, PFPA, and HFBA. 
 
 
Figure 3-21 Chemical structures of THC-COOH derivatives by esterification of carboxyl 
group with HFIP and acylation of hydroxyl group with three perfluorinated anhydrides; 
TFAA, PFPA, and HFBA.  
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Figure 3-22 Chemical structures of THC-COOH derivatives by esterification of carboxyl 
group with PFPOH and acylation of hydroxyl group with three perfluorinated anhydrides; 
TFAA, PFPA, and HFBA. 
 
 Chromatographic behaviour and MS characteristics using full-
scan mode 
Analysis of derivatives was carried out using 2D GC-MS in full-scan mode. As 
unextracted standards were used, the deans switch valve was kept on all the time 
and the cryo focusing trap was switched off with all derivatives to produce 
comparable data for all combinations. Therefore, there was no need to identify 
the retention time for each derivative on the FID at this stage. Ammonia was 
employed as buffer gas in NCI due to its superior thermalizing power. This power 
is estimated to be approximately seven times higher than methane. However, less 
fragmentation is expected with ammonia in the chemical ionization spectrum. 
This is because the proton infinity of ammonia (204.0 kcal/mole) is higher than 
that of methane; hence, less energy is transferred in the ionization reaction.   
Chromatographic and mass spectrometric identification data were assessed 
according to the European Commission (EC) recommendations (169). The minimum 
acceptable retention time for the analyte under examination is twice the 
retention time corresponding to the void volume of the column. All derivatives 
were found to elute from the two capillary columns at acceptable retention times. 
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The shortest retention time was achieved with the HFIP-PFPA derivative at 9.8 
minutes. Chromatographic retention times and MS characteristics of all derivatives 
are shown in Figure 3-23, Figure 3-24, and Figure 3-25, and summarised in Table 
3-12. All derivatives that involve methylation of carboxyl group with iodomethane 
were found to have poor mass spectra with only one ion of good intensity. The 
best mass spectra were produced from derivatives that involved using HFIP for 
esterification of the carboxyl group. Therefore, these three derivatives were 
subject to further comparison of their sensitivity using SIM mode.  
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(A)  
(B)  
(C)  
 
(D)  
Figure 3-23 FS chromatograms of THC-COOH derivatives using a unextracted standard at 1µg/mL, (B) FS-NCI-MS of THC-COOH- iodomethane-TFAA, (C) 
FS-NCI-MS of THC-COOH- iodomethane -PFPA, (D) FS-NCI-MS of THC-COOH- iodomethane -HFBA derivative  
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(A)  
(B)  
(C)  
(D)  
Figure 3-24 FS chromatograms of THC-COOH and THC-COOH-d3 derivatives using a unextracted standards at 1µg/mL, (B) FS-NCI-MS of THC-COOH-HFIP-
TFAA, (C) FS-NCI-MS of THC-COOH-HFIP-PFPA, (D) FS-NCI-MS of THC-COOH-HFIP-HFBA derivative 
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(A)  
(B)  
(C)  
(D)  
Figure 3-25 (A) FS chromatograms of THC-COOH derivatives using a unextracted standard at 1µg/mL, (B) FS-NCI-MS of THC-COOH-PFPOH-TFAA, (C) FS-
NCI-MS of THC-COOH-PFPOH-PFPA, (D) FS-NCI-MS of THC-COOH-PFPOH-HFBA derivative ........................................................................................
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Table 3-12 Summary of derivatisation combinations RT and fragmentation ions. 
Combination RT (min) drug ions (m/z) IS ions (m/z) Common 
CH3-TFAA 15.8 454 457 - 
CH3-PFPA 15.0 484 487 147 
CH3-HFBA 15.2 534 537 197 
HFIP-TFAA 10.2 422, 590 425, 593 166 
HFIP-PFPA 9.8 620, 472, 492 623, 475, 495 147 
HFIP-HFBA 9.9 492, 670, 522, 344 495, 673, 525, 347 197 
PFPOH-TFAA 13.0 572, 422 575, 425 - 
PFPOH-PFPA 11.8 602, 474 605, 477 147 
PFPOH-HFBA 11.9 652, 474 655, 477 197 
Underlined ions are for fragments with highest intensities. 
 
 Sensitivity comparison of selected derivatives using SIM mode. 
In SIM mode, the instrument is set to gather data at the masses of interest, instead 
of stepping the mass filter over a wide range of masses. Since the mass 
spectrometer collects data at only the masses of interest, it responds only to those 
compounds that possess the selected mass fragments. In essence, the instrument 
is focused on only the compounds of interest. Also, because only a few masses are 
monitored, much more time may be spent looking at these masses, with the 
attendant increase in sensitivity. Ions of highest intensity were chosen for SIM 
methods. Ions that were found mutual in the analyte of interest and its deuterated 
ISTD were avoided. European Commission recommends a minimum of 3 
identification points for confirmation assays of cannabinoids using GC-EI or CI-MS. 
Each ion in SIM mode is counts as one point. Therefore, three ions are necessary 
for satisfactory compound identification. It was possible to select three ions for 
HFIP-PFPA and HFIP-HFBA derivatives, however, only two ions were available from 
the HFIP-TFAA derivative mass spectrum for the SIM method. In addition to the 
analyte ions, two ions from the deuterated ISTD derivatives were added to each 
SIM group. Due to the very close retention times of the derivatives, three separate 
SIM methods were created for analysis. The methods shared exactly the same 
parameters except MS ions and dwell time. Dwell time for each SIM group was 
ensured to yield 15-20 cycles across a peak. Therefore, 100 ms was selected with 
109 
 
 
4 ions per group, and 50 ms for 5 ions per group. After triplicate analysis using 
unextracted standards (100 and 1000 pg), the signals produced from HFIP-PFPA 
and HFIP-HFBA derivative ions were slightly better than those from TFAA-HFIP. 
The combination of HFIP-PFPA was initially selected as the derivatisation reagent. 
However, the reaction outcome was not reproducible when used for derivatisation 
of the hair extract later in the study. The best derivatisation combination that 
produced acceptable sensitivity and reproducible data was determined to be 
TFAA-HFIP. 
 Summary 
The work carried out in this chapter was to select the optimal extraction 
conditions for all cannabinoids from hair samples. Cyclohexane:EtOAc (3/1, v/v) 
was found be the best extracting solvent for THC, CBD, CBN and 11-OH-THC. LLE 
resulted in better extraction recoveries for THC, CBD, CBN and 11-OH-THC from 
hair than SALL. SPE was selected as the best option for extraction of THC-COOH 
from hair. Acidification of the hair digest followed by centrifugation was found to 
be the most practical option for preparing the hair digest for SPE. Silanised high 
recovery vials were employed with both extractions and resulted in al least 15% 
improvement in detection sensitivity. Derivatisation of THC-COOH with TFAA-HFIP 
combination was the most appropriate option that provided reproducible reaction 
outcomes. 
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 Method development and validation for 
cannabinoids using GC-EI-MS and 2D GC-NCI-
MS 
 Introduction 
In this project, sample preparation and extraction methods were developed and 
optimised as explained in the previous chapter. Direct LLE of the hair digest 
selectively and efficiently isolated THC, CBD, CBN and 11-OH-THC, and the extract 
was derivatised using BSTFA with 1% TMCS and analysed using GC-EI-MS. Extraction 
of the hair digest using SPE after pH adjustment produced clean extracts with 
reasonable recovery for THC-COOH, when derivatised with HFIP-TFAA and 
analysed using 2D GC-NCI-MS. Before these two analytical methods can be 
employed for the quantitative determination of cannabinoids in hair samples from 
cannabis users, they have to be validated to ensure they are fit for purpose. Many 
organisations or scientific societies have published guidelines or recommendations 
for method validation aiming at ensuring high quality and reliable data.  These 
have included The Food and Drug Administration (FDA) Guidance for industry-
bioanalytical method validation (2001) (170), Society of Forensic Toxicologists/the 
American Academy of Forensic Sciences (SOFT/AAFS) forensic toxicology 
laboratory guidelines (2006) (5),  the United Kingdom and Ireland Association of 
Forensic Toxicologists (UKIAFT) forensic toxicology laboratory guidelines (2010) 
(171), and the standard practices for method validation in forensic toxicology 
which was published by the Scientific Working Group for Forensic Toxicology 
(SWGTOX) in May 2013 (172). According to the latest SWGTOX guidelines, 
validation parameters vary depending on whether the method will be used for 
qualitative or quantitative analysis. In the case of a qualitative method, only a 
few parameters are subject to investigation including; the limit of detection, 
interference study, carryover and stability of analyte in given matrices. For 
quantitative methods, where concentrations are to be reported, additional 
parameters are subject to investigation including; linearity, bias and precision, 
limit of quantification. 
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 Aims 
The aim of work presented in this chapter is to describe the two instruments 
acquisition parameters, principles of keys components in the 2D GC-NCI-MS, 
included establishing the approximate retention time on the primary column, the 
Dean’s switch cut time, the GC oven and cryo-focusing trap settings, the retention 
times on the secondary column and the correct ions to monitor using SIM. 
Moreover, to quantitatively validate the GC-EI-MS method for quantitation of THC, 
CBD, CBN and 11-OH-THC and 2D GC-NCI-MS for quantitation of THC-COOH using 
fortified hair matrices. Sample preparation was carried out using the optimised 
procedure reported in the previous chapter. 
 Gas chromatography–mass spectrometry (GC-MS) 
Gas chromatography–mass spectrometry (GC-MS) is an analytical method that 
combines the features of gas-chromatography and mass spectrometry to identify 
different substances within a test sample. GC-MS has several applications 
including but not limited to drug detection, fire investigation, environmental 
analysis, explosives investigation, and identification of unknown samples. It has 
been widely regarded as a "gold standard" for forensic substance identification 
due to its high specificity. The main component of GC-MS is shown in Figure 4-1. 
  
 
Figure 4-1 Schematic diagram showing the main components of standard GC-MS system 
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The main two components of the GC system are the inlet (or injector) and the 
capillary column. The main role of inlet is to transfer the sample to the capillary 
column by converting the analytes into its volatile state and introducing it into a 
continuous flow of carrier gas, typically, helium. The most popular inlet for 
capillary column gas chromatography is the combined split/splitless inlet. The 
other GC component is the capillary column. The main function of the GC column 
is to separate the different components of a mixture based on their polarities. 
This causes each compound to elute at a different time, known as the retention 
time (RT) of the compound. Capillary column is composed of tubing, usually made 
of fused silica and stainless steel, and stationary phase. There are many stationary 
phases. Most are high molecular weight, thermally stable polymers that are liquids 
or gums. The most common stationary phases of this type are the polysiloxanes 
and polyethylene glycols. The most basic polysiloxane is the 100% methyl 
substituted. When other groups are present, the amount is indicated as the 
percent of the total number of groups. For example, a 5% diphenyl-95% dimethyl 
polysiloxane contains 5% phenyl groups and 95% methyl groups. For GC-MS, a "MS" 
version is available commercially and is claimed to provide low column bleeding 
into the MS. This is achievable by strengthening polymer siloxane backbone by 
incorporating phenyl or phenyl-type groups. An ultra-inert version is also recently 
available and is claimed to provide the lowest column bleed and highest column 
inertness for a wide range of analytes, including active compounds and trace level 
samples. DB-5MS, HP-5MS UI, DB-17MS are the columns employed in the work 
presented in this chapter and are all examples of these columns. The two 
dimensional GC-MS (2D GC-MS or GCxGC-MS) is an advanced version of the 
conventional GC-MS. This instrument employs a pair of GC columns , usually of 
different polarities, connected in series through a modulator. All effluent from 
the first column (comprehensive) or part of it (heart-cut) is trapped in the 
modulator for a fixed period of time before being focused and injected into the 
second column.  
The effluent from the standard GC-MS or 2D GC-MS, carrying the analytes of 
interest, passes through the transfer line (interface) and enters into the mass 
spectrometer. The three main components of the MS are the ionisation source, 
analyser and detector. The most common form of ionization sources is electron 
ionization (EI), also called electron impact. In this ionisation method, molecules 
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that arrive into the source body are bombarded with free electrons, emitted from 
a filament, causing the molecule to fragment in a characteristic and reproducible 
way. This "hard ionization" technique produces fragments of low mass to charge 
ratio (m/z) and few, if any, molecular ions reach the molecular mass unit. 
Typically, 70 eV (electron Volts) is the electron energy applied to the system in 
the EI source. The common usage of 70 eV as the electron energy enables spectra 
comparison with spectra libraries software usually integrated into the analysis 
system and provided by the manufacturer. Examples of most known sources of 
libraries include National Institute of Standards (NIST), Wiley, the American 
Academy of Forensic Scientists (AAFS). 
Chemical ionisation (CI) is a softer ionisation method than electron impact (EI). 
The layout of a chemical ionization ion source is shown is Figure 4-2. The principle 
of CI is transferring electron, proton, or other charged species from the reagent 
gas to the neutral molecule of interest in its gaseous phase. In negative chemical 
ionization (NCI) mass spectra are obtained by deprotonation of acidic analytes like 
THC-COOH. Electron capture (EC) or electron attachment is one process of special 
interest when performing NCI. Its importance comes from the superior sensitivity 
it provides with many analytes. In EC, a freely moving external electron, not 
provided by reagent gas, is incorporated into the orbital of the molecule and EC 
occurs when these electrons approach their thermal energy.  
 
Figure 4-2 Schematic layout of a chemical ionization ion source.  
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Mass analyser is component of MS responsible for filtering sample ions, based on 
their mass-to-charge ratio (m/z). The most common mass analysers employed in 
the MS is the single quadrupole (SQ). SQ consists of four cylindrical rods, set 
parallel to each other and connected together electrically. A radio frequency (RF) 
voltage with a DC offset voltage is applied between one pair of rods and the other. 
Ions produced by ionisation source will travel down the quadrupole between the 
rods, however, only ions of certain m/z will reach the detector for a given ratio 
of voltages and other ions will collide with the rods. The mass analyser is often 
operated in two modes; full-scan (FS) and selected ion monitoring (SIM). When 
collecting data in FS mode, a target range of mass fragments, usually dictated by 
molecular weight of targeted analytes or derivatives, is determined and put into 
the instrument's method. Typically, a range of 50-400 m/z would be monitored. 
The sensitivity of the instrument in FS mode is decreased due to performing fewer 
scans per second since each scan will have to detect a wide range of mass 
fragments. The two main uses of FS mode are the identification of unknown 
substances in a sample and to help in instrument method development during 
early stages by determining the retention time and the mass fragment fingerprint 
of a particular analyte before moving to a SIM mode.  
In SIM mode, much lower detection limit is achievable as only certain ion 
fragments of good intensities, selected from FS spectrum, are targeted.  This 
means that the analyser is only looking at a small number of ions during each scan. 
The final component of the MS is the detector. The detector role is to record 
either the charge induced or the current produced when an ion passes by or hits 
a surface. Typically, some type of electron multiplier is often used. 
 GC-EI-MS  
 Analytical instrument parameters 
The GC–MS system used for analysis of THC, CBD, CBN and 11-OH-THC is an Agilent 
GC model 6890 Series coupled with an Agilent 5975N mass selective detector. 
Cannabinoid TMS derivatives were separated on a fused silica capillary column 
DB5-MS+DG (30 m length x 0.25 mm (ID) x 0.25 µm film thickness). The oven 
temperature program is shown in Table 4-1. The temperatures for the injection 
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port, ion source, quadrupole and interface were set at 250, 230, 150 and 280 oC, 
respectively. Split injection was used with a split ratio of 1:1 to inject 1 µl. The 
flow of the carrier gas (helium) through the column was set constant at 1.0 mL/ 
min. To determine the retention times and characteristic mass fragments, 
electron impact (EI) mass spectra of the analytes were recorded by total ion 
monitoring. For quantitative analysis the chosen diagnostic mass fragments were 
monitored in selected ion monitoring (SIM) mode m/z:371, 386, 303 for THC–TMS; 
390, 337, 458 for CBD–di-TMS; 367, 368, 382 for CBN–TMS, 371, 474, 459 for 11-
OH-THC di-TMS; and 374, 389 for THC–TMS-d3 as internal standard for THC, CBD 
and CBN, and 374, 462 for 11-OH-THC 2-TMS-d3 as internal standard for 11—OH-
THC. For quantification, peak area ratios of quantifier ions of the analytes to the 
internal standard (underlined) were calculated as a function of the concentration 
of the substances. The MSD was used in the electron impact mode at 70 eV. The 
MSD was auto-tuned weekly with perfluorotributylamine. Data acquisition and 
analysis were performed using standard software supplied by the manufacturer 
(Agilent ChemStation). 
Table 4-1 Oven temperature program of GC-EI-MS 
Initial temperature: 80 °C Initial time: 1.00 min 
Ramps:   
Rate (°C/min) Final temp Final time 
30 270 5.00 
10 300 5.00 
Run time: 20.33  
 
 Initial testing of the method  
In order to identify the retention times and mass fragments of each compound and 
its deuterated ISTD, 100 µl of CBD, CBN, THC, 11-OH-THC working standard 
solutions and 100 µl of THC-d3 and 11-OH-THC-d3 working standard solutions all 
at 1 µg/mL were transferred into a vial. The solvent was evaporated to dryness 
under a stream of nitrogen at room temperature and the residue was derivatised 
using 50 µl BSTFA with 1% TMCS at 80 ᴼC for 20 minutes. This was then transferred 
to the GC auto sampler vial and injected for analysis using the GC-MS method 
which was routinely used in the Forensic Medicine and Science laboratory, 
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University of Glasgow for the identification and measurement of THC and THC-
COOH in blood. Analyses were performed using FS mode to identify the retention 
times and mass fragments of each compound and their deuterated ISTD. Examples 
of mass spectra and chromatograms are shown in the previous chapter. Prior to 
carrying out a full validation study, the method was tested with full calibration 
including several points covering the expected LOD and LOQ ranges and quality 
control standards. The silanised high recovery vials were used as the derivatisation 
and injection medium. There were two major issues from this initial testing that 
were subsequently evaluated and overcome. 
- Co-eluting background interferences 
- Detector saturation at high calibration curve points 
 
 Co-eluting background interferences 
There was co-eluting background interference present on the CBD peak at m/z 
337. These interferences affected the ratios of the quantitation and qualifier ions 
at the lower concentrations. The interferences were observed on the calibration 
standards. The source of the background interferences was investigated and it was 
determined that the background interferences originated from the hair matrix. It 
was not possible to eliminate the interference. The ion at m/z 301 was assessed 
as a possible alternative qualifier ion, however, the same interference problem 
was encountered. Therefore, to rectify this, the ion at m/z 337 was kept as the 
qualifier ion as the interference was affecting only lower concentrations. The ion 
at m/z 458 was used for monitoring the ion ratio instead with the quantifier ion 
at m/z 390. In addition, the LOQ was later elevated to 10 ng instead of 8 ng to 
ensure a consistent ratio at the lower concentrations. 
 Detector saturation at high calibration curve points 
The limit of detection (LOD) was within the expected range (0.04 – 0.2 ng/mg) for 
all analytes. However, the calibration curves for all analytes were found not to 
give the good linearity that was established earlier using the 7 mL vial as a 
derivatisation medium. Due to the wide range of concentrations reported in the 
literature for cannabinoids in hair, and also the lack of data on the concentrations 
present in hair of targeted ethnicity, a wide calibration range was proposed. 
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Primarily, up to 400 ng/50mg of hair (equivalent to 8 ng/mg) was proposed. 
However, detector saturation encountered with analytes at high concentrations 
was found to affect the linearity and did not allow such a wide calibration. 
Detector saturation for all analytes started at 150 ng/50mg. Therefore, as a 
compromise, and to avoid other solutions may involve changes in the optimised 
sample preparation method, such as increasing the volume of the derivatisation 
reagent to reduce the signal, the impact of applying different split ratios on both 
low and high ends of the calibration were tested using a trial and error approach. 
It was found that a split ratio of 1:1 maintained the LOD and LOQ within the 
expected range and slightly improved the linearity calibration range up to 200 
ng/50 mg for CBN and 11-OH-THC and 300 ng/50 mg for THC and CBD. 
 2D GC-NCI-MS 
 Historical overview on the MDGC 
According to the classical terminology in column chromatography, separations are 
commonly called two- or multidimensional (2DGC or MDGC) when separations of 
all or certain selected groups of sample components are repeated in two or more 
columns of different polarity, which are coupled in series to the column in which 
the first separation was carried out. The separation is called ‘heart-cutting’ when 
only one or more chosen elution regions is sent to the second column for further 
separation, and ‘comprehensive’ when the entire chromatogram eluting from the 
primary column is submitted to the secondary column. The first demonstration of 
MDGC was reported by Simmons and Snyder in 1958 (173). This early version 
involved ‘Heart-cutting’ analysis by connecting two or more gas-liquid 
chromatographic columns in such a manner that preliminary cuts prepared by the 
first column could be charged directly to one or more secondary columns. Ten 
years later, Dean invented a switching device that enables transferring a portion 
of the GC run onto a secondary column using the gas flow (174). A significant 
development in the technique arose in the early 1990s, when comprehensive two-
dimensional gas chromatography was proposed by Phillips and Liu (175). Since 
then, it has undergone a reasonably predictable development.  
Many review articles have been published reviewing different aspects relating to 
MDGC. In 1994, Schomburg reviewed the principles, instrumentation and methods 
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for some typical applications of MDGC (176). Phillips and Beens summarise the 
development of comprehensive MDGC instrumentation and applications up to 1999 
(177). A year later, in a two-part review article, Wolfgang reviewed concepts, 
instrumentation, and applications of the conventional ‘heart-cutting’ MDGC  (178) 
and the comprehensive MDGC (179). In 2002, Pursch et al published a review on 
modulation techniques and applications in comprehensive two-dimensional gas 
chromatography. Kueh et al reviewed, in 2003, the application for 2D GC to the 
analysis of drugs in doping control (180). In another two-part review, Adahchour 
et al reviewed, in 2006, recent developments in comprehensive MDGC including 
instrumental set-up in part 1 (181) and modulation and detection in part 2 (182). 
The same group published, two years later, a review summarising the recent 
developments in the applications of comprehensive MDGC (183). The Marriott et 
al review, published in 2012, provided a technical overview of recent method 
implementation for both the heart-cut MDGC and the comprehensive MDGC (184). 
The two most recent reviews in the literature for applications and future prospects 
of MDGC techniques were by Tranchida et al, in 2012, for Heart-cutting MDGC 
(174), and Edwards et al, in 2015, for the comprehensive MDGC (185). 
It was noticed that the symbols and abbreviations for the two types of MDGC are 
inconsistent amongst researchers.  For instance, Wong et al have described the 
abbreviation (GC-GC) to refer to the MDGC in ‘heart-cutting’ mode and (GCxGC) 
to refer to the comprehensive version (186). However, in an earlier publication, 
Phillips et al used the abbreviation (GC-GC) to refer to the comprehensive version. 
Other publications such as that by Moore et and Guthery et al have used the 
abbreviation (GCxGC) to refer to the two-dimensional GC separation of any type 
(141,157). In 2003 Schoenmakers et al published a position paper defining various 
nomenclature and conventions in comprehensive MDGC (187). Therefore, the 
abbreviation (GC-GC) will be used throughout to describe the techniques 
employed in this work ‘heart-cutting two-dimensional GC’. 
Applications of MDGC have ranged from petroleum to environmental and biological 
samples analysis. Despite the fact that MDGC approaches are available for a long 
period, they are still not widely employed in the field of bioanalysis. This, 
possibly, reflects the general preference of standard GC over the MDGC. MDGC 
techniques have been reported in only in few publications for analysis of 
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cannabinoids in different biological matrices. Moore et al developed a method to 
detect THC-COOH in hair by using GC–GC in combination with electron capture 
chemical ionization (ECCI) MS. To enhance the ECCI detection, THC-COOH was 
derivatised using fluorinated acylation agents. The measured detection 
concentration was 0.05 pg/mg hair (141). In the subsequent year, Marin’s group 
reported a new method to detect the two metabolites THC-COOH and 11-OH-THC 
in meconium using GC-GC-MS (188). The method was validated and trace amounts 
of THC-COOH were detected in ten samples from babies born to drug-abuse 
patients. The separation in the secondary column was necessary as the targeted 
analytes co-eluted with other interfering substances during the first-column 
separation. Milman et al reported a combination of SPE and GC-GC-MS for the 
quantitative determination of THC, CBD, CBN, 11-OH-THC and THC-COOH in oral 
fluid (189). They used NCI for the detection of THC-COOH after derivatization with 
TFAA and HFIP; the other analytes were detected using EI after derivatization with 
BSTFA. Jones et al reported a method for quantitation of THC-COOH in 60 matched 
pairs of hair and fingernail (158). Samples were first digested using NaOH and were 
subject to SPE extraction and derivatisation with HFIP-PFPA. Analysis was 
achieved using GC-GC equipped with a low thermal mass (LTM) Series II System 
and tandem MS operated in the NCI mode. 
 Analytical instrument parameters 
The GC–MS system used for analysis of THC-COOH was an Agilent GC model 6890 
Series coupled with an Agilent 5975N mass selective detector. THC-COOH 
derivatives were separated first on a low polarity column ultra-inert HP5-MS (30 
m length x 0.25 mm (ID) x 0.25 µm film thickness). A cut containing the analyte 
of interest was determined and transferred into the secondary analytical column. 
The secondary column was of medium polarity DB-17MS (15 m length x 0.320 mm 
(ID) x 0.25 µm film thickness). The oven temperature program is shown in Table 
4-2. The temperatures for the injection port, ion source, quadrupole and interface 
were set at 250, 106, 150 and 280 °C, respectively. The injection volume was 1 µl 
of sample. Pulsed splitless injection was used with 50 psi pulse pressure and 0.80 
min pulse time. The pressure of the carrier gas (helium) through the primary and 
secondary columns was set constant at 30.39 and 7.26 psi, respectively. At these 
pressure values, the flow in the primary and secondary columns is calculated to 
be about 2 mL/min in the primary column, and 3 mL/min in the secondary column.  
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The primary detector was flame ionisation detector (FID) and was set at 250°C 
with the hydrogen and air flows at 40 mL/min and 450 mL/min, respectively.  
The secondary detector was MS operated in NCI mode with a gain factor of 14. To 
determine the retention times and characteristic mass fragments, mass spectra of 
THC-COOH and its deuterated ISTD derivatives were recorded by total ion 
monitoring. For quantitative analysis the chosen diagnostic mass fragments were 
monitored in the selected ion monitoring (SIM) mode m/z:422, 590 for THC–COOH 
derivative; and 425, 593 for THC–COOH-d3 as IS. For quantification, peak area 
ratios of quantifier ions of the analytes (underlined) to the internal standard were 
calculated as a function of the concentration of the substances.  
For the ionisation source, different gases can be used as the reagent or collision 
gas, such as, methane and ammonia. In this method ammonia, with 35 mL/min 
flow rate, was chosen due to its superior thermalizing power over methane. 
Despite the fact that use of ammonia has some advantages, it has also some 
drawbacks. The use of ammonia affects the maintenance requirements of the 
mass spectrometer detector (MSD). Typically resulting in the need to clean the 
source more often, as well as requiring more frequent replacement of the rough 
pump oil. When the pressure of the ammonia supply exceeds 5 psi, it will start 
condensing from a gas to a liquid. It tends to break down vacuum pump fluids and 
seals also and to prevent and minimize the pump damage, shutting off the CI gas 
after each run and more frequent vacuum system maintenance becomes 
necessary. 
The MSD was auto-tuned weekly. Data acquisition and analysis were performed 
using standard software supplied by the manufacturer (Agilent ChemStation). 
In addition to the secondary analytical column, conversion of an Agilent 6890 gas 
chromatograph into a heart-cutting GC system required the addition of another 
two components: the modulator and cryo-focusing trap. Hardware configuration 
of GC-GC-MS system is shown is Figure 4-3. The operating parameters for the 
Dean’s switch, determination of cut time and cryo-focusing trap will be covered 
in the sections 4.5.3, 4.5.4 and 4.5.5   
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Table 4-2 Oven temperature program of GC-GC-NCI-MS 
Initial temperature: 150 °C Initial time: 1.00 min 
Ramps:   
Rate (°C/min) Final temp Final time 
50 220 0.00 
10 263 0.00 
120 180 0.00 
10 230 0.00 
Post temp: 320 °C  
Post time: 2.00 min 
Run time: 12.39 
 
 
Figure 4-3 Schematic representation of an Agilent two dimensional 6890N gas chromatograph 
(GC) coupled with a 5975B mass selective detector (MSD), flame ionization detector (FID) and 
an auto-sampler. 
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 Dean’s switch 
As mentioned earlier, Dean’s Switch technology has been in use since 1967. 
However, the classical configurations that employ traditional rotary valves, 
stainless-steel tubing and fittings have a high thermal mass and do not track oven 
temperature very well, and hence are susceptible to leaks over time and can cause 
peak broadening. The employed Dean’s switch in this work is a recently innovated 
chromatographic device by Agilent, called Capillary Flow Technology (CFT), and 
is claimed to eliminate these chromatographic problems. Agilent’s Dean's Switch 
combines individual switch components into a single, smaller device with a three-
port manifold connected pneumatically to a solenoid valve as shown in Figure 4-4. 
 
Figure 4-4 Photo of Capillary Flow Technology Dean's Switch.  
 
In addition to the two columns, a deactivated restrictor tubing (0.18 mm ID) was 
connected to the Dean’s switch at one end and was attached to the primary 
detector FID at the other end. After determination of the desired method 
parameters (column dimensions, temperature, flows, etc.), the Dean's switch 
calculator software is often employed to calculate the restrictor length and 
pressure set points to operate the system. A screenshot of the Agilent Dean’s 
switch calculator is shown in Appendix III. In the method developed for this work, 
the restrictor length was 0.751 m. The Pressure Control Module (PCM) is the 
preferred switching gas source, as it automatically compensates for changes in 
atmospheric pressure, however, it was not possible to build in a PCM as the GC 
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second inlet was already occupied. The three channel Aux Pressure controller was 
used instead and was programmed to operate at a pressure of approximately 10 
psi. This supplied switching gas allowing all the flow from the primary column to 
vent through the restrictor column to the FID until the time of THC-COOH elution. 
The Dean’s switch was then turned on to allow the carrier gas to enter the 
secondary analytical column, which has different separation properties, for 0.18 
minutes. The switch times have to be very short due to the low internal volume 
of the pneumatic coupler (190). The flow was then redirected to the FID vent until 
the end of the analysis. Determination of the cut time is explained further in 
section 4-5-4. Conventionally, this method is used to separate compounds that do 
not separate on the primary column, however, with dirty matrices such as hair, it 
is a practical option to get rid of potential matrix effect and interferences. The 
basic layout of the Dean’s switch and flow directions is shown in Figure 4-5. 
 
Figure 4-5 (A) Dean’s switch basic layout, and the flow direction when the valve is switched 
OFF (B) and ON (C). Adobted from ref (190).  
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 Determination of Dean’s switch cut times 
It was important to make sure that the Dean’s switch transferred the whole 
analyte to the secondary column. A partial cut of the first column eluent will 
hugely affect the sensitivity. Therefore, a blank methanol and a high 
concentration mixture of THC-COOH and its deuterated ISTD (100 µl of 1 µg/mL 
working solution for both analyte and IS) were dried under a stream of nitrogen 
and derivatised with 50µl TFAA and 30µl HFIP. The mixture was incubated at 80 
°C for 20 minutes, and then injected. The signals were monitored, primarily, on 
FID and then on MS detector The two FID chromatograms of the blank and drug 
were compared against each other as shown in Figure 4-6. 
 
Figure 4-6 FID chromatograms of unextracted, derivatised blank (a) and 100 ng of THC-COOH 
and its internal standard (b) Enlarged area shows the THC-COOH derivative peak retention 
time 6.75 min.  
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A peak with retention time (RT) 6.75 minutes was observed only in the 
chromatogram that contained the analyte of interest.  The peak width was 0.11 
minutes (starts at 6.71 and finishes at 6.80 minutes). Based on this result, the 
Dean’s switch valve was programmed to cut from 6.65 to 6.83 (0.18 minutes) using 
ChemStation software. This very narrow cut was chosen to avoid transferring the, 
untargeted peaks, which were eluting close to analyte of interest, to the 
secondary column. Moreover, to eliminate the possibility of overloading the 
pneumatic coupler. This cut is flexible to minor changes in retention time, 
however, it must be re-evaluated after carrying out a major maintenance such as 
cutting the column which may result in a significant decrease of RT. This accuracy 
of cut was confirmed further by carrying out MS analysis. 
 
 Cryo-focusing trap 
The Cryo trap is installed at the beginning of the secondary column. It is designed 
to efficiently trap eluents from a capillary GC separation with the use of 
appropriate cryogens to cool the trap, and then to re-vaporise the trapped 
components for subsequent capillary GC separation using rapid but controlled 
heating of the trapping zone. The trap settings in this work were established based 
on the cut time that was determined previously as explained in section 4.5.4. The 
settings were controlled and dealt with in ChemStation as back inlet and are 
shown in Table 4-3. 
Table 4-3 Cryo trap settings 
Initial temperature: 280 C Initial time: 5.60 min 
Ramps:   
Rate (°C/min) Final temp Final time 
800 100 2.00 
800 280 0 
Cryo type: Nitrogen 
 Pressure: 7.26 psi 
Gas type: Air 
 
The aim of using a cryo trap with the two dimensional GC analysis is to focus the 
analytes at the start of secondary column which is believed to improve the 
sensitivity and peak shape. To cool down the column from 280 to 100 C at a rate 
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of 800 C/minute, we need only 0.225 minute (time = distance / speed => time = 
180 / 800 = 0.225 minutes). However, starting the trap one minute earlier ensures 
that the trap is cold before the THC-COOH derivative arrival. To attain the best 
focusing result, the second oven must be kept at a low temperature during heart-
cutting. This explains the fast ramp-down described previously in Table 4-2 at the 
maximum rate 120 C/min. Figure 4-7 is a screenshot from Agilent ChemStation 
Software illustrating combined GC oven and cryo-focusing trap settings for the 
duration of the analysis time. 
 
Figure 4-7 Screenshot from Agilent ChemStation Software illustrating the GC oven (Oven 
temp) and cryotrap (Bk Inl Temp) settings for duration of the analysis time 
 
 Backflush 
One of the advantages of Dean’s switch is that it enables basic MDGC operations 
such as backflushing. Backflush can be defined as reversal of flow through a 
column which leads to forcing late-eluting sample components back out the inlet 
end of the column. Therefore, backflush capabilities can significantly reduce GC 
run times and prolong column life. In this work, post-run backflush was 
programmed within the analytical run; post-run temperature was increased to 320 
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°C and held for 2 min, while column 1 and 2 pressures were ramped rapidly to 1 
and 50 psi, respectively. 
 Initial testing of the method  
Initially, retention times and mass fragments of THC-COOH and its deuterated 
ISTD, THC-COOH-d3 were confirmed as described previously in chapter 3. Prior to 
carrying out a full validation study, the method was tested with full calibration 
including several calibrators covering the expected LOD and LOQ ranges as well as 
quality control standards. Calibrator and QC standards were prepared as shown in 
Table 4-4. The silanised high recovery vials were used as the derivatisation and 
injection medium. Initially, detection sensitivity was found not to provide 
sufficient identification criteria within the expected range (0.1 –2 pg/mg) with 
extracted hair samples. Different attempts were carried out to improve the 
detection sensitivity, it was possible to improve the detection sensitivity 
significantly employing an ultra-inert column as the primary separation column. 
The instrument was able to detect as low as 10 pg total with a S/N ratio > 10 when 
unextracted standards were injected. 
 Materials and Methods  
 Materials  
These were previously described in chapter 3, section 3.3.. 
 Preparation of calibrations standards  
Working solution mixture (WS#1) at 1 µg/mL for THC, CBD, CBN, 11-OH-THC and 
THC-COOH was prepared as described in section 3.3.3. An aliquot of this solution 
was used to prepare a working solution (WS#2) at 10 ng/mL by 1:100 dilution. An 
aliquot of WS#2 was used to prepare a third working solution (WS#3) at 1 ng/ml by 
1:100 dilution. Stock and working solutions were stored at -20 °C. Calibrators were 
freshly prepared for each analysis from these working calibrant solutions by adding 
the appropriate volume to approximately 50 mg of drug- free hair in a glass 
extraction tube. The calibration procedure is shown in Table 4-4. 
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 Preparation of internal standard solution  
A working solution of 1 µg/ml was prepared for THC-d3, 11-OH-THC-d3 and THC-
COOH-d3 as described in section 3.3.4. Internal standard concentration was 
chosen to be equivalent to the medium QC sample.  
 Preparation of quality control standards 
Quality control samples (QCs) were prepared and analysed in addition to 
calibration standards and specimens to carry out bias and accuracy calculations. 
QCs were also tested later with case samples batches to ensure that accurate 
results were being obtained for the specimens. The working solutions used for 
preparation of QCs were different from the calibration standards but were 
prepared the same way. Stock and working solutions were stored at -20 °C. Three 
QC levels were freshly prepared for each analysis by adding an appropriate volume 
of the working control solutions to approximately 50 mg of drug-free hair in a glass 
extraction tube. The procedure of preparing QC samples is shown in Table 4-4. 
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Table 4-4 The preparation of limit of detection (LOD), limit of quantitation (LOQ), calibration 
standards containing ∆9-tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), 
11-hydroxy-∆9-tetrahydrocannabinol (11-OH-THC), 11-nor-∆9-tetrahydrocannabinol-9-
carboxylic acid (THC-COOH) and low, medium and high quality control samples for the 
validation studies. 
Analytes 
Working 
solutions 
Volume 
(µl) 
pg 
total 
 
 
equivalent 
pg/mg 
 Comments 
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, C
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, C
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, 1
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0.1 
 
 
 
 
 
 
 
 
 
 
10 10 0.2 
SoHT 
recommended 
LOQ 
15 15 0.3  
20 20 0.4  
25 25 0.5 Expected LOD 
50 50 1 Expected LOQ 
75 75 1.5  
100 100 2  
150 150 
C
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L
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R
A
T
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3 Low QC 
200 200 4  
10 ng/mL 
(WS#2) 
30 300 6 IS level Medium QC 
50 500 10 
 
 
 
 
80 800 16 High QC 
100 1000 20  
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  equivalent 
ng/mg 
  
100 1 
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0.02 
 
 
 
 
 
 
 
 
200 2 0.04 
Expected LOD for 
THC 
 
1 µg/ml 
(WS#1) 
4 4 0.08 
Expected LOQ for 
THC 
6 6 0.12 
SoHT 
recommended 
LOQ for THC 
8 8 0.16  
10 10 0.2 Low QC 
20 20 
C
A
L
IB
R
A
T
IO
N
 
0.4  
50 50 1  
100 100 2 IS level Medium QC 
200 200 4 
 
 
 
 
300 300 6 High QC 
400 µl 400 8  
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 Method validation experiments 
 Interference Studies 
The interferences can be defined as the non- targeted compounds. According to 
Scientific Working Group for Forensic Toxicology (SWGTOX) standard practices for 
method validation, interference studies must be carried out to evaluate the ability 
of the analytical method to distinguish the target analyte in a complex matrix 
from interferences from common sources (172). Three main sources of 
interferences were evaluated. Firstly, matrix interferences were evaluated by 
analysing 10 hair samples from different donors using the final extraction method 
and instrumentation to demonstrate the absence of common interferences from 
the matrix by comparing the chromatograms. Secondly, another possible source 
of interferences is the stable-isotope internal standards. The deuterium-labelled 
internal standards may contain the non-labelled compound, as an impurity, which 
could impact on quantitation results of its non-labelled analogue. Therefore, 100 
µl of each unextracted internal standard at 1µg/ml was derivatised with BSTFA or 
TFAA-HFIP and injected into the corresponding analytical system. The signals of 
the analytes of interest were then monitored. Thirdly, the most important source 
of interferences is the endogenous drugs or metabolites that may be present in 
the case sample due to exposure or active consumption. Therefore, a wide range 
of commonly encountered analytes were evaluated by injecting neat reference 
materials after derivatisation into the system. Appendix IV shows a list of 91 
compounds included in the study.  
 Limits of Detection (LOD) and Limits of Quantification (LOQ) 
LOD can be defined as the estimation of the lowest concentration of an analyte in 
a sample that can be reliably differentiated from blank matrix and identified by 
the analytical method. LOQ is an estimate of the lowest concentration of an 
analyte in a sample that can be reliably measured with acceptable bias and 
precision. There are a number of different approaches for determining the LOD 
and LOQ proposed in SWGTOX guidelines. The selected approach in this study was 
to estimate the LOD and LOQ using background noise. 40-50 mg of pooled blank 
hair from at least three sources was spiked with decreasing concentrations. These 
were extracted and analysed in duplicate (two separate samples) over a minimum 
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of three runs. Instrument LOD is considered the lowest concentration that gives a 
reproducible instrument response and which also can be distinguished from the 
matrix background noise with signal to noise ratio (S/N) ≥ 3, while LOQ is 
considered the lowest concentration that gives a reproducible instrument 
response with S/N ratio ≥ 10.  S/N ratios were calculated using ChemStation 
software. These can be calculated manually using the following Equation 4-1: 
Equation 4-1  
𝑆/𝑁  =
ℎ𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑎𝑛𝑎𝑙𝑦𝑡𝑒
𝑎𝑚𝑝𝑙𝑖𝑡𝑢𝑑𝑒 𝑜𝑓 𝑛𝑜𝑖𝑠𝑒
 
 
The LOD and LOQ of the GC-EI-MS method for THC, CBD, CBN and 11-OH-THC were 
determined by spiking 50 samples of pooled blank hair with decreasing 
concentrations of mixed working solution within the expected range of LODs and 
LOQs; 2, 3, 4, 6, 8 and 10 ng/50 mg. The samples were extracted and analysed in 
duplicate for three separate runs. Similarly, LOD and LOQ of 2D GC-NCI-MS for 
THC-COOH was determined over the range; 10, 20, 30, 40, 50, 60 and 70 pg/50 
mg of hair. The concentrations that yielded a reproducible instrument response 
with S/N ratio ≥ 3 and S/N ratio ≥ 10, and met all the predefined detection and 
identification criteria, such as retention time, peak shape, mass spectral ion 
ratios, were selected as LOD and LOQ, respectively. 
 Calibration Model  
The calibration model can be defined as the mathematical model that 
demonstrates the relationship between the concentration of analyte and the 
corresponding instrument response. Establishing calibration model is an obligatory 
prerequisite for all quantitative methods. The correlation between the signal 
response (peak area ratio of analyte and internal standard) and analyte 
concentration in the sample was assessed over a minimum of five replicates per 
concentration. The concentration range for calibration curves was chosen on the 
basis of concentrations reported in previous works. For GC-EI-MS, the calibration 
curve for each analyte was established using zero calibrator, calibrator at LOQs, 
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20 ng, 50 ng, 100 ng, 200 ng and 300 ng per 50 mg of hair. For 2D GC-NCI-MS, the 
calibration curve was assessed using the following concentrations; zero calibrator, 
calibrator at LOQ, 150 pg, 300 pg, 500 pg, 800 pg and 1000 pg/50 mg of hair. 
 Bias and precision 
Bias, which also can be referred to as accuracy or trueness, can be defined as the 
closeness of agreement between the true value of the analyte concentration and 
the mean result that is obtained by applying the experimental procedure. Usually, 
bias is reported as a percent difference. Precision can be defined as the measure 
of the closeness of agreement between a series of measurements obtained from 
multiple samplings of the same homogenous sample. For validation of quantitative 
methods, two different types of precision studies are usually conducted. These 
two types are within-run precision and between-run precision. It can be called 
(intra-day) and (inter-day) precisions as well. Bias and precision studies can be 
carried out concurrently. 
For the purpose of calculation of bias and accuracy, a minimum of three separate 
samples per concentration at two different concentrations were analysed over 
five different runs. The bias percentage was calculated for each concentration 
using Equation 4-2: 
Equation 4-2 
Bias (%) at a concentration =  
 
[
𝑔𝑟𝑎𝑛𝑑 𝑚𝑒𝑎𝑛 𝑜𝑓 𝑐𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛𝑥 − nominal 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛x
nominal 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛x
] ∗ 100 
 
Using Microsoft excel spreadsheet, both within-run and between-run precisions 
were calculated using the One-Way Analysis of Variation (ANOVA) approach with 
the varied factor (run number) as the grouping variable. Using mean square within 
groups (MSwg) and mean square between groups (MSbg) obtained from ANOVA table 
and number of observations in each group (n), within-run CV (%) and between-run 
CV (%) were calculated using the equations 4-3 and 4-4 below. 
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Equation 4-3 
Within-run CV (%) = 
[
√𝑀𝑆𝑤𝑔
𝑔𝑟𝑎𝑛𝑑 𝑚𝑒𝑎𝑛 𝑓𝑜𝑟 𝑒𝑎𝑐ℎ 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
] ∗ 100 
 
 
Equation 4-4 
Between-run CV (%) = 
[
 
 
 √𝑀𝑆𝑏𝑔 +
(𝑛 − 1) ∗ 𝑀𝑆𝑤𝑔
𝑛
𝑔𝑟𝑎𝑛𝑑 𝑚𝑒𝑎𝑛 𝑓𝑜𝑟 𝑒𝑎𝑐ℎ 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
]
 
 
 
∗ 100 
 
The bias and precision of GC-EI-MS for THC, CBD, CBN and 11-OH-THC, and 2D GC-
NCI-MS for THC-COOH were determined by spiking 50 mg of pooled blank hair at 
two or three quality (QC) levels as shown in Table 4-5. All QC samples were 
analysed in triplicate over five runs.  
Table 4-5 Summary of QC levels employed for bias and accuracy studies 
Analyte 
GC-EI-MS – concentration in ng/mg 
Low QC Med QC High QC 
THC 0.2 2 6 
CBD 0.2 2 6 
CBN 0.2 2 - 
11-OH-THC 0.2 2 - 
 2D GC-NCI-MS – concentration in pg/mg 
THC-COOH 3 10 16 
 
 Carryover  
Carryover can be defined as the appearance of unintended analyte signal in 
samples transferred from a previously run positive sample. This signal will, 
subsequently, lead to inaccurate quantitation. As part of method validation, 
carryover was evaluated by injecting two blank QC samples immediately after the 
highest calibration level over five runs whilst establishing the calibration model. 
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The obtained chromatograms were then examined visually for presence of 
interfering signal for all analytes. 
 Method validation results  
 Interference Studies 
There were no significant interferences observed from the drug-free hair sources 
or deuterated ISTD. None of the 91 commonly encountered compounds (shown in 
Appendix IV) caused interference to signals for the ions monitored for any of the 
target analytes or internal standards.  
 Limits of Detection and Limits of Quantification 
LOD and LOQ results for all analytes are presented in Table 4-6. LODs for THC, 
CBD and CBN ranged from 0.04 to 0.12 ng/mg. The achieved LOQ for THC was 
lower than the cut-off recommended by the Society of Hair Testing (SoHT) (≤ 0.1 
ng/mg). The presence of a co-eluting interference at m/z 337 for CBD resulted in 
elevating its LOD and LOQ to achieve an acceptable ion ratio. Figure 4-8 shows 
the effect of the interference at m/z 337 in two extraction ion chromatograms 
from two samples containing different amounts of CBD. To a lesser extent, a small 
amount of co-eluting interference at m/z 371 has led to a minor distortion of THC 
ion ratios for the low standards The SoHT do not have a recommended cut-off for 
CBD and CBN. Previously published methods for analysis of THC, CBD and CBN in 
hair matrices have reported limits of detection ranging from 0.0002 to 2.5 ng/mg 
for THC, 0.005 to 0.9948 ng/mg for CBD and 0.002 to 0.991 ng/mg for CBN 
(115,124,130,132,133,135,137,138,145,147,153,191).  
Despite the fact that 2D GC-NCI-MS showed very good sensitivity for the detection 
of THC-COOH in unextracted standards (as low as 10 pg total), the detection limit 
using extracted standards, was higher than this at 50 pg total, equivalent to 1 
pg/mg when 50 mg of hair was used. This is higher than the cut-off recommended 
by SoHT (≤ 0.2 pg/mg). Previously published methods for analysis of THC-COOH in 
hair matrices have reported limits of detection ranging from 0.01 to 50 pg/mg 
(137,151,152,155,158,160–163). Extracted chromatograms for the ions of lowest 
intensity at the LOD and LOQ for all analytes are shown in Figure 4-9. 
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Table 4-6 Method LOD and LOQ of cannabinoids in hair  
Analytes 
GC-EI-MS – concentration in ng total (ng/mg) 
LOD LOQ 
THC 2 (0.04) 4 (0.08) 
CBD 8 (0.16) 10 (0.20) 
CBN 4 (0.08) 6 (0.12) 
11-OH-THC 6 (0.12) 8 (0.16) 
 2D GC-NCI-MS – concentration in pg total (pg/mg) 
THC-COOH 30 (0.6) 50 (1) 
 
 
Figure 4-8 Extracted ion chromatogram CBD identification ions. (A) showing the signal from 
ion at m/z 337 in a standard containing 10ng total, and (B) sample containing 66.7 ng total. 
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Figure 4-9 Extracted chromatograms for the ions of lowest intensity at the LOD and LOQ for 
(A) ∆9-tetrahydrocannabinol (THC), (B) cannabidiol (CBD), (C) cannabinol (CBN) (D), 11-
hydroxy-∆9-tetrahydrocannabinol (11-OH-THC), (E) 11-nor-∆9-tetrahydrocannabinol-9-
carboxylic acid (THC-COOH). 
 
 Calibration Model 
The calibration models for all analytes were linear with R2 >0.99. The calibration 
range for each analyte is shown in Table 4-7 . Representative calibration curves 
for all analytes are shown in Figure 4-10 
Table 4-7 Calibration ranges for all analytes 
Analyte Calibration range 
THC 4-300 ng total 
CBD 10-300 ng total 
CBN 6-200 ng total 
11-OH-THC 8 to 200 ng total 
THC-COOH 50-1000 pg total 
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Figure 4-10 Representative calibration curves for ∆9-tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN) 11-hydroxy-∆9tetrahydrocannabinol 
(11-OH-THC), 11-nor-∆9- tetrahydrocannabinol-9-carboxylic acid (THC-COOH) plotted as the total concentration ratio against the response ratio. 
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 Bias and precision 
To find out how much of the compound is in the unknown or QC sample, a 
calibration curve for each compound has be created first using, at least, four 
levels, and then an aliquot of the case sample to be prepared and analysed in 
exactly the same way as for the calibration sample. The area of the peak produced 
by presence of unknown amount of the compound is then compared against the 
calibration curve to calculate the exact amount of the compound in the sample. 
Agilent ChemStation software offers different calculation procedures for 
determining the concentration of each component present in a mixture. Typically, 
each calculation procedure uses the peak area for the calculation and produces a 
different type of report. The internal standard (IS) procedure is one of these 
methods and is accomplished by adding a known amount of a component to both 
calibration and unknown samples to serves as a normalizing factor. The calibration 
points are constructed by calculating concentration ratio and a response ratio for 
each level of a particular peak in the calibration table. The concentration ratio is 
the amount of the compound divided by the amount of the internal standard at 
this level. The response ratio is the area of the compound divided by the area of 
the internal standard at this level. The quantitative results of bias and precision 
runs for THC, CBD, CBN, 11-OH-THC and THC-COOH are shown in Table 4-8, Table 
4-9, Table 4-10, Table 4-11 and Table 4-12. The mean square values, obtained 
from ANOVA analysis, for within and between groups for THC, CBD, CBN and 11-
OH-THC at different QC levels are shown in Table 4-13, and for THC-COOH in Table 
4-14. Mean, bias, within and between-run precision results for THC, CBD, CBN and 
11-OH-THC are summarised in Table 4-15, and for THC-COOH in Table 4-16.  
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Table 4-8 Quantitative THC results (ng/mg) of bias and precision runs. 
THC 
Low (0.2 ng/mg) run1 run2 run3 run4 run5 
repl.1 0.26 0.25 0.24 0.23 0.26 
repl.2 0.27 0.25 0.20 0.19 0.23 
repl.3 0.27 0.23 0.18 0.23 0.22 
      
Med (2 ng/mg) run1 run2 run3 run4 run5 
repl.1 2.09 2.01 1.99 2.00 2.06 
repl.2 2.15 1.99 1.98 1.98 2.10 
repl.3 2.10 2.00 2.00 1.96 2.08 
      
High (6 ng/mg) run1 run2 run3 run4 run5 
repl.1 6.30 5.76 5.17 6.08 5.98 
repl.2 5.71 5.75 4.95 6.04 6.09 
repl.3 5.41 5.76 5.35 6.07 6.03 
 
Table 4-9 Quantitative CBD results (ng/mg) of bias and precision runs 
CBD 
Low (0.2ng/mg) run1 run2 run3 run4 run5 
repl.1 0.24 0.23 0.27 0.24 0.21 
repl.2 0.24 0.23 0.26 0.23 0.22 
repl.3 0.24 0.24 0.27 0.24 0.23 
      
Med (2 ng/mg) run1 run2 run3 run4 run5 
repl.1 1.58 1.67 1.66 1.80 1.88 
repl.2 1.46 1.91 1.90 1.80 1.91 
repl.3 1.60 1.99 1.97 1.86 1.85 
      
High (6 ng/mg) run1 run2 run3 run4 run5 
repl.1 5.01 5.97 5.73 6.58 6.33 
repl.2 5.10 6.20 6.33 6.40 6.25 
repl.3 5.39 5.87 5.62 6.58 6.18 
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Table 4-10 Quantitative CBN results (ng/mg) of bias and precision runs. 
CBN 
Low (0.2ng/mg) run1 run2 run3 run4 run5 
repl.1 0.25 0.23 0.24 0.23 0.20 
repl.2 0.25 0.22 0.25 0.23 0.18 
repl.3 0.25 0.22 0.24 0.23 0.19 
      
Med (2 ng/mg) run1 run2 run3 run4 run5 
repl.1 1.79 2.01 1.86 2.01 2.17 
repl.2 2.04 2.05 1.73 2.01 2.21 
repl.3 1.91 1.95 1.68 1.94 2.21 
 
Table 4-11 Quantitative 11-OH-THC results (ng/mg) of bias and precision runs. 
11-OH-THC 
Low (0.2 ng/mg) run1 run2 run3 run4 run5 
repl.1 0.21 0.20 0.21 0.21 0.25 
repl.2 0.21 0.21 0.21 0.20 0.26 
repl.3 0.21 0.22 0.20 0.22 0.25 
      
Med (2 ng/mg) run1 run2 run3 run4 run5 
repl.1 1.90 2.03 1.88 1.89 1.90 
repl.2 1.92 2.07 1.88 1.89 1.92 
repl.3 1.90 2.07 1.90 1.90 1.93 
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Table 4-12 Quantitative THC-COOH results (pg/mg) of bias and precision runs. 
THC-COOH 
Low (3 pg/mg) run1 run2 run3 run4 run5 
repl.1 3.28 3.04 3.45 3.35 3.38 
repl.2 3.36 3.22 3.26 3.47 2.97 
repl.3 3.22 3.16 3.48 3.29 3.43 
      
Med (10 pg/mg) run1 run2 run3 run4 run5 
repl.1 8.96 8.96 9.07 9.79 9.24 
repl.2 8.94 9.4 9.31 10.18 9.46 
repl.3 9.50 9.27 13.55 8.34 9.56 
      
High (16 pg/mg) run1 run2 run3 run4 run5 
repl.1 16.28 15.96 15.72 16.44 15.45 
repl.2 14.76 16.08 15.85 15.03 15.99 
repl.3 14.60 14.24 15.17 15.61 15.99 
 
Table 4-13 The mean square values for within- and between groups for THC, CBD, CBN and 
11-OH-THC at different QC levels. 
QC (ng/mg)  THC CBD CBN OH-THC 
0.2 
BG 0.001716 0.001684 0.001558 0.001185 
WG 0.000421 4.87E-05 2.3E-05 3.55E-05 
2 
BG 0.011134 0.05732 0.076565 0.014678 
WG 0.000318 0.012382 0.005785 0.000189 
6 
BG 0.398717 0.774702 
 
WG 0.049771 0.045964 
 
Table 4-14 The mean square values for within- and between groups for THC-COOH at 
different QC levels. 
QC (pg/mg)  THCCOOH 
3 
BG 0.031388 
WG 0.019708 
10 
BG 1.138515 
WG 1.496016 
16 
BG 0.163483 
WG 0.528927 
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Table 4-15 Summary of mean, bias, within- and between-run precision results for THC, CBD, 
CBN and 11-OH-THC 
THC Low (0.2 ng/mg) Med (2 ng/mg) High (6 ng/mg) 
Mean (ng/mg) 0.23 2.03 5.76 
Bias (%) 17.42 1.62 -3.93 
Within-Run CV (%) 8.74 0.88 3.87 
Between-Run CV (%) 12.37 1.24 5.99 
    
CBD Low (0.4 ng/mg) Med (2 ng/mg) High (6 ng/mg) 
Mean (ng/mg) 0.24 1.79 5.97 
Bias (%) 19.79 -10.51 -0.51 
Within-Run CV (%) 2.91 6.22 3.59 
Between-Run CV (%) 4.12 8.92 5.98 
    
CBN Low (0.2 ng/mg) Med (2 ng/mg) 
 
Mean (ng/mg) 0.23 1.97 
Bias (%) 13.78 -1.41 
Within-Run CV (%) 2.11 3.86 
Between-Run CV (%) 2.98 5.56 
    
11-OH-THC Low (0.2ng/mg) Med (2 ng/mg) 
 
Mean (ng/mg) 0.22 1.93 
Bias (%) 8.42 -3.38 
Within-Run CV (%) 2.75 0.71 
Between-Run CV (%) 3.89 1.01 
 
Table 4-16 Summary of mean, bias, within- and between-run precision results for THC-
COOH. 
THC-COOH Low (3 pg/mg) Med (10 pg/mg) High (16 pg/mg) 
Mean (ng/mg) 3.291 9.569 15.545 
Bias (%) 9.708 -4.314 -2.844 
Within-Run CV (%) 4.265 12.783 4.679 
Between-Run CV (%) 6.079 22.645 6.882 
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 Carryover  
No signal was observed in the blank QC samples at the retention time for THC, 
CBD, CBN, 11-OH-THC and THC-COOH. Carryover was therefore not deemed to be 
a problem. 
 Conclusions 
The GC-EI-MS method was validated for the analysis of THC, CBD, CBN and 11-OH-
THC in hair. 2D GC-NCI-MS was validated for analysis of THC-COOH in hair. The 
two methods validation was carried out for interference, limit of detection (LOD) 
and limit of quantitation (LOQ), linearity, within and between-day precision, and 
carryover for all cannabinoids compounds. The developed methods were robust, 
quick and simple to conduct, and could be integrated into the routine work 
conducted in the laboratory for hair analysis. Matrix interferences for THC and 
CBD were encountered. It is believed that the effect of these interferences is 
limited to cases where THC and CBD are present in low concentrations. Further 
work on LLE extract cleanliness could eliminate these interferences. In general, 
the LOQ's were acceptable for all cannabinoids. The LOQ for THC was better than 
the SOHT recommendation, whereas, the LOQ for THC-COOH was 5 times higher 
than that recommended by SoHT. Both developed methods were subsequently 
used in a study involving hair samples collected from known cannabis users in 
Saudi Arabia, to explore detection rates and concentrations ranges in this part of 
the world. The results from these analyses are reported and discussed in the next 
chapter. 
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 Application of the validated methods to 
analyse cannabinoids in hair of Saudi patients 
undergoing drug rehabilitation 
 Introduction 
Up to this stage, both methods developed for the measurement of cannabinoids 
in hair samples had only been tested with hair samples spiked with methanolic 
drug standards. Therefore, it was important to assess its practicality and utility 
when applied to authentic hair specimens obtained from known cannabis users. In 
addition, the correlation between the concentrations of each cannabinoid and the 
self-reported use of cannabis was statistically studied. The detection rate of each 
cannabinoids was also investigated as the hair samples were collected from an 
ethnic group that has never been studied. The validity of using a single sample to 
carry out a liquid-liquid extraction (LLE) followed by solid-phase extraction (SPE) 
for quantitation of THC-COOH was also investigated. 
 Ethical approval 
Ethical approval was reviewed and granted by the National Committee of Medical 
and Bioethics at the Ministry of Health (MOH) in Saudi Arabia, and the Research 
Ethics Committee within the College of Medical, Veterinary and Life Sciences 
(MVLS), University of Glasgow. Copies of ethical approval letters from both 
authorities, the hair collection instructions and consent form are shown in the 
following appendices Appendix V, Appendix VI, Appendix VII and Appendix VIII. 
 Authentic hair specimens 
The specimens provided were from cannabis users who had admitted using 
cannabis and also their urine samples had screened positive for cannabinoids at 
the time of admission to the addiction hospital (Alamal Hospital, Jeddah, Saudi 
Arabia). Twenty specimens were collected from the posterior vertex region of 
male cannabis users with no major hair treatment reported. Each sample was 
labelled with a unique identifier number at the time of collection. In the 
laboratory, specimens were stored in a dark and dry place at room temperature 
until the time of analysis.  
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The hair colour and length were recorded for each hair specimen at the time of 
receipt. Hair specimens of more than 3 cm total length were segmented into 
segments and each segment was placed in a separate 20 mL chromacol 
environmental vial. The 1st segment representing the most recent growth was 3 
cm for all hair specimens except those that were less than 3 cm in total length. A 
summary of the visual properties of each hair specimen and number of segments 
are shown in table 5-1. 
Table 5-1 Visual properties of hair specimens and segments 
Sample No. Hair Colour Hair Length (cm) No. of segments 
S1 Black <1 1 
S2 Black 4 1 
S3 Black 3 1 
S4 Black 4 1 
S5 Black 6 2 
S6 Black 7 2 
S7 Black 1.5 1 
S8 Black 6 2 
S9 Black 7 1 
S10 Black 7 1 
S11 Black 3 1 
S12 Black 16 5 
S13 Black 5 1 
S14 Black 4 1 
S15 Black 3 1 
S16 Black 5 1 
S17 Black <1 1 
S18 Black 2.5 1 
S19 Black 2.5 1 
S20 Black 4 1 
 
Participants were interviewed and asked to describe their cannabis use according 
to the designed questionnaire shown in Appendix IX. Table 5-2 shows a summary 
of the answers given to questions that provide information regarding (A) the 
number of joints used per day and (B) the number of days used per week. This 
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information was collated by Dr Ahmed Alasmari from Ministry of Health, Saudi 
Arabia under the instruction of Farouq Alzahrani. In the same table, weekly use 
score (C) was calculated from the provided information in (A) and (B). Use score 
was calculated by multiplying the minimum and maximum number of joints 
(cannabis and tobacco) or spliffs (cannabis only) by the minimum and maximum 
number of days used and this was then averaged. The user who donated sample 
number 8 (S8) reported a monthly use therefore was assigned zero as the minimum 
number of days per week to one as the maximum. Cannabis consumers in Saudi 
Arabia are commonly known to roll joints rather than spliffs, however, the exact 
method of consumption was not monitored in this study. 
Table 5-2 Summary of answers given to cannabis consumption questions and weekly 
cannabis use score listed by specimen number (S1 – S20) 
Sample 
No. 
(A) joints/day (B) days/week (C) Weekly use score 
From To From To From To Average 
S1 1 3 1 2 1 6 3.5 
S2 5 10 3 4 15 40 27.5 
S3 2 3 1 2 2 6 4 
S4 1 2 7 7 7 14 10.5 
S5 2 3 1 2 2 6 4 
S6 3 4 3 4 9 16 12.5 
S7 20 25 7 7 140 175 157.5 
S8 1 2 0 1 0 2 1 
S9 1 2 3 4 3 8 5.5 
S10 1 2 3 4 3 8 5.5 
S11 1 2 1 2 1 4 2.5 
S12 1 2 1 2 1 4 2.5 
S13 3 4 3 4 9 16 12.5 
S14 15 20 7 7 105 140 122.5 
S15 4 5 2 3 8 15 11.5 
S16 15 20 7 7 105 140 122.5 
S17 5 6 7 7 35 42 38.5 
S18 20 30 7 7 140 210 175 
S19 1 2 3 4 3 8 5.5 
S20 1 3 2 3 2 9 5.5 
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 Preparation of hair specimens  
 Washing the hair specimens  
To remove drug deposited on the outer surface of hair, it was important to solvent 
wash hair segments. Solvent washes were carried out to according to the following 
protocol and kept for later analysis. 3 mL deionised water were added to each 
specimen tube containing the hair specimens, sonicated for 3 minutes and 
transferred to a 7 mL vial for later analysis. This was labelled as water wash (W) 
followed by specimen number. For instance, the water wash for specimen number 
one was labelled as W-S1. This was repeated two times with three mL of DCM.  
The DCM washes were removed into individual clean specimen tubes and labelled 
as wash DCM 1 and DCM 2 followed by specimen number. To aid the hair drying 
process, a final rinse of 1 mL of acetone was added to the specimen tubes, swirled 
around the hair specimens and removed immediately. This rinse was discarded. 
The hair specimens were left to dry completely overnight.  
 
 Cutting the hair specimens  
The 20 mL Chromacol environmental vials have a wide open top and allowed for 
hair cutting to be carried out inside the vials with scissors. Once the hair 
specimens were completely dry, they were cut as finely as possible into 
approximately 1-2 mm pieces with sharp scissors to aid the hair digestion process. 
The scissors were wiped clean with methanol in between the cutting of each hair 
segment. 
  Weighing out the hair specimens  
Each hair specimen was weighed out into a 7 mL screw cap tube and then the hair 
decanted into a digestion and extraction tube. It was necessary to weigh samples 
into the 7 mL vials as the digestion tubes are tapered and will not stand on the 
analytical balance. In addition, it was found that leaving specimens overnight 
resulted in statically charged hair samples becoming more neutralised which 
facilitated dealing with the hair specimens and the accuracy of the hair mass 
transferred into the digestion tube. The mass of hair specimen varies depending 
on the amount of hair available for analysis. Most of the specimens were in the 
range of 30 - 50 mg. The exact amount weighed out was recorded for each 
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specimen. Approximately 50 mg of drug-free hair was also weighed out for each 
calibration standard. 
 Preparation of calibration standards and addition of internal 
standards 
After the hair was weighed out, a full calibration curve was prepared to run 
alongside the hair specimens as previously described in Table 4-4 with the 
inclusion of two additional points as discussed in section 4.7.3. Internal standard 
solutions (100 µL) containing 1 ng/µL THC-d3 and 11-OH-THC-d3 (equivalent to 2 
ng/mg) and (30 µL) containing 10 pg/µL THC-COOH-d3 (equivalent to 6 pg/mg) 
were added to each calibration standard and authentic hair specimen with the 
exception of the blank. 
 Digestion and extraction  
The digestion and extraction was conducted according to the method that was 
developed in chapter 4. The final protocols that were followed are shown in figure 
5.1. 
 Analysis of the solvent washes  
In routine work, it is common practice to analyse the hair washes if the analysis 
of the hair specimen produces a positive result to exclude the possibility of 
external contamination. Hair specimens can be contaminated either due to 
exposure to cannabis smoke, which increases the concentrations of parent 
cannabinoids only THC, CBD and CBN, or from secretions of sweat or sebaceous 
glands surrounding the hair, which may, in addition to parent cannabinoids, 
increase the concentrations of two main metabolites 11-OH-THC and THC-COOH. 
In this work, for each hair specimen, one water wash and two solvent washes were 
produced during the preparation of the hair specimens. These were labelled W, 
DCM 1 and DCM 2. Prior to analysis of these hair specimens no work had been 
undertaken to determine the best method of analysis for these washes. If there 
were cannabinoids present due to contamination from external sources, it would 
be expected that the concentration of the cannabinoids would be higher in the 
washes than in the hair itself. It was therefore anticipated that analysis by 
standard GC-MS for the TMS derivatives of all analytes would be sufficient to 
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detect the presence of cannabinoids in the washes. Washes were not tested for 
the presence of THC-COOH.   
 Preparation of solvent washes for analysis 
All washes were stored in fridge at 4 °C. At the day of analysis, washes were left 
to dry overnight in the fume hood. Once samples were completely dry, they were 
reconstituted with 1 ml of 1M NaOH and 100 ng (100 µl of 1 µg/mL internal 
standard solution mixture containing THC-d3 and 11-OH-THC-d3) was added. 
Washes were then subjected to the LLE method developed for hair samples as 
shown in points 1 and 1.1 in Figure 5-1. 
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Figure 5-1 Protocol for digestion and extraction of hair specimen
153 
 
 
 
 Qualitative identification of analytes  
 THC/CBD/CBN/11-OH-THC  
Mass spectrometry equipped with an electron ionisation (EI) source was operated 
in selective ion monitoring (SIM) mode, monitoring ions were: m/z 371, 386, 303 
for THC–TMS; 390, 337, 458 for CBD–di-TMS; 367,368, 382 for CBN–TMS, 371, 474, 
459 for 11-OH-THC di-TMS, and 374, 389 for THC–TMS-d3 as internal standard for 
THC, CBD and CBN, and 374, 462 for 11-OH-THC di-TMS-d3 as internal standard for 
1-OH-THC. Underlined ions were used as the quantifying ions, and the others used 
as qualifiers. Each analyte was identified and confirmed positive by the presence 
of its three SIM ions in the mass spectrum at the correct RT (± 0.15 min) and in 
the correct ratio (± 20% of the calibrator ion ratio) (192). 
 THC-COOH  
Mass spectrometry equipped with negative chemical ionisation (CI) source was 
operated in selective ion monitoring (SIM) mode, monitoring ions: 422, 590 for 
THC–COOH TFAA/HFIP derivative; and 425, 593 for THC–COOH-d3 derivative as 
internal standard for THC–COOH. Underlined ions were used as the quantifying 
ions, and the others used as qualifiers. As NCI is a softer ionization technique than 
EI, positive identification of THC-COOH was different to the other analytes. 
Positive identification was based on the criteria set by Moore et al with similar 
techniques (141,152). Moore et al stated that: 
1. The selected SIM ions in the mass spectrum should be present within 30% of 
the calibration ratio. 
2. The peak should be present at the correct retention time compared to the 
internal standard. 
3. Should be compared to known controls/calibrators in the same batch 
4. There should also be satisfactory chromatographic removal of other peaks 
arising from the matrix. 
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 Calculation of concentrations in authentic specimens 
A case sample is a sample containing an unknown amount of the compound to be 
quantified. To find out how much of the compound is in the unknown sample, the 
method described previously in section 4.8.4 for the quantitation of validation QC 
samples was followed. To simplify calculations and allow for varying hair mass, 
the calibration curves for each analyte were constructed as ng total (for THC, 
CBD, CBN and 11- OH-THC) and pg total (for THC-COOH) rather than as ng/mg and 
pg/mg. When an analyte had been identified as present qualitatively, the peak 
area of the analyte and internal standard was calculated by the Agilent 
ChemStation software package. Integration of extracted ion chromatograms for 
each calibrator, QC, sample and case sample were reviewed and adjusted, if 
needed, using the QEdit tool on ChemStation. The software takes the appropriate 
response factors obtained from a previous calibration stored in the method. Using 
the internal standard concentration and peak areas from the run, the software 
calculates component concentrations. This gave a calculated value for the total 
concentration of drug in the whole weight of the hair sample. The concentration 
of analyte per mg of hair was then calculated.  
 Statistical Analysis  
Statistical analysis was carried out using IBM SPSS Statistics Version 22 on the 
concentrations of THC, CBD, CBN and THC-COOH detected in the first segments 
only of hair specimens. For THC-COOH, concentrations resulting from the analysis 
of sample (B) were used for statistical analysis. As the data was found not to follow 
a normal distribution, non-parametric tests were employed.  The Mann Whitney U 
test was used to assess if there was any significant difference in distribution of 
the concentrations of THC, CBD, CBN and THC-COOH detected between non-daily 
and daily users. Spearman’s Rank Correlation Test (1-tailed) was used to assess 
whether the concentrations of THC, CBD, CBN and THC-COOH correlated with the 
number of joints smoked by each user. A p value < 0.05 was considered significant. 
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 Results from analysis of authentic hair specimens  
 Results of analysis of the washes  
There was no 11-OH-THC detected in any of the washes. Also, none of the analytes 
were detected in any of the water washes. In the first DCM wash (DCM1), THC was 
detected for one case (S5-2), CBD and CBN were detected in the washes of five 
cases (S2, S5-1, S-52, S6-1, S6-2) and four cases (S5-1, S-52, S6-1, S6-2), 
respectively. In the second DCM wash (DCM2) for S5-2, THC was detected in the 
same wash but with approximately 70% decrease in concentration. CBD 
concentrations fell below the detection limit in two out of the five samples (S2, 
S5-1) for DCM2. No significant decrease was observed in the concentrations from 
washes of the other three samples. CBN was detectable in the second wash of all 
four samples, and with the exception of S5-2, there was no significant decrease 
in the concentrations of CBN between the two washes. The concentrations of the 
cannabinoids detected in the DCM washes of each hair specimen are summarised 
in Figure 5-2. 
 
Figure 5-2 The concentrations of ∆9-tetrahydrocannabinol (THC), cannabidiol (CBD), 
cannabinol (CBN) (ng total) detected in the DCM washes of each hair specimen. Specimens 
that are not included did not have positive washes for any cannabinoid. 
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 Concentrations detected in authentic hair specimens 
Of the 20 hair specimens (27 segments) analysed, only eight contained no 
detectable cannabinoids or metabolites. All specimens were negative for 11-OH-
THC as expected. THC, CBD and CBN were detected in 4, 14 and 4 specimens 
respectively. THC-COOH was detected in 8 specimens, when specimen (A) was re-
extracted, and in 15 specimens when sample (B) was tested. A summary of the 
range, mean and median concentrations detected for each analyte are shown in 
Table 5-3. The concentrations of the cannabinoids detected in each hair specimen 
are shown in Table 5-4, and Table 5-5. Figure 5-3, Figure 5-4, Figure 5-5, and 
Figure 5-6 display the extracted ion chromatograms for a hair specimen (S5-1) that 
was positive for THC, CBD, CBN and has the second highest THC-COOH 
concentration. For comparison, the extracted blank and two lowest extracted 
standards for each analyte are also shown. 
Table 5-3 Descriptive statistics of the concentrations detected for ∆9-tetrahydrocannabinol 
(THC), cannabidiol (CBD), cannabinol (CBN) and 11-nor-∆9-tetrahydrocannabinol-9-
carboxylic acid (THC-COOH) in 27 authentic hair specimens from cannabis users. 
 
THC 
(ng/mg) 
CBD 
(ng/mg) 
CBN 
(ng/mg) 
THC-COOH 
sample (A) 
(pg/mg) 
THC-COOH 
sample (B) 
(pg/mg) 
Mean 0.17 1.07 0.53 2.71 2.58 
Median 0.11 0.45 0.40 2.65 2.14 
Minimum 0.11 0.20 0.31 1.05 0.93 
Maximum 0.34 4.42 1.02 5.53 7.01 
No. positive 4 14 4 8 15 
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Table 5-4 Concentrations of ∆9-tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol 
(CBN) in each hair specimen 
Sample ID Weight (mg) 
Drug concentrations (ng/mg) 
THC CBD CBN 
s1 29.6 N.D 0.29 N.D 
s2 55.7 N.D 0.40 N.D 
s3 52.2 N.D N.D N.D 
s4 50.5 N.D N.D N.D 
s5-1 51.3 0.11 1.30 0.33 
s5-2 50.2 0.34 4.42 1.02 
s6-1 50.1 N.D 1.41 0.31 
s6-2 50.0 0.11 2.24 0.48 
s7 47.1 N.D N.D N.D 
s8-1 50.2 0.12 1.99 N.D 
s8-2 49.2 N.D N.D N.D 
s9 50.5 N.D N.D N.D 
s10 49.3 N.D N.D N.D 
s11 50.4 N.D N.D N.D 
s12-1 48.2 N.D N.D N.D 
s12-2 48.7 N.D N.D N.D 
s12-3 51.5 N.D 0.21 N.D 
s12-4 49.1 N.D 0.37 N.D 
s12-5 50.2 N.D 0.50 N.D 
s13 51.5 N.D 0.20 N.D 
s14 49.9 N.D 0.21 N.D 
s15 53.3 N.D N.D N.D 
s16 50.1 N.D 0.23 N.D 
s17 52.2 N.D N.D N.D 
s18 49.9 N.D N.D N.D 
s19 50.4 N.D N.D N.D 
s20 34.4 N.D 1.22 N.D 
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Table 5-5 Concentrations of 11-nor-∆9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) 
in each hair specimen (sample A and B for each subject). 
sample ID 
LLE followed by SPE for 
fraction ‘B’ of sample (A) 
SPE for sample (B) 
weight 
(mg) 
THCCOOH 
(pg/mg) 
weight 
(mg) 
THCCOOH 
(pg/mg) 
s1 29.6 3.22 55.1 2.48 
s2 55.7 1.20 50.7 2.33 
s3 52.2 N.D 50.4 0.93 
s4 50.5 N.D 51.9 N.D 
s5-1 51.3 4.18 35.4 4.80 
s5-2 50.2 2.41 49.7 3.49 
s6-1 50.1 1.05 55.6 2.68 
s6-2 50.0 N.D 50.5 1.89 
s7 47.1 5.53 29.5 7.01 
s8-1 50.2 N.D 53.1 N.D 
s8-2 49.2 N.D 54.9 N.D 
s9 50.5 N.D 48.3 1.32 
s10 49.3 N.D 50.1 N.D 
s11 50.4 N.D 51.8 N.D 
s12-1 48.2 N.D 48.2 N.D 
s12-2 48.7 N.D 50.3 N.D 
s12-3 51.5 N.D 51.9 N.D 
s12-4 49.1 1.18 49.1 N.D 
s12-5 50.2 N.D 41.5 N.D 
s13 51.5 N.D 49.1 N.D 
s14 49.9 N.D 52.0 1.82 
s15 53.3 N.D 49.8 2.14 
s16 50.1 N.D 52.2 2.06 
s17 52.2 N.D 50.4 1.54 
s18 49.9 N.D 26.4 N.D 
s19 50.4 N.D 52.3 2.43 
s20 34.4 2.89 43.7 1.79 
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Figure 5-3 Extracted ion chromatograms for ∆9-tetrahydrocannabinol for (a) an extracted 
blank (b) an extracted standard containing 4 ng total THC and (c) cannabis positive hair 
specimen S5-1 (51.3 mg) containing 0.11 ng/mg THC. 
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Figure 5-4 Extracted ion chromatograms for cannabidiol (CBD) for (a) an extracted blank (b) 
an extracted standard containing 10 ng total CBD (c) cannabis positive hair specimen S5-1 
(51.3 mg) containing 1.3 ng/mg CBD 
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Figure 5-5 Extracted ion chromatograms for cannabinol (CBN) for (a) an extracted blank (b) 
an extracted standard containing 6 ng total CBN (c) cannabis positive hair specimen S5-1 
(51.3 mg) containing 0.33 ng/mg CBN 
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Figure 5-6 Extracted ion chromatograms for 11-nor-∆9-tetrahydrocannabinol-9-carboxylic 
acid (THC-COOH) for (a) an extracted blank (b) an extracted standard containing 50 pg total 
THC- COOH (c) cannabis positive hair specimen S5-1 (51.3 mg) containing 4.17 pg/mg THC-
COOH. 
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Table 5-6 summarises the interpretation of results. The interpretation was carried 
out based on the fact that the presence of parent cannabinoids (THC, CBD and 
CBN) exclusively will prove exposure to cannabis only, while detecting a 
metabolite will prove ingestion. Absence of all cannabinoids was interpreted as 
no exposure or ingestion. Each (3 cm) segment represents the history of the 
corresponding three months. Sample s12 was segmented to 5 segments. Only the 
fourth and fifth segments were tested positive for CBD.  These segments 
correspond to the past 6-9 months and 9-12 months. Therefore, result 
interpretation was categorised as exposure to cannabis in the past year. 
Table 5-6 A summary of the interpretation of the results. 
 THC CBD CBN 11-OH-THC THCCOOH Interpretation 
s1 -  - - + 
Ingestion in past 3 months 
s2 -  - - + 
s3 - - - - + 
s5-1 + + + - + 
s5-2 + + + - + 
s6-1 - + + - + 
s6-2 + + + - + 
s7 - - - - + 
s9 - - - - + 
s14 - + - - + 
s15 - + - - + 
s16 - + - - + 
s17 - - - - + 
s19 - - - - + 
s20 - + - - + 
s8-1 +  - - - 
Exposure in past 3 months 
s8-2 - - - - - 
s10 - + - - - 
s13 - + - - - 
s12-1 - - - - - 
Exposure in past year 
s12-2 - - - - - 
s12-3 - + - - - 
s12-4 - + - - - 
s12-5 - + - - - 
s4 - - - - - 
No exposure/ingestion 
in past 3 months 
s11 - - - - - 
s18 - - - - - 
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 Correlation of results with cannabis score assigned to each 
hair specimen 
 Type of user 
From the information provided on the interview questionnaire, all users, except 
user number 8, described their cannabis use as either one or more times a week 
or daily cannabis use. Donor number 8 claimed monthly use. Therefore, samples 
were grouped into either daily or non-daily users. There were 14 Non-daily users 
and 6 daily cannabis users. It was found that there was no difference in the 
distribution of concentrations observed for both types of users for THC, CBD, CBN 
and THC-COOH. It is noteworthy that the highest THC-COOH concentration was 
quantified from a daily user's hair sample. The box-plots for each group are shown 
in Figure 5-7.  
 
 
Figure 5-7 Boxplot diagram representing the median and interquartile range of concentrations 
detected in daily and non-daily cannabis users for ∆9-tetrahydrocannabinol (THC), 
cannabidiol (CBD), cannabinol (CBN) (ng/mg) and 11-nor-∆9-tetrahydrocannabinol-9-
carboxylic acid (THC-COOH) (pg/mg). There was no significant difference (p>0.05) in the 
distribution of concentrations detected between daily and non-daily users. 
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 Weekly use score  
A weekly use score was calculated based on self-report information given by each 
user. During the interview, users were asked questions about their weekly 
cannabis use behaviour during the previous three months. An average weekly score 
was assigned based on how many days per week they smoked cannabis and how 
many joints or spliffs they smoked on a day in a week. The ranges of two values 
were multiplied to provide the range provided for the joints or spliffs smoked per 
week. Highest and lowest values were then averaged to give an estimation of 
weekly use score. As all donors reported a constant use pattern in the previous 
three months, the weekly use score was accepted to represent the 3 months’ use. 
Concentrations of analytes in the first segments only, which represent the 
cannabis consumption in no more than three months, were included in the 
statistical analysis. The data was examined to determine if there was any 
correlation between weekly use score and the concentrations of each cannabinoid 
and metabolite detected. It was assumed that there would be an increase in 
concentrations as the weekly use score increased. It was found that there was no 
correlation between the weekly use score and the THC, CBD, CBN and THC-COOH 
concentration when examined individually or when both type of users (daily and 
non-daily) were compared. The scatter plot diagram for all analytes compared to 
the number of joints smoked is shown in Figure 5-8.  
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Figure 5-8 Scatter plot diagram showing no correlation between the weekly use score and 
the concentrations of ∆9-tetrahydrocannabinol (THC) ng/mg (Spearman ρ = 0.416, p > 0.05, 
R2 0.042) cannabidiol (CBD) ng/mg (Spearman ρ  = 0.416, p > 0.05, R2 0.0.064) cannabinol 
(CBN) ng/mg  (Spearman ρ = 0.416, p > 0.05, R2 0.0.029) and 11-nor-∆9-
tetrahydrocannabinol-9-carboxylic acid (THC-COOH) pg/mg (Spearman ρ = 0.176, p > 0.05, 
R2 0.097) detected in authentic hair specimens. 
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 Discussion of results  
 Detection rate of different cannabinoids in case specimens 
Four (20%) of the 20 hair specimens had no detectable ∆9-THC, CBD, CBN, or THC-
COOH at or above the described LOQs. THC-COOH was present in more hair 
specimens than ∆9-THC with 7 specimens (35%) having only THC-COOH, one (5%) 
only ∆9-THC and 3 (11.1%) with both. CBD had a high detection rate with 8 positive 
samples (40%). CBN was detected in 2 (10%) hair samples. The main metabolite 
THC-COOH had the highest detection rate of all cannabinoids and was detected in 
13 (65%) hair samples. Table 5-7 summarises the numbers and percentages of 
positive and negative hair specimens for each analyte in both daily, non-daily user 
and both groups combined. Table 5-8 summarises the numbers and percentages of 
positively identified analytes in all 20 cases. 
Table 5-7 Numbers and percentages of negative and positive samples for ∆9-
tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN) and 11-nor-∆9-
tetrahydrocannabinol-9-carboxylic acid (THC-COOH) in daily, non-daily and both type of 
users combined.  
Daily users Non-Daily users All users 
 
Positive Negative Positive Negative Positive Negative 
THC 0 (0%) 6(100%) 2 (14.3%) 12 (85.7%) 2 (10%) 18 (90%) 
CBD 2 (33.3%) 4 (66.7%) 7 (50%) 7 (50%) 9 (45%) 11 (90%) 
CBN 0 (0%) 6 (100%) 2 (14.3%) 12 (85.7%) 2 (10%) 18 (90%) 
THC-COOH 4 (66.7%) 2 (33.3%) 9 (64.3%) 5 (35.7%) 13 (65%) 7 (35%) 
 
Table 5-8 Qualitative results from research of ∆9-tetrahydrocannabinol (THC), cannabidiol 
(CBD), cannabinol (CBN) and 11-nor-∆9-tetrahydrocannabinol-9-carboxylic acid (THC-
COOH) in 20 hair samples 
  Number of sample Percentage % 
None 4 20 
THC only 1 5 
CBD only 2 10 
THCCOOH only 7 35 
CBD, THC-COOH 4 20 
CBD, CBN, THC-COOH 1 5 
THC, CBD, CBN, THC-COOH 1 5 
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 Validity of using two extraction procedures on the same hair 
sample for THC-COOH quantitation 
Typically, drug testing in biological samples goes through two stages, screening 
and confirmation. It is also possible that analysis might need to be repeated for 
several reasons. Insufficient hair mass is one of the problems that is usually 
encountered in hair testing. In this thesis, a method to analyse THC-COOH in 
situations where a limited amount of sample is available is proposed. The validity 
of retaining the aqueous layer of sample (A) after carrying out a liquid-liquid 
extraction for THC, CBD, CBN and 11-OH-THC and re-extracting later using solid-
phase extraction for THC-COOH was investigated. After carrying out the LLE, vials 
that contained the aqueous layer were capped and stored in the fridge at 4C. As 
the aim of this study was to monitor the changes in concentrations, internal 
standard for THC-COOH was not added until the time of SPE extraction. The 
obtained concentrations after analysis were compared against those quantified in 
sample (B) which was extracted using SPE only. Figure 5-9 shows a comparison of 
concentrations of samples A and B for each subject. Negative samples in both 
procedures were excluded from the bar chart. 16 samples were tested positive for 
at least one extraction procedure. Half of the samples (n=8) were tested positive 
only in sample (B). 5 samples had higher concentrations in sample (B) than sample 
(A) with a mean % increase of 22.5% (7-43%). The remaining three samples were 
found to have higher concentrations in sample (A). Two of these three samples 
were found to have higher concentrations in samples (A) than sample (B) with a 
mean % increase of 18.3% (13-23.6%), and one sample was positive only in sample 
(A). To conclude, it is believed that retaining the LLE aqueous layer for further 
extraction is an acceptable approach when there is insufficient sample for further 
analysis. The noticed decrease in concentration could be due to loss of analyte 
with LLE extraction or a stability issue during storage between the two analyses 
or both. Adding IS for THCCOOH analysis earlier will correct the decrease in 
concentration but will not change the rate of false negatives. 
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Figure 5-9 Concentrations of 11-nor-∆9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) quantified in sample (A) after LLE followed by SPE and in 
sample (B) after SPE.
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 Comparison of results to other studies  
There have been many studies published in the literature looking at the 
concentrations of different cannabinoids in hair. The targeted analytes vary 
between studies. The majority have focussed on measuring only the main 
metabolite THC-COOH, as it is believed to, at least, minimise claims of external 
exposure, whilst others have only measured the major parent cannabinoids (THC, 
CBD and CBN), which can only confirm exposure to cannabis. Simultaneous analysis 
for the main psychoactive cannabinoid (THC) and its main metabolite was found 
popular in the literature as well. Only four studies have determined 
concentrations for all four compounds. Table 5-9 lists the references by the 
targeted analyte(s) and the number of studies where they were analysed. 
Table 5-9 Classification of cannabis in hair publications based on targeted analyte(s). 
Targeted analytes n References 
THC-COOH only 15 (123,139,141,143,151,152,154–
156,158,160–163,193) 
THC, CBD &CBN 12 (124–
127,132,133,135,136,144,145,148,15
9) 
THC & THC-COOH 9 (128,134,137,138,140,142,147,153,1
94) 
THC only 7 (116,121,122,129,191,195,196) 
THC, CBD, CBN & THC-COOH 4 (115,120,130,131) 
THC, CBN & THCA A 2 (117,118) 
THC & THCA A 2 (65,146) 
THC, THC-COOH & 11-OH-THC 2 (150,167) 
THC, CBD, CBN & THCA A 1 (197) 
THC, CBN & THC-COOH 1 (114) 
11-OH-THC 1 (198) 
THC, THC-COOH & THC-COOglu 1 (108) 
THC, THC-OOH, Alcohol & THC-
COOEt 
1 (149) 
Total 58  
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In the following sections (5.7.3.1 – 5.7.3.4), the concentrations detected in this 
study (shown in tables 5.4 and 5.6 (SPE only)) have been compared to those 
reported in the previous studies. Based on the above table 5-9, the number of 
studies that targeted THC, CBD, CBN and THC-COOH in hair specimens in the 
literature are 43, 18, 21 and 43, respectively. Several studies have been excluded 
from comparison. Examples of these are studies which focussed mainly on method 
development and validation where no case samples, or only proficiency test  
samples were tested (65,120,122,151,195), or only one case sample (121,167), or 
where no quantitative data on concentrations were provided on the case sample 
analysed (129,163,197), or studies where only the range was given but no mean 
values were reported (142,148,160,167), or only the mean value was reported 
(131,154,161). One study was excluded (128) as the same data was presented in 
another publication (138). Studies that were carried out to measure the 
concentrations after passive exposure to cannabis were also excluded (146,197). 
Apart from three studies (123,132,137), where hair specimens were collected from 
post-mortem cases, the hair specimens analysed were from known cannabis users.  
 THC  
Studies included in the THC concentration comparison are listed in Table 5-10. 
The mean, minimum and maximum concentrations detected in each study are 
shown in the same table. To facilitate representation of these data on the high-
low diagram, each study was given a code. The concentrations of THC in previous 
studies were found to range from 0.003 ng/mg to 60.41 ng/mg. Concentrations 
detected in this study were similar to the wide concentration range of THC 
detected in other studies. The mean values reported in each study ranged from 
0.041 to 22.79 ng/mg and the mean value reported in this study was 0.17 ng/mg. 
A high-low diagram illustrating the ranges observed for all studies is shown in 
Figure 5-10. Due to the very high concentration observed in study (THC1), it was 
necessary to rescale the diagram to allow a proper visual comparison of studies 
that reported low concentrations as shown in Figure 5-11. 
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Table 5-10 List of studies included in comparison of ∆9-tetrahydrocannabinol (THC) 
concentrations detected in hair matrices. Mean, minimum and maximum concentrations 
detected in ng/mg are shown. Each study was given a code to use for diagram 
representation. 
Ref. Author(s) (year) 
 
Code on 
diagram 
Mean Min. Max. 
 
(147) Han et al (2011) THC1 22.790 7.520 60.410 
(130) Villamor et al (2005) THC2 2.930 0.040 9.290 
(108) Pichini et al (2015) THC3 2.670 0.339 12.125 
(194) Moeller and Sachs (1993) THC4 2.000 0.400 6.200 
(191) Kauret et al (1996) THC5 1.501 0.009 16.700 
(138) Jurado et al (1996) -SPAIN* THC6-F 0.970 0.060 7.630 
(137) Cirimele et al (1995) THC7 0.740 0.260 2.170 
(138) Jurado et al (1996) – FRANCE* THC6-S 0.630 0.020 2.170 
(149) Nadulski et al (2010) THC8 0.546 0.090 2.040 
(135) Nadulski & Pragst (2007) THC9 0.490 0.120 4.200 
(124) Strano-Rossi & Chiarotti (1999) THC10 0.400 0.100 0.700 
(125) Musshoff et al (2003) THC11 0.360 0.250 0.370 
(145) Skopp et al (2007) THC12 0.343 0.090 0.710 
(140) Minoli et al (2012) THC13 0.290 0.010 2.620 
(196) Koster et al (2014) THC14 0.261 0.089 0.385 
(118) Moosmann et al (2015) THC15 0.180 0.000 1.200 
(116) Breidi et al (2012) THC16 0.145 0.050 0.350 
(115) Baptista et al (2002) THC17 0.198 0.030 0.280 
(150) Wilkins et al (1995) THC18 0.177 0.019 0.552 
(132) Cirimele et al (1996) THC19 0.150 0.100 0.290 
(133) Kim et al (2005) THC20 0.140 0.060 0.270 
(126) Salomone et al (2012) THC21 0.427 0.050 0.553 
(136) Emidio et al (2010) - HS THC22 0.069 0.020 0.232 
(144) Emidio et al (2010) - HF THC23 0.056 0.041 0.070 
(153) Mieczkowski (1995) THC24 0.043 0.030 0.438 
(134) Huestis et al (2007) THC25 0.041 0.003 0.110 
(127) Míguez-Framil et al (2014 THC26 0.037 0.011 0.068 
(159) Tassoni et al (2015) - group A  THC27 0.730 0.017 1.740 
*The concentrations in this study were reported in two groups, each was representing 
concentrations detected different country, (F) for France and (S) for Spain. 
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Figure 5-10 High-low diagram representing minimum, maximum and mean concentrations of 
∆9-tetrahydrocannabinol (THC) detected in each study. The high-low bars and mean marker 
representing the data in this study are in red. 
 
Figure 5-11 Zoomed in high-low diagram representing studies with minimum, maximum and 
mean concentrations of ∆9-tetrahydrocannabinol (THC) detected in each study. The high-
low bars and mean marker representing the data in this study are in red.  
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 CBD  
Studies included in the CBD concentration comparison are listed in Table 5-11. 
The mean, minimum and maximum concentrations detected in each study are 
shown in the same table. To facilitate representation of these data on high-low 
diagram, each study was given a code. The concentrations of CBD in previous 
studies were found to range from 0.001 ng/mg to 19.02 ng/mg. The mean values 
reported across the range of studies ranged from 0.01 to 4.30 ng/mg. The mean 
value reported in this study was 1.07 ng/mg. A high-low diagram illustrating the 
ranges observed for all studies is shown in Figure 5-12. 
Table 5-11 List of studies included in comparison of cannabidiol (CBD) concentrations 
detected in hair matrices. Mean, minimum and maximum detected concentrations in ng/mg 
are shown. Each study was given a code to use for diagram representation 
Ref. Author(s) (year) 
 
Code on 
diagram 
Mean Min. Max. 
 
(125) Musshoff et al (2003) CBD1 4.360 0.810 19.020 
(130) Villamor et al (2005) CBD2 4.190 0.010 15.260 
(149) Nadulski et al (2010) CBD3 1.334 0.030 5.190 
(132) Cirimele et al (1996) CBD4 0.440 0.030 3.000 
(135) Nadulski & Pragst (2007) CBD5 0.370 0.013 12.100 
(126) Salomone et al (2012) CBD6 0.323 0.018 1.862 
(145) Skopp et al (2007) CBD7 0.231 0.060 0.570 
(127) Míguez-Framil et al (2014 CBD8 0.179 0.008 0.585 
(115) Baptista et al (2002) CBD9 0.162 0.040 0.470 
(133) Kim et al (2005) CBD10 0.040 0.020 0.050 
(136) Emidio et al (2010) - HS CBD11 0.014 0.013 0.020 
(144) Emidio et al (2010) - HF CBD12 0.010 0.001 0.018 
(159) Tassoni et al (2015) * CBD13 1.100 0.050 2.360 
*Data from (group A) specimens, nonpreviously treated with acid hydrolysis included. 
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Figure 5-12 High-low diagram representing minimum, maximum and mean value for the 
concentrations of cannabidiol (CBD) detected in each study. The high-low bars and mean 
marker representing the data in this study are in red. 
 
 CBN  
Studies included in the CBN concentration comparison are listed in Table 5-12. 
The mean, minimum and maximum concentrations detected in each study are 
shown in the same table. To facilitate representation of these data on the high-
low diagram, each study was given a code. The concentrations of CBN in previous 
studies were found to range from 0.008 ng/mg to 6.66 ng/mg. The mean values 
reported across the range of studies ranged from 0.021 to 1.63 ng/mg. The mean 
value reported in this study was 0.53 ng/mg. A high-low diagram illustrating the 
ranges observed for all studies is shown in Figure 5-13. 
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Table 5-12 List of studies included in comparison of cannabinol (CBN) concentrations 
detected in hair matrices. Mean, minimum and maximum detected concentrations in ng/mg 
are shown. Each study was given a code to use for diagram representation 
Ref. Author(s) (year) 
 
Code on 
diagram 
Mean Min. Max. 
 
(130) Villamor et al (2005) CBN1 1.630 0.030 6.660 
(125) Musshoff et al (2003) CBN2 0.480 0.120 1.480 
(133) Kim et al (2005) CBN3 0.360 0.050 1.380 
(149) Nadulski et al (2010) CBN4 0.320 0.050 0.800 
(115) Baptista et al (2002) CBN5 0.303 0.210 0.380 
(127) Míguez-Framil et al (2014 CBN6 0.209 0.008 0.335 
(145) Skopp et al (2007) CBN7 0.136 0.050 0.340 
(132) Cirimele et al (1996) CBN8 0.130 0.010 1.070 
(135) Nadulski & Pragst (2007) CBN9 0.120 0.016 0.850 
(136) Emidio et al (2010) - HS CBN10 0.096 0.031 0.300 
(126) Salomone et al (2012) CBN11 0.066 0.031 0.205 
(144) Emidio et al (2010) - HF CBN12 0.021 0.090 0.107 
(159) Tassoni et al (2015) * CBN13 1.310 0.090 2.610 
(118) Moosmann et al (2015) CBN14 0.048 0.000 0.740 
*Data from (group A) specimens, nonpreviously treated with acid hydrolysis included. 
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Figure 5-13 High-low diagram representing minimum, maximum and mean value for the 
concentrations of cannabinol (CBN) detected in each study. The high-low bars and mean 
marker representing the data in this study are in red. 
. 
 
 THC-COOH  
Studies included in the THC-COOH concentration comparison are listed in Table 
5-13. The mean, minimum and maximum concentrations detected in each study 
are shown in the same table. To facilitate representation of these data on high-
low diagram, each study was given a code. The concentrations of THC-COOH in 
previous studies were found to range from 0.02 pg/mg to 5000 pg/mg. The mean 
values reported across the studies ranged from 0.259 to 3300 pg/mg. The mean 
value reported in this study (sample B) was 2.58 pg/mg. A high-low diagram 
illustrating the ranges observed for all studies is shown in Figure 5-14. Due to the 
very high concentration observed in studies THCA1 to THCA6, it was necessary to 
rescale the diagram to allow a proper visual comparison of studies that reported 
low concentrations as shown in Figure 5-15. 
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Table 5-13 List of studies included in comparison of 11-nor-∆9-tetrahydrocannabinol-9-
carboxylic acid (THC-COOH) concentrations detected in hair matrices. Mean, minimum and 
maximum detected concentrations in pg/mg are shown. Each study was given a code to use 
for diagram representation 
Ref. Author(s) (year) 
Code on 
diagram 
Mean Min. Max. 
(194) Moeller and Sachs (1993) THCA1 3300 1700 5000 
(138) Jurado et al (1996)-SPAIN THCA2-S 500 60 3870 
(130) Villamor et al (2005) THCA3 440 50 800 
(137) Cirimele et al (1995) THCA4 160 70 330 
(123) Kintz et al (1995) THCA5 120 20 390 
(138) Jurado et al (1996)-France THCA2-F 100 50 390 
(115) Baptista et al (2002) THCA6 28 10 90 
(152) Moore and Guzaldo (2001) THCA7 3.26 0.6 12.9 
(162) Park et al (2014) THCA8 3.25 0.13 15.75 
(155) Han et al (2011) (A)* THCA9-A 2.96 0.06 33.44 
(143) Han et al (2011) (B)** THCA10-B 2.62 0.19 13.82 
(143) Han et al (2011) (A)** THCA10-A 2.54 0.14 9.01 
(147) Han et al (2011) THCA11 2.27 0.1 11.68 
(143) Han et al (2011) (C)** THCA10-C 1.84 0.1 9.01 
(140) Minoli et al (2012) THCA12 1.41 0.05 49.74 
(156) Kim et al (2011) THCA13 1.09 0.05 9.38 
(141) Moore el al (2006) THCA14 0.922 0.09 1.94 
(134) Huestis et al (2007) THCA15 0.89 0.1 7.3 
(155) Han et al (2011) (B)* THCA9-B 0.37 0.05 7.24 
(158) Jones et al (2013) THCA16 0.36429 0.02 9.011 
(139) Kim and In (2007) THCA17 0.35 0.14 0.85 
(153) Mieczkowski (1995) THCA18 0.322 0.03 1.53 
(108) Pichini et al (2015) THCA19 0.259 0.09 0.39 
*THCA9 A and B are two sets of data from the same publication. 
**THCA10 A, B and C are two sets of data from the same publication. 
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Figure 5-14 High-low diagram representing minimum, maximum and mean value for the 
concentrations of 11-nor-∆9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) detected 
in each study. The high-low bar and mean dot representing the data in this study are in red. 
 
 
 
Figure 5-15 Zoomed-in high-low diagram representing minimum, maximum and mean value 
for the concentrations of 11-nor-∆9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) 
detected in each study. The high-low bar and mean marker representing the data in this 
study are in red  
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 Conclusions from comparison with other studies  
Despite the fact that the reported concentrations for THC in hair in the literature 
were found to vary over a wide range, the mean concentrations of THC, CBN and 
CBD in the studies included in this comparison show insignificant difference when 
tested using the Kruskal-Wallis test. Figure 5-16 shows a boxplot diagram of the 
mean concentrations of THC, CBD, CBN and THC-COOH in all studies included for 
comparison in addition to this study. It is possible that this greater variation in 
THC concentrations is a result of using inappropriate derivatisation regent in some 
studies.  The use of perfluorinated anhydrides alone or coupled with 
perfluoroalcohols, such as HFIP/TFAA or PFPOH/PFPA, will results in identical 
retention times and mass spectra for THC and CBD. This may explain the elevated 
levels of THC reported in some studies that were included in the comparison 
(137,138,147,191). 
The current LOQ of 4 ng total (0.08 ng/mg based on 50 mg hair) for THC in this 
study was close to the SOHT recommended cut-off value (0.1 ng/mg). However, 
there were only four hair specimens (from three users out of twenty) that had 
quantifiable THC peaks above 4 ng total. Based on this and the concentrations 
reported in the other studies, a lower cut-off might be more appropriate. There 
is no recommended cut-off for CBD and CBN. However, based on the obtained 
concentrations in this study and comparison of the mean concentrations reported 
in the literature, a similar cut-off to THC may be appropriate. 
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Figure 5-16 Boxplot diagrams representing the median and interquartile range of mean 
concentrations (ng/mg) of ∆9-tetrahydrocannabinol (THC) (n=29), cannabidiol (CBD)(n=14), 
cannabinol (CBN) (n=15) in hair of cannabis users.  
Kruskal-Wallis test was carried out to compare the mean concentrations of THC, CBD and 
CBN. There was no significant difference (p>0.05) in the distribution of THC, CBD and CBN 
concentrations. The mean concentration from THC1 is not included in the statistical analysis 
nor represented in the boxplot. 
 
The current LOQ for THC-COOH of 50 pg total (1 pg/mg based on 50 mg hair) was 
capable of detecting 74.3% and 66.7% of non-daily and daily cannabis users, 
respectively. It would be necessary to improve detection sensitivity in order to 
detect lower concentrations. Improvement of the detection sensitivity for THC-
COOH would require further work to improve the clean-up of the structurally 
similar lipophilic organic acids resulting from the hair matrix which elevate the 
background noise (163). Amongst the studies that have been reported, there has 
been a wide range of concentrations reported for THC-COOH. This broad range 
may be attributed to the variance in instrumental capabilities and analytical 
method sensitivity.  The mean values across all the studies ranged from 0.26 to 
3300 pg/mg (m=194.8 pg/mg). There were 6 studies which detected much higher 
concentrations than the other 17 studies (115,123,130,137,138,194). When these 
studies were excluded, the means ranged from 0.25 to 3.26 pg/mg (1.6 pg/mg). 
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The mean concentration detected in this study was 2.3 pg/mg which is similar to 
the values reported in previous literature. 
 Correlation of concentrations detected with self-reported 
cannabis use  
Twenty specimens from known cannabis users were analysed in this study. It was 
found that both analytical methods are suitable for detecting THC, CBD, CBN and 
THC-COOH in both types of users. However, there was no difference in the 
concentrations of THC, CBD, CBN and THC-COOH detected for weekly and daily 
users. As non-daily and daily use is not reflective of the actual dose consumed by 
a user, the weekly use score was calculated based on information provided by 
users on their use history. This score is an estimation of number of joints/spliffs 
they had smoked on a weekly basis in the three months prior to admission to the 
addiction hospital. Users reported a constant behaviour of smoking over the three 
months, therefore, the correlation between the concentrations in the hair 
segment that represent the last three months and weekly use score was 
investigated. Statistical analysis showed no correlation between the 
concentrations of the individual analytes detected and weekly use score. The lack 
of correlation can be explained by the following factors including: variability of 
hair-growth cycle, multiple mechanisms of drug incorporation and considerable 
variation in uptake of drug from blood to hair, influence of cosmetic treatments 
and hygienic practices, uncertainty of dosages ingested by abusers (number of 
joints/spliffs and days), typical underestimation of self-reported doses, unknown 
purity of compounds (THC and CBD content), rate of sweating and amount of 
apocrine and sebaceous gland secretions between individuals and degree of 
exposure to cannabis smoke. Better correlation may have been achieved if these 
factors were taken into account with a greater sample size. 
 Conclusion  
This chapter has demonstrated that the two methods developed and validated in 
chapters 3 and 4 are suitable for the analysis of authentic hair specimens for the 
detection of THC, CBD, CBN and THC-COOH. The authentic hair specimens were 
collected from cannabis users, who were admitted to Al-amal addition hospital, 
Jeddah, Saudi Arabia. Users reported the number of joints/spliffs they smoked in 
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a day and the number of days in a week. The first method on the standard GC-MS 
was found to be suitable to prove exposure by detection of the main cannabinoids, 
THC, CBD and CBN. While the other method using the 2D GC-MS was found suitable 
to prove ingestion by detection of THC-COOH. Similar to conventional biological 
samples, the detection of other cannabinoids (cannabinol (CBN), cannabidiol 
(CBD)) in hair serves as a plausible control due to their higher stability as 
compared to THC. There was no correlation between the concentrations of all 
analytes and the frequency of use or self-reported doses. A lower LOQ for the 
main cannabinoid THC may increase the detectability. CBD and THC-COOH had 
the highest detection rate. 11-OH-THC was not detected in any case sample. This 
was expected due to the higher LOQ. The use of fraction ‘B’ of sample (A) to carry 
out further clean-up using SPE for THC-COOH was proven to be an acceptable 
approach. However, case samples with much lower concentrations may become 
undetectable. 
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 Introduction to Environmental Tobacco 
Smoke (ETS) Exposure  
 Introduction 
 Indoor air pollutants  
According to the United States Environmental Protection Agency (EPA), air 
pollution happens when the air contains gases, dust, fumes or odour in harmful 
amounts. That is, amounts which could be harmful to human and animal health or 
comfort or which could cause damage to plants and materials. In the World Health 
Organisation (WHO) 2014 report, it was estimated that air pollution, household 
and ambient, has caused the deaths of around 7 million people worldwide in 2012 
which is about one in eight of total global deaths (199). This finding more than 
doubles previous estimates and confirms that air pollution is now the world’s 
largest single environmental health risk. From the same report, 4.3 million deaths, 
globally, were attributable to indoor (household) air pollution alone. The main 
sources of indoor air pollution worldwide include indoor combustion of solid fuels, 
outdoor air pollutants, emissions from construction materials and furnishings, 
tobacco smoking, and inadequate maintenance of ventilation and air conditioning 
systems. While some indoor air pollutants, such as environmental tobacco smoke 
(ETS), are gaining increasing attention globally, profiles of indoor air pollutants 
and the consequential health risks are generally very different in developed and 
developing countries.  
In Europe, ETS has been of concern since 1987 when the first edition of the air 
quality guidelines for Europe included a chapter on radon and an annex on tobacco 
smoke, indoor air pollutants with substantial adverse public health impacts. In the 
second edition published in 2000, a section on indoor air pollutants and added 
manmade vitreous fibres to radon and tobacco smoke was provided (200). Since 1 
July 2007, smoke-free workplace laws have been in effect across the whole of the 
UK.  
In the United States of America (USA), tobacco smoke has been identified as a 
toxic air contaminant since 2005 (201). The Surgeons General and EPA have 
undertaken a more proactive role in informing the American public on health risks 
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associated with environmental tobacco smoke exposure (202–208). As smoking 
bans in the United States are entirely a product of state and local criminal and 
occupational safety and health laws, there is no national-wide ban of smoking so 
far. In 2000, California became the first state to ban smoking in bars and 
restaurants. As of July, 2016, 25 States have enacted Statewide bans on smoking 
in workplaces and restaurants and bars, according to the American Nonsmokers 
Right Foundation (ANRF) (209). 
In  Singapore, the Health Promotion Board (HPB) estimated that ETS caused twice 
as many deaths as all other types of air pollution combined (210). The 2005 WHO 
global update of the air quality guidelines drew attention to the large impact on 
health of indoor air pollution in developing countries (211). 
 Environmental Tobacco Smoke (ETS) Exposure  
Smoking is a widely acknowledged threat to human health. Environmental tobacco 
smoke (ETS), also known as second-hand smoke (SHS), involuntary smoking (IS) or 
passive smoking (PS), is a significant contaminant of indoor air following active 
smoking. Although ETS is not a leading human cause of air pollution, it poses a 
substantial health risk especially after long-term exposure in enclosed spaces. It 
is the main source of exposure to a large number of chemicals that are known to 
be hazardous to human health. In a study conducted in Italy in 2004, the 
particulate matter released from three lit cigarettes was found to be ten times 
higher than the output from a diesel engine after 30 minutes in a controlled 
environment (212). Tobacco can be smoked in different forms such as smoking of 
a cigarette, cigars, pipes, and water pipes2 such as shisha, hookah, narghile, or 
hubble-bubble. However, cigarettes and bidis3 were found to be the main sources 
of exposure among non-smokers or smokers from secondary smoking by others. 
ETS contains approximately 50 chemicals recognized as known and/or possible 
human carcinogens, other animal carcinogens, and many toxic and irritant agents 
(213). Since 1928, there have been reports published drawing attention toward 
                                         
2 Water pipes are known by other various names such as gaza, hookah, narghile, shisha, hubble-
bubble and, are commonly smoked in the Eastern Mediterranean region, in some parts of Asia 
including India, and in North Africa. A typical modern water pipe consists of a head with holes in 
the bottom, a metal body, a glass water bowl, and a flexible hose with a mouthpiece 
3 Bidis are small, thin, hand-rolled cigarettes primarily made of coarse and uncured tobacco. These 
kind of cigarettes account for about 60% of smoked tobacco products in India. 
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the harmful effects of ETS (214). Evidence relating to the negative health effects 
of ETS have accumulated over the years from many studies carried out in different 
parts of the world, however, ETS remains a common indoor air pollutant across 
the world. Approximately 85-90% of the smoke from each cigarette turns out in 
the air to be ETS.  
Two types of smoke are produced by a lit cigarette; mainstream and sidestream 
smoke. Mainstream smoke (MS) is the smoke that is inhaled by the smoker through 
the filter tip of the cigarette, and then exhaled. While sidestream smoke (SS) from 
the burning end of the cigarette goes straight into the atmosphere. Toxic 
chemicals from ETS pollution are detected well beyond the period of active 
smoking, and contaminate furniture, clothes, food, equipment and other 
materials. Even in well-ventilated places, these toxins can persist for weeks and 
months after smoking (215).  
 Composition of tobacco smoke 
ETS usually consists of approximately 85% sidestream smoke and 15% mainstream 
smoke. Sidestream smoke, which has a higher temperature and does not pass 
through the cigarette's filter tip, has higher concentrations of chemicals than 
mainstream smoke. Analysis of mainstream and sidestream cigarette smoke 
particulate matter by laser desorption mass spectrometry has revealed that they 
have a very similar composition (216). However, other toxic compounds and 
combustion products may vary in their concentrations (217). Tobacco smoke is a 
mixture of more than 5300 compounds, 500 of which have been measured in 
mainstream and sidestream smoke (218). Of these by-products of ETS, 172 are 
known toxic substances. There are over 70 carcinogens in tobacco smoke that have 
been evaluated by the International Agency for Research on Cancer (IARC) 
monographs programme as having adequate evidence for carcinogenicity in either 
laboratory animals or humans (219). Many tobacco alkaloids are present in the 
ETS, including nornicotine, anatabine and anabasine, however, the addictive 
properties of tobacco smoke are believed to be due to the presence of nicotine, 
the principal tobacco alkaloid in smoke (220). 
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 Implementation and effectiveness of smoke-free policies 
As tobacco smoke is classified as carcinogenic, the impact of environmental health 
on humans becomes more obvious. In fact, this has encouraged policymakers, 
public health strategists and air quality experts to prioritise clean air. Since the 
WHO encouraged participant nations to follow Article 8 of the Framework 
Convention on Tobacco Control4 (FCTC) (221), smoke-free policies have come into 
effect worldwide to protect people from ETS. Following the FCTC treaty, the WHO 
published in 2007 guidelines on the protection from tobacco smoke, to support 
countries’ efforts for implementation of Article 8 (222). Since then, the WHO 
published a series of reports that follow the status of the tobacco epidemic and 
the effectiveness of polices implemented to stop it. The first WHO report on the 
global tobacco epidemic was published in 2008. This report provided countries 
with a guideline to reverse the highly destructive global tobacco epidemic and 
introduced the so called ‘MPOWER5’ package (223). The second report was 
published in 2009, this report concentrated on the progress made in implementing 
the smoke-free policies and reported a worldwide implementation in enclosed 
workplace and public places, and public transportation (224). Ireland was the first 
country with comprehensive smoke-free legislation implemented in 2004 before 
FCTC came into force in 2005, followed by countries like Norway, New Zealand, 
Italy, Spain, Uruguay, England and many provinces or states in Canada, the USA 
and Australia. In Scotland, legislation to ban smoking in most enclosed public 
places was introduced in March 2006. Following the expansion in implementing 
the smoke-free polices, many studies have been conducted to measure the impact 
of the new legislation on public health and smoking cessation in different countries 
(225–230). The third WHO report, published in 2011, examined in depth the two 
principal strategies to provide health warnings – labels on tobacco product 
packaging and anti-tobacco mass media campaigns. It provides a comprehensive 
overview of the evidence base for warning people about the harms of tobacco use 
as well as country-specific information on the status of these measures.  
                                         
4 FCTC is a treaty adopted by the 56th World Health Assembly on 21 May 2003. 
5 MPOWER encompasses six policies proposed to counter the tobacco epidemic and reduce its 
deadly toll. 
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The fourth report provided a special focus on legislation to ban tobacco 
advertising, promotion and sponsorship (TAPS) in WHO Member States and an in-
depth analyses of TAPS bans were performed, allowing for a more detailed 
understanding of progress and future challenges in this area. The latest report, 
published in 2015, has a particular focus on tobacco taxation and includes in-depth 
analyses of tobacco taxes and prices in all WHO Member States, allowing a detailed 
understanding of progress and future challenges in this area. The WHO 2015 report 
estimated that about 2.8 billion people (40% of the world’s population) in more 
than half of the world’s countries, have implemented at least one MPOWER 
measure at the highest level of achievement. Despite the wide enforcement of 
smoke-free legislation worldwide, some sources reported that around 93% of the 
world’s population is still living in countries not covered by fully smoke-free public 
health regulations (214). Moreover, some studies showed that smoking ban polices 
in public places have led to an increase in indoor exposure, particularly in young 
children, to tobacco smoke as smokers shifted smoking from public to private 
places (231). 
 Measurement of ETS Exposure 
It is difficult to measure the exposure of a passive smoker to environmental 
tobacco smoke. Many factors have a role to play in determining the degree of 
exposure which in turn makes it difficult to standardise the exposure levels. These 
include, the number and type of cigarettes, the number of smokers present in the 
room, the rate and manner of smoking, the room size, temperature, air exchange 
rate (ventilation) and humidity. All of these factors have to be considered 
carefully when interpreting the data regarding constituents of ETS obtained from 
indoor space. 
Historically, ETS can be assessed by different means such as questionnaires, air 
monitoring, modeling of concentrations, or biological markers. In the 1980’s it was 
established that cigarette smoking is a powerful source of fine indoor airborne 
particulate matter <2.5 µm (PM2.5) and gas phase nicotine which was found to be 
a sensitive and specific marker of ETS. Unlike nicotine, many other markers, 
although present in the ETS, are not specific to tobacco smoke, such as PM2.5, may 
arise from a range of sources. So far, none of the markers in use, however, meet 
all of the 1986 National Research Council (NRC) criteria. Additionally, there is no 
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single constituent that will reveal the full disease risk from the complex mixture 
that comprises ETS. It can be concluded that the purpose of the study dictates the 
choice of method for measuring ETS.  
According to the 1986 NRC report, the ideal marker for ETS exposure measurement 
should be; 1) exclusive (or almost exclusive) to tobacco smoke, 2) a component of 
tobacco smoke that is present in an adequate amount so that it can be measured 
even at low ETS levels, and 3) present at a fairly constant ratio across different 
brands of cigarettes to other tobacco smoke constituents (or contaminants) of 
interest. In addition to the above criteria, it is important to obtain reliable 
information on the amount, transport, and the fate of such chemicals in normal 
indoor environments. The majority of ETS exposure studies have used either PM2.5 
as an indicator to the degree of exposure due to its extensive release from the 
tobacco combustion within indoor spaces or nicotine due to its exclusive presence 
in tobacco smoke. Other proxy constituents have been measured in a number of 
studies as indicators of ETS exposure either in personal or indoor space monitoring. 
Carbon monoxide, cotinine, nitrogen oxides, acrolein, nitroso-compounds, and 
benzo[a] pyrene are some of the compounds or classes of air contaminants that 
have been measured under field conditions as indicators of ETS exposure. 
Biomarkers specific to ETS can be targeted in different biological samples to 
indicate the level of exposure.   
 Biological markers 
Nicotine and its metabolites, and metabolites of 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone (NNK) are considered to be specific biomarkers to ETS 
exposure. Metabolites of nicotine (cotinine, trans-3'-hydroxycotinine and their 
glucuronides, and nicotine glucuronide) and NNK (NNAL (4- [methylnitrosamino]-
1-[3-pyridyl]-1-butanol) and its glucuronides) can be measured in people exposed 
to ETS, with high sensitivity in different biological matrices. The selection of an 
ETS biomarker and biological matrix is based on many factors including the aim of 
the study, the scientific or public health knowledge gap, subjects, and available 
resource. A combination of different biomarkers, or matrices, is often the best 
approach (232).  
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About 75% of the nicotine absorbed by the body is metabolised to form cotinine 
(220). Cotinine concentrations are more constant during the day with a longer 
half-life (t1/2) (about 16 hours) than nicotine (about 2 hours). This makes cotinine 
the preferred biomarker to measure ETS exposure in blood, saliva and urine. 
Despite the fact that cotinine has a similar half-life (t1/2) in blood, saliva and urine, 
the cotinine concentrations in urine averaged four to six times higher than those 
in blood or saliva, making urine a more sensitive and convenient matrix to test for 
low-level exposure (233). Up to 15 metabolites of nicotine including nicotine N-
oxide, cotinine, norcotinine, cotinine N-oxide and trans 3-hydroxy cotinine have 
been detected in urine [2]. Many studies reported the use of urine tests to measure 
the amount of cotinine in the body (234–236). Cotinine use as a biomarker of 
environmental tobacco smoke exposure was reviewed by Benowitz (237). 
Unlike biological fluids, deposited nicotine on the outer surface of hair can be 
targeted to measure the ETS exposure. This is because it does not undergo a 
further enzymatic biotransformation. Chemical transformation of nicotine is 
possible either before adhering to the hair during burning of tobacco or later by 
atmospheric oxidation and/or reacting with hair treatment products (238). 
However, it is assumed that the slow reaction speed at ambient temperature will 
not degrade a high percentage of nicotine, and therefore, nicotine is still a valid 
ETS exposure indicator.  Al-delaimy et al measured and compared the two most 
popular biomarkers, hair nicotine and urine cotinine with questionnaire reports of 
ETS exposure for 322 children aged 3-27 months and concluded that hair nicotine 
is a more accurate biomarker, especially for assessment of long-term ETS exposure 
(239). In a recently published study, Kim et al conducted a similar experiment but 
this time, comparing utility of hair nicotine and salivary cotinine, as a biomarker 
of long-term ETS exposure, with questionnaire reports of ETS exposure for 289 
adult participants for smokers (N = 109) and non-smokers with exposure history (N 
= 105) and non-smokers with no exposure history (N = 77). According to the 
authors, hair nicotine was found to be a better indicator for long-term exposure, 
while salivary cotinine levels showed a better correlation with recent tobacco 
exposure. Both hair nicotine and its main metabolite cotinine have been most 
frequently measured in different published studies for different purposes  (240–
243).  
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 Health Effects of ETS 
ETS exposure is one of the most common avoidable health threats in the 
community. Worldwide, it is predicted that approximately one third of adults are 
regularly exposed to ETS. On the European list of the ten most common causes of 
severe human illness, smoking is ranked second. According to the 2009 WHO 
report, the estimated number of deaths that are attributable to tobacco is about 
5 million people each year worldwide, of which 28% were expected to be children 
(224). The EPA has as classified tobacco smoke pollution as a known cause of 
cancer in humans (Group A carcinogen). It estimates that ETS causes 
approximately 3,000 lung cancer deaths and 37,000 heart disease deaths in non-
smokers each year. Tobacco-specific nitrosamines (TSNAs) comprise one of the 
most important groups of carcinogens in tobacco products. These nitrosamine 
carcinogens are formed by the action of nitrous acid on nicotine, nornicotine, 
anabasine, and anatabine during curing and processing of tobacco (220). Eight 
tobacco-specific nitrosamines have been identified. N-Nitrosonornicotine, 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), and 4-(meth-ylnitrosamino)-
1-(3-pyridyl)-1-butanol (NNAL) are the most carcinogenic. The higher 
cardiovascular disease risk amongst smoke-exposed non-smokers is attributed to 
the oxidant gas exposure from ETS as it is believed to cause inflammation and 
subsequent endothelial dysfunction (244). Up to the present time, research has 
been focused on the health implications to children and adult non-smokers. 
Studies have established that ETS exposure among populations of different ages is 
a general health risk and exerts serious consequences on the cardio-respiratory 
system (245,246). Of all deaths attributable to second-hand tobacco smoke, 31% 
occur among children and 64% occur among women. 
 Health effects of ETS on neonates 
In pregnant women, the risk includes reduced foetal growth, low birth weight, 
pre-term delivery and sudden infant death (201,247). The other risks are 
spontaneous abortion, intrauterine growth retardation, adverse impacts on 
cognition and behaviour, allergic sensitization, elevated decreased pulmonary 
function growth and adverse effects on fertility or fecundity, and elevated risk of 
stroke (201).  
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 Health risks to children 
Tobacco smoke pollution is especially harmful to young children. Worldwide, at 
least 40% of children are regularly exposed to ETS after birth (214). EPA estimates 
that ETS is responsible for between 150,000 and 300,000 lower respiratory tract 
infections in infants and children under 18 months of age annually, resulting in 
between 7,500 and 15,000 hospitalizations each year (200). Tobacco smoke 
pollution is harmful to children with asthma. The EPA estimates that for between 
200,000 and one million asthmatic children, exposure to ETS worsens their 
condition (248). Although ETS exposure is a well-recognised risk factor for cancer 
among adults, there was evolving evidence that it might also be linked with 
childhood cancers (247,249,250). Diseases such as adult cardiovascular disease are 
now believed to be progressive inflammatory diseases started in childhood (251).  
 Health effects of ETS on animals 
There are only a few studies in the literature that have investigated the effects 
of smoking on animals. Tobacco smoke contains three known animal carcinogens 
(248). The N-nitrosodimethylamine (NDMA), which is an animal carcinogen of a 
volatile nature, reported to be present in tobacco smoke and released 20-100 
times higher in sidestream (SS) than in main stream (MS) smoke (248). The 
association between ETS and disease has been difficult to prove as assessed by 
questionnaire-based studies (252–254). However, in dogs, ETS exposure appears 
to increase the relative risk of cancer of the lung (255), nasal cavity and paranasal 
sinuses(254). Hawkins et al investigated the relationship between ETS exposure 
and chronic coughing in dogs but no association was confirmed (256). In contrast, 
Roza and Viegas reported an association of ETS exposure with elevated numbers 
of macrophages and lymphocytes and macrophage anthracosis in bronchioalvealor 
lavage fluid collected from Yorkshire terriers (257). In pet cats, the finding of 
research carried out by Bertone et al suggested that the passive exposure to 
tobacco smoke may increase risk of malignant lymphoma and oral squamous cell 
carcinoma (258,259). 
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 Nicotine and Related Alkaloids in Tobacco Products 
The basic raw materials used in the tobacco industry are plants of the genus 
Nicotiana, belonging to the Solanaceae family (Figure 6-1). For which there are 67 
sub-species originating from the Americas and Australia. The most common 
species used in the industry is Nicotiana tabacum L. At present, these plants are 
cultivated in many other parts of the world for production of tobacco leaf for 
cigarettes.  
 
Figure 6-1 Nicotiana tabacum L 
 
Nicotine is the major tobacco alkaloid occurring at about 1.5% by weight in 
commercial cigarette tobacco and comprising about 95% of the total alkaloid 
content. The minor alkaloids nornicotine, anatabine and anabasine are the most 
abundant in most tobacco products. However, nornicotine levels are highest in 
cigar tobacco, anatabine levels are lowest in chewing tobacco and oral snuff, and 
anabasine levels are lowest in chewing tobacco (260). In general, the tobacco 
alkaloids are not considered as carcinogenic. Figure 6-2 shows the chemical 
structure of most abundant tobacco alkaloids. 
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Figure 6-2 Structures of tobacco alkaloids. 
 
Nicotine, which was first isolated in 1828 from tobacco, is an extremely toxic 
alkaloid that leads to stimulation of autonomic ganglia and the central nervous 
system (CNS) (261).  
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 Chemical properties of Nicotine 
Nicotine is also called 3-(1-methyl-2-pyrrolidinyl) pyridine according to the IUPAC6 
nomenclature. As illustrated in Figure 6-3, it is a bicyclic compound with both a 
pyridine and a pyrrolidine ring. The molecule possesses an assymetric carbon and 
so exists in two enantiomeric forms. 
 
 
Figure 6-3 Nicotine chemical structure 
 
Nicotine in tobacco is largely the levorotary (S)-isomer; only 0.1–0.6% of total 
nicotine content is (R)-nicotine (220). Unlike nicotine, the minor alkaloids 
anatabine, nornicotine, and anabasine and their N-nitroso derivatives are present 
to a substantial degree as the (R)-isomer (about 16, 20, and 42%, respectively) in 
tobacco products (220). Although nicotine (NIC) has a simple chemical structure, 
it undergoes an extensive biotransformation in the body and produces many 
metabolites. The presence of both aromatic and aliphatic carbon and nitrogen 
atoms on the nicotine structure provide many sites for different metabolic 
reactions.  
 
                                         
6 the IUPAC nomenclature of organic chemistry is a systematic method of naming organic 
chemical compounds as recommended by the International Union of Pure and Applied 
Chemistry (IUPAC).  
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 Nicotine Pharmacology in Humans 
 Absorption 
After a puff, nicotine is extracted from burning tobacco and carried proximally on 
tar droplets, which are inhaled. When tobacco smoke reaches the small airways 
and alveoli of the lung, nicotine is rapidly absorbed. This is due to the huge surface 
area of the alveoli. Moreover, the dissolution of nicotine in the fluid (pH 7.4) in 
the human lung facilitates transfer across membranes. Shortly after a puff, high 
levels of nicotine reach the brain in 10–20 s (260).  
 Metabolism 
Nicotine is mainly transformed in the liver. The most important metabolite of 
nicotine in humans is cotinine. Quantitatively, approximately 70 – 80% of nicotine 
is converted to cotinine. This conversion involves two steps; firstly, nicotine is 
converted to the nicotine-Δ1′ (5′)-iminium ion, by CYP2A6, which is further 
transformed into cotinine by the aid of cytoplasmic aldehyde oxidase (AO) 
enzyme. The second most abundant nicotine metabolite is nicotine N′-oxide (NNO) 
(4-7%). The formation of this metabolite is mediated by flavin-containing mono-
oxygenase 3 (FMO3) enzyme. In humans, the 1′-(S)-2′-(S)-trans-isomers are usually 
formed. Approximately 0.4-0.8% of nicotine is biotransformed into nornicotine by 
oxidative N-demethylation. Nicotine glucuronides (phase II metabolites) are 
formed by methylation of the pyridine nitrogen resulting in the nicotine 
isomethonium ion and glucuronidation. This reaction is catalysed by uridine 
diphosphate-glucuronosyltransferase (UGT) enzyme(s) producing (S)-nicotine-N-β-
glucuronide. About 3–5% of nicotine is converted to nicotine glucuronide and 
excreted in urine in humans (220,260). Figure 6-4 shows the main metabolic 
pathways of nicotine.  
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Figure 6-4 Main metabolic pathways of nicotine 
 
 Distribution 
Smoking is a unique form of drug administration in that entry into the circulation 
is through the pulmonary rather than the systemic venous circulations. The time 
interval between smoking and entry into the brain is shorter than after intravenous 
injection. Nicotine enters the brain quickly, but then brain levels decline rapidly 
as nicotine is distributed to other body tissues. Because it is lipid soluble, nicotine 
has a large distribution volume (2 to 3 L/kg) and readily permeates cell 
membranes. 
 Excretion 
It is important to mention that the percentages reported in section 6.6.2 represent 
the primary metabolic conversion products only and do not represent the final 
proportions of excreted metabolites in urine. Only 5% of a dose of NIC is excreted 
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unchanged in urine within a 24-hour period. The main metabolites of nicotine in 
urine are 3′-Hydroxycotinine and its glucuronide conjugate and Nicotine-N′-oxide 
(NNO) which account for 40-60% and 4%, respectively. The quantities of all other 
known metabolites are less than 5%. Acidity of urine enhances nicotine excretion 
and has limited effect on cotinine excretion. The elimination half-life of nicotine 
in humans, ranges from 1 to 3 hours while cotinine has a much longer elimination 
half-life of 10 to 14 hours. 
 Applications for measuring hair nicotine 
concentrations (HNC) 
By reviewing the literature, 49 papers were identified to report a usage for the 
measurement of hair nicotine concentrations (HNC). Based on the main aim of the 
work, it was possible to classify them into 4 categories as illustrated in the below 
Table 6-1.  
Table 6-1 Main applications of HNC in the literature 
Main category Subcategory References 
Report on advances 
in analytical 
method(s)  
 (196,262–267) 
Pharmacological 
study 
(268,269) 
ETS exposure-disease 
relationship 
(239,244,270,271) 
 
 
 
 
ETS exposure 
Mixed-gender 
adults 
(240,261,265,272–282) 
Women only (283–285) 
Infants or children (239,243,244,252,267,270,271,286–
288) 
Infants or children 
with their 
caregiver 
(241,242,289–296) 
Companion 
animals (pets) 
(238,297) 
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Reporting advances in the analytical methods was the main aim of several papers. 
Simultaneous and sensitive methods for measurement of nicotine and cotinine in 
small amounts (1 mg) of human hair using LC-MS/MS using a guard column and 
without analytical column was reported by Ryu et al (264). Nicotine and cotinine 
were included in a LC-MS/MS simultaneous methods for 14 and 17 drugs of abuse 
in hair by Kronstrand et al (266) and Koster et al (196), respectively. Pichini et al 
reported an attempt to develop hair reference material for nicotine and cotinine 
and evaluated different hair treatments and extraction procedures (262). Sporkert 
et al developed a solid-phase micro-extraction (SPME)  method for a number of 
organic compounds including nicotine with a 1 ng/mg limit of detection (263). 
Karačonji et al optimised the SPME method that Sporkert et al started and focused 
on analysis of nicotine in hair and achieved a lower limit of detection at 0.02 
ng/mg (267).  
Another reason for quantifying nicotine, with/without its metabolites, in hair is 
to investigate long-term ETS exposure-associated diseases and possible links 
among groups of people. Groner et al measured hair nicotine concentrations in 
145 subjects (9 to 18 years old) to investigate the impact of ETS exposure on 
cardiovascular status during childhood (244). Collaco et al investigated hair 
nicotine levels in 117 children with bronchopulmonary dysplasia (271).  
Another reason for measuring HNC is to assess the pharmacology of nicotine in a 
selected group of subjects. Klein et al published a paper that looked into the 
changes in nicotine metabolism in 28 pregnant women who self-reported a steadily 
smoking behaviour during the whole gestational period (268). The paper reported 
an increase in nicotine and cotinine metabolism during pregnancy. Apelberg et al 
examined racial variations in HNC among 103 daily tobacco smokers. The authors 
concluded that, under controlled smoking conditions, black smokers have 
considerably higher nicotine levels in their hair than white smokers. The most 
dominant application for measurement of hair HNC is to measure ETS exposure 
and assess the utility of hair nicotine and/or its metabolites to discriminate active 
from passive smokers. Validity and acceptability of HNC for ETS exposure were 
examined by comparing the concentrations with the self-reported, or parental-
reported use in cases involving children using a questionnaire. This category can 
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be further divided into 5 subcategories based on the different subjects. This will 
be covered in the following 5 sections.  
 ETS exposure studies employing mixed-gender adult 
subjects 
To assess ETS exposure, Jones et al measured air nicotine in 240 bars and 
nightclubs in 24 cities, and found elevated levels of nicotine in non-smoking and 
smoking workers’ hair (n=625) (280). Similarly, Iglesias et al, evaluated the 
contribution of occupational against non-occupational ETS exposure to overall 
HNC in non-smoking bar and restaurant employees from Santiago, Chile (281). 
They concluded that working hours was the major determinant of hair nicotine 
concentrations in non-smoking employees in venues where smoking is allowed. In 
addition to air and hair nicotine, Agbenyikey et al measured the fine fraction of 
particulate matter (PM2.5) to assess ETS exposure in selected hospitality venues in 
Ghana (279). The authors found unacceptably high levels of ETS in public places 
where smoking was allowed. The concentrations of nicotine in air and non-smoking 
employee’s hair were strongly and positively correlated with PM2.5 concentrations 
in the air. To compare ETS exposure, biomarker concentrations found in different 
biological fluid and hair, Kim et al compared nicotine levels in hair with cotinine 
levels in saliva samples collected from the same subjects (282). Hair nicotine 
concentrations were found to be a more useful biomarker for the assessment of 
long-term exposure to tobacco, while, on the other hand, salivary cotinine 
concentrations were better reflecting recent tobacco exposure. Toraño et al 
determined simultaneously nicotine, cotinine and thiocyanate in urine, saliva and 
hair of 44 subjects (276). The authors were able to correctly classify 93.2% of 
active smokers from passive smokers by a combination of these three biomarkers 
using discriminant analysis. Polycyclic aromatic hydrocarbons (PAHs) are 
carcinogens formed as by-products of incomplete combustion of organic material. 
As PAH is not a specific indicator of ETS exposure, Appenzeller et al developed a 
simultaneous method to determine nicotine and twelve mono-hydroxy-PAHs in 
human hair. The work aimed to assess tobacco smoke contribution in PAH exposure 
(265). The method presented in their work is a useful tool for the accurate 
biomonitoring of chronic exposure to PAH and correct identification of the sources 
of exposure. 
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 ETS exposure studies employing women only 
Hair nicotine is an excellent tool for assessment of cumulated exposure to tobacco 
smoke exposure over a long time period. Several studies employed mother hair to 
test for nicotine concentrations, as an indicator of exposure during pregnancy, 
and then correlated these to their neonatal outcome. Using hair as a sample of 
choice,  the effect of maternal tobacco smoke exposure, through active or passive 
smoking, on preterm birth, foetal growth and/or birth weight was assessed in four 
different articles (283–285,298). All four studies confirmed the finding of studies 
that were performed using different biological matrices and agreed that the 
exposure from active and, to lesser extent, passive smoking is closely associated 
with infants being small for gestational age, low birth weight births, and increases 
risk of infant health problems.  
 ETS exposure studies employing infants or children 
Children, in particular, seem to be the most vulnerable population to be affected 
by ETS exposure. It is believed that the exposure to ETS considerably contributes 
to morbidity and mortality amongst children (299). As a result, many studies 
focused on assessing levels of exposure in children. Rasoloharimahefa-Rasamoela 
et al conducted a prospective cohort study to determine the ETS exposure among 
318 children (aged 10-11) in Brussels (288). Their findings indicated that about 2-
3% of children were active smokers despite the fact that they did not declare 
themselves as such, 53.4% of the children who did not actively smoke or live with 
a smoker had hair nicotine concentrations ranging from 0.63 ng/mg to 7.91 ng/mg. 
Similarly, Woodruff et al measured nicotine and cotinine in hair samples from 143 
Latino children to assess their exposure to tobacco smoke (270). This study 
suggested that hair nicotine may be a more valid and practical biological measure 
than hair cotinine. Sørensen et al quantified the nicotine and cotinine 
concentrations in hair and plasma of 411 infants and compared the data with 
parentally reported levels of exposure (243). The authors concluded that the 
association between ETS exposure and nicotine in hair is the strongest association 
even at relatively low exposure levels. 
202 
 
 
 ETS exposure studies employing infants or children with 
their caregiver 
Smoker parents (or primary caregivers) are usually the main source of long-term 
systemic tobacco exposure to children. Many studies tested either one or both 
parents with their infant or child. Seong et al examined the contribution of 
paternal smoking to maternal and neonatal ETS exposure during pregnancy. This 
was achieved by testing hair samples from sixty three trios over two years (295). 
The study findings indicated that paternal smoking inside the home leads to 
significant foetal and maternal exposure to ETS. Similar conclusions were drawn 
by Chan et al in Hong Kong. In Chan’s study, they looked into the exposure of the 
mother and children in families with a smoking father to assess the effectiveness 
of a newly-enforced smoke-free policy. Parents and their infants (<2 year of age) 
were recruited by Tzatzarakis et al to assess the validity and usefulness of hair 
nicotine–cotinine evaluation as a biomarker for monitoring ETS (296). The study 
findings identified the use of hair samples as an effective method for assessing 
exposure to tobacco. Maternal active or passive smoking during pregnancy is 
associated with foetal risk. Many studies looked into the levels of exposure in 
pregnant mothers and compared these with levels in newly-born babies’ hair 
(241,289,290). In a multicountry study (31 countries), hair samples from 2480 
women and children, potentially exposed to ETS, were analysed for nicotine. The 
study reported an increased risk of premature death and disease from exposure 
to ETS among women and children living with active smokers. 
 ETS exposure studies employing the companion animals 
(pets) 
ETS exposure as a results of passive smoking was investigated using fur samples 
from companion animals (pet dogs) only in one paper by Bawazeer  et al (238). 
The limited number of dogs (15 dogs) was a major limitation, however, the levels 
of biomarkers detected in the dog’s fur gave a clear indication that companion 
animals fur could be a promising alternative to human hair to monitor long-term 
cumulative ETS exposure. Bertone et al carried out a study to evaluate whether 
exposure to ETS may increase the risk of feline malignant lymphoma in 80 cats 
with malignant lymphoma and 114 controls (258). The study findings indicated 
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that duration and quantity of exposure to ETS is positively associated with the risk 
of malignant lymphoma in cats.  
 Summary of experimental methods for the analysis of 
NIC and COT in hair 
 Hair collection  
According to the Society of Hair Testing (SOHT) guidelines for drug testing in hair, 
the posterior vertex region of the head, as close as possible to the scalp, is the 
preferred region due to the uniformity of growth rate. Many studies that targeted 
hair nicotine reported collection of the samples from this region 
(196,241,267,268,270,278,284,285). Other areas have been reported. Zahlsen et 
al reported hair sampling from the borderline between hair and the naked skin 
behind each ear (274). This site, according to authors, has sufficient contact with 
surrounding air to measure the exposure.  
 Hair storage 
After collection, hair samples can be stored at room temperature for years within 
closed envelopes without loss or degradation of hair nicotine. Hertting et al 
identified nicotine in hair samples from Egyptian Mummies while Musshoff et al 
determined nicotine in hair samples of pre-Columbian mummies (300,301). 
 Hair mass 
The SOHT guidelines do not recommend a specific hair mass for analysis, however, 
as a rule of thumb, it is always recommended to use as small hair sample as 
possible. This is compromised sometimes by the method sensitivity. In the 
reviewed literature, researchers reported different hair mass ranging from a few 
milligrams (243,264,287,295) to 100 mg (273). In fact most of studies reported 
hair mass in the range of 10-50 mg (196,238,267,276,277). The employed 
analytical method and recruited subjects may dictate the hair mass volume. Lower 
hair volume was reported when RIA only was used (241,270). Jacqz-Aigrain 
reported collecting 50-80 mg maternal hair and only 5-10 mg neonatal hair (290). 
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 Hair washing 
The first step after sample collection is the washing step to remove external 
contamination. Indeed, the question of whether the hair should or should not be 
washed, especially in case of ETS exposure studies, remains an issue. In general, 
it is preferable to include a washing step if the experiment is designed to measure 
inhaled exogenous nicotine or metabolites. In contrast, a washing step is not 
necessary when active smoking is excluded and the aim of the study is to measure 
the nicotine from ETS whether inhaled or deposited on the outer surface of hair.  
It is becoming common practice to refer to hair levels of nicotine and cotinine 
from unwashed hair as total nicotine and total cotinine. A range of washing 
solvents, including, water, acetone, methanol, dichloromethane, and detergent 
washes has been reported to be used to wash nicotine from the hair 
(238,241,252,263,270). Haley and Hoffmann compared the efficiency of acetone 
and hexane for hair washing. Dichloromethane (DCM) is believed to be a very 
effective solvent for washing nicotine from hair compared to a range of solvents 
(262). DCM has been reported as the washing solvent for nicotine from the hair in 
many studies (243,252,277,287,292,293,295). When washing is essential, it is good 
practice to retain the washings for analysis, if needed. 
 Hair digestion 
Following hair washing, the next step is to remove the incorporated drugs out of 
the keratinous matrix. Even if the research aims to investigate the ETS exposure 
only, it is important to get access to the drugs inside the hair. The deposition of 
drugs that are smoked, such as marijuana and nicotine from atmosphere could 
also be a possible route of incorporation into hair (302–305). Several laboratory 
methods have been developed to get access to the analytes of interest in hair, 
namely alkali or acid hydrolysis or extraction with organic solvents (mostly used 
methanol, hexane, acetone). Basic extraction using sodium hydroxide (NaOH) is 
favourable when substances (like THC, nicotine, antidepressants) are stable in 
aqueous NaOH. It is also the most reported method in the literature for extraction 
of nicotine from hair  (252,262,264,265,267,273,274,287,293,297,298). However, 
Stout et al, based on their experiment, claim that sodium sulfide digestion of hair 
is a more efficient method of recovery of base-stable drugs from hair than the 
commonly used sodium hydroxide digest (306). Moreover, Bawazeer et al 
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compared the efficiency of alkaline and methanol for extraction of nicotine and 
its metabolite from dog’s fur and concluded that the levels of nicotine obtained 
by  both methods were found to be comparable (238).  
 Extraction (sample clean-up) 
Following hair digestion, some form of further cleaning is usually required. The 
sample preparation could be as simple as “dilute (or centrifuge) and shoot” or 
more complex such as liquid-liquid extraction (LLE), solid-phase extraction (SPE) 
or solid-phase microextraction (SPME). Several methods have been described for 
the analysis of nicotine and its metabolite in hair. Many methods describe an 
extensive sample preparation by incubating the hair sample followed by LLE 
(261,272–274,277,287,293,295,298),  SPE  (252,262,278,287,297) or SMPE 
(263,267). The selection of extract cleaning method is dictated by many factors 
including employed digestion method and analytical instrumentation. Using 
alkaline hydrolysis will produce a very dirty extract which requires an extensive 
cleaning step before injection into a system such as GC-MS or LC-MS. In previous 
studies, diethyl ether was used most often for the extraction of hair nicotine 
(261,272–274,287,293,295,298). However, Chetiyanukornkul et al compared the 
extraction recoveries of diethyl ether and dichloromethane and reported better 
recoveries with the DCM (277).  
 Instrumentation 
Concentrations of nicotine and its metabolites have been determined by using a 
range of techniques, including gas chromatography (GC) (coupled with nitrogen-
selective detection (NSD) and mass spectrometry(MS)) and High Performance 
Liquid Chromatography (HPLC) coupled with Ultraviolet (UV) detection, 
electrochemical detection (ECD) and MS. Gas or liquid chromatography with mass 
spectrometry is most commonly used due to its advantage of simultaneous 
measurement of nicotine and its metabolites with deuterium labels used as 
internal standards. Table 6-2 summarises the instrumentations used in the 
included 49 papers. 
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Table 6-2 Analytical tecniques reported in the literture for analysis of nicotine and its 
metabolites in hair matrices 
Chromatography Detector References 
Gas chromatography NSD (NPD)  (271,272,279,291,294) 
MS (243,261,263,265,267,269,273–
276,280–283,292,293) 
 MS/MS (307) 
HPLC UV (252,262) 
ECD (239,244,284,287,308) 
MS  (238,277,296,297) 
MS/MS (196,264,266,278,295,298) 
Radioimmunoassay NA (240–242,268,270,285,286,290) 
No method reported  (288,289) 
 
There have been several studies investigating the concentrations of NIC and COT 
in hair after passive exposure. The range of concentrations detected in children 
hair is compared against the concentrations obtained in this thesis and shown in 
detail in section 8.8.1. 
 Aims  
 Method development for analysis of NIC and COT in hair 
The main aim of this project was to develop an analytical method for the 
quantification of NIC and COT in hair. The method developed for hair was used to 
analyse fur samples from dogs to establish the extent of exposure to ETS. There 
are many methods in the literature for the analysis of nicotine and cotinine in 
human hair, but there is only one method that has been applied to dogs’ fur 
specimens. Only one LC-MS method has been applied to dogs fur specimens and 
this did not achieve the sensitivity required for testing levels of NIC and COT in 
passively exposed subjects to ETS (238). A method was required that provided the 
acceptable selectivity and sensitivity for all of the chosen analytes. It needed to 
be relatively quick to enable efficient throughput in the laboratory. Optimised 
methanolic extraction with centrifugation provides a quick and simple method for 
the extraction of nicotine and cotinine from dogs’ fur samples. LC/MS-MS is an 
ideal instrumental technique for quantification of nicotine and cotinine in fur 
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specimens as it provides the required sensitivity (low pg/mg concentration range) 
and selectivity by eliminating unwanted background matrix interferences that are 
common in animal fur specimens. 
 Application of method to fur samples from companion pet 
dogs exposed to ETS 
There is limited data available for concentrations of NIC and COT detected in pet 
dog fur and the effect of ETS exposure on pets in general. It is not well-known 
whether pets’ fur can be used to measure the long-term ETS exposure and mimic 
the levels that children are exposed to or not. Unlike human hair, dogs’ fur is 
exposed only to limited hair treatments. This can be considered as an advantage 
for dog fur over human hair.  The extensive range of human hair treatments and 
washing is known to affect the concentrations and complicate results 
interpretation. The developed and validated method was applied to analyse 66 
pet dog fur samples that were collected and submitted for analysis from the School 
of Veterinary Medicine, University of Glasgow. This included a cross-section of 
cases that were representative of the cases normally received for treatment in 
the veterinary clinic. Analysis for NIC and COT was carried out to investigate the 
ETS exposure. Analysis of these cases was conducted to compare the results with 
the owner-reported ETS exposure levels in a questionnaire. 
 Cut-off values of hair nicotine and cotinine in companion 
animals fur to discriminate the degree of exposure to 
tobacco smoke 
As dogs have comparable hair growth rate to humans (297), it is expected that 
HNC should therefore mirror a similar time frame of ETS exposure. Our 
measurements on dog’s fur exposed to various degrees of ETS indicate that cut-
off limits for hair nicotine between heavy and light exposure may exist. Earlier 
studies proposed cut-offs to distinguish active and passive smokers. Zahlsen et al 
indicated that a cut-off limit probably exists somewhere between 2 and 5 ng/mg 
(274) . Kintz et al  indicated a cut-off limit at 2 ng/mg (273).   
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 Method Development and Validation of a 
Method for the Analysis of NIC and COT in Hair 
matrices 
 Introduction 
Nicotine (NIC) and cotinine (COT) are two of the most abundant naturally 
occurring tobacco-specific alkaloids. Various analytical methods have been 
described in the literature for analysis of nicotine and its metabolites in hair 
matrices. Different sample preparation procedures and instrumentation were 
reviewed in chapter 6. This chapter will focus on the method development and 
optimisation and validation carried out as part of this study. Chromatographic 
separation of nicotine and cotinine was achieved using a hydrophilic interaction 
chromatography (HILIC) column. Identification was achieved on the MS detector. 
Optimal MS parameters were obtained from direct infusion. The aim of this project 
was to develop and validate a method for the determination of nicotine and 
cotinine using liquid chromatography tandem mass spectrometry (LC-MS/MS). An 
optimised methanolic extraction method was employed. Validation was carried 
out according to guidelines of Scientific Working Group for Forensic Toxicology 
(SWGTOX). The validated method was then applied to the analysis of sixty-six fur 
samples to investigate dogs’ exposure to indoor and outdoor ETS.  
 Materials and Methods 
 Chemicals and reagents 
Cerilliant certified reference materials for s(-)-nicotine (1 mg/ml), (-)-cotinine (1 
mg/ml),  and internal standards, (+\-)-nicotine-d4 (100 µg/ml), (+\-)-cotinine-d3 
(100 µg/ml) and formic acid were obtained from Sigma Aldrich Company Ltd., 
Dorset, UK. Acetonitrile, methanol and dichloromethane (DCM) (HPLC grade) were 
obtained from VWR International Ltd, UK. Captiva Premium Syringe PES Filters 
(polyethersulfone (PES) membrane, 15 mm diameter, 0.2 µm pore size, LC/MS 
certified), were obtained from Agilent Technologies, UK. Chromacol 
Environmental Vials and 7 mL silanised vials were purchased from Thermo Fisher 
Scientific, UK. Ultrapure deionised water was obtained from the in-house Millipore 
purification system. 
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 Instrumentation 
Analysis was carried out using an Agilent LC–MS-MS triple quadruple G6430A mass 
spectrometer equipped with an Agilent 1200 series autosampler, A quaternary 
pump SL with degasser and thermostatted column compartment was used. Positive 
electrospray ionization (+ESI) was used and the MS operated in multiple reaction 
monitoring mode (MRM). Analytes of interest were separated on a SeQuant ZIC-
HILIC® column (150 x 4.6 mm, 5 µm), protected by a guard column with identical 
packing material (20 x 2.1 mm) both obtained from Merck Millipore, UK. 
 LC-MS-MS Operating Conditions 
The optimal conditions were achieved using a nebulizer pressure at 15 psi, a 
capillary voltage of 4,000 V, nitrogen gas heated to 350 °C and delivered at 11 
L/min. The column temperature was maintained at 40 °C. Gradient elution was 
employed using a mobile phase consisting of A: deionised water with 0.1% formic 
acid (FA) and B: Acetonitrile with 0.1% FA at a flow rate of 0.5 mL/min. The total 
run time was 30 min. The gradient mobile phase system started at 60:40 A/B 
increasing to 40:60 A/B within 10 min. The percentage organic content was then 
decreased to 60:40 A/B in 0.2 minutes and maintained for 19.8 min in order to 
condition the column before the next injection. LC and MS source parameters are 
summarized in Table 7-1. Optimal MS parameters were obtained by direct infusion 
of both drugs of interest and their deuterated ISTD to the electrospray ionisation 
(ESI) source in positive mode. The infusion solution consisted of 50/50 (v/v) of 
aqueous and organic mobile phase at a concentration of 1 µg/ml for all analytes. 
Following European Union Decision 2002/657/EC, 5 identification points were 
achieved by monitoring 2 precursor ions, each with 1 daughter ion for each 
analyte. The retention time ions ratios for both analytes are additional 
identification criteria that were monitored. Table 7-2 summarises the optimal MS 
transitions and parameters.  
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Table 7-1 Summary of LC and Ion Source Parameters 
LC Parameters 
Column SeQuant® ZIC®-HILIC (5µm,200Å) PEEK 150 x 4.6 
mm with guard column of the same packing 
material 
Mobile phase  A: dH2O with 0.1% FA and B: ACN with 0.1% FA  
10 mins: 60:40 A/B  40:60 A/B  
0.2 mins: 40:60 A/B  60:40 A/B 
19.8 mins:  maintained at 60:40 A/B 
Flow rate 0.5 mL/min 
Injection volume 20 µL  
Column Temperature  40ºC 
Run Time 30 minutes 
Mass Spectrometry Parameters 
Operating mode ESI-positive mode 
Gas temperature 350ºC 
Gas flow 11 L/min 
Nebulizer Pressure 15 psi 
Capillary Voltage 4000 V  
Scan mode MRM 
 
Table 7-2 MRM transitions of NIC, COT, NIC-d4 and COT-d3 
Drug Precursor 
Ion (m/z) 
FV* Abundance 
of precursor 
ion  
Product 
ion (m/z) 
CE# Abundance 
of product 
ion  
s(-) Nicotine, 
MW: 162.23 
163.00 100 35000 130 
117 
106 
10 
20 
20 
4000 
6500 
2500 
(±)-Nicotine-
d4, MW: 
166.20 
167.00 110 60000 136.2 
110.10 
10 
20 
3200 
1500 
(-)-Cotinine, 
MW: 176.22 
177.10 130 20000 98.00 
80.10 
20 
30 
5000 
15000 
(±)-Cotinine-
d3, MW: 
179.19 
180.00 115 28000 101.1 
80.10 
20 
30 
5000 
16000 
*Fragmentor Voltage 
#Collision Energy 
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 Preparation of Dogs’ Fur Sample  
 Blank fur 
It is recommended by SWGTOX to matrix match calibration standards and QCs to 
the type of specimens that are being analysed. Blank fur samples used for 
development and validation of the method were collected from 21 dogs of non-
smoker owners and reported to be living in tobacco-free houses with no active 
smoker. Samples were wrapped in aluminium foil and stored in the hair collection 
envelopes at room temperature within forensic medicine and science (FMS). The 
scissors were cleaned between participants, using methanol, and then dried with 
a paper towel before cutting the next sample. The fur samples were transferred 
from the collection envelope with clean tweezers. The used scissors and tweezers 
were cleaned with methanol before and after each sample. There was no contact 
between fur samples and hands during the sampling procedure. All 20 blank fur 
samples were pretested for the presence of nicotine and cotinine before pooling 
the fur to create a large analyte-free control. Table 7-3 summarises the results of 
blank fur screening tests. Sample analysis was carried out using the final optimised 
procedure that will be described in this chapter. Samples were designated positive 
if the signal to noise ratio was greater than 10 for all transitions. Samples were 
designated as positive at a concentration less than the limit of quantitation (<LOQ) 
where the measured concentration was less than LOQ but all transitions were 
present. All samples that tested positive or less than LOQ are highlighted in red in 
Table 7-3 .and Although all blank fur samples had a signal for the nicotine 
precursor transition, they were considered negative when one or both product 
transitions had a signal to noise ratio of less than 3. 
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Table 7-3 Screening results of 21 blank fur samples 
Blank ID Results Blank ID Results 
NIC COT NIC COT 
B1 NEG NEG B12 NEG NEG 
B2 <LOQ NEG B13 NEG NEG 
B3 NEG NEG B14 <LOQ NEG 
B4 NEG NEG B15 <LOQ NEG 
B5 <LOQ NEG B16 <LOQ NEG 
B6 NEG NEG B17 NEG NEG 
B7 NEG NEG B18 NEG NEG 
B8 POS POS B19 POS NEG 
B9 NEG NEG B20 <LOQ <LOQ 
B10 NEG NEG B21 POS <LOQ 
B11 <LOQ NEG 
   
 
The homogenized pools stocks were prepared by pooling negative blank fur 
specimens shown in Table 7-3. The pooled blank fur control was stored in 20 mL 
capped Chromacol environmental vials at room temperature to be used for 
preparation of calibrator and quality control specimens. 
 Fur washing 
20 mL Chromacol environmental vials with screw caps were used to store and 
weigh the fur prior to carrying out the wash procedure and extraction. The utilised 
washing procedure involved both organic solvent and aqueous solutions. As 
dichloromethane (DCM) is considered to be a suitable wash solvent because it does 
not swell the fur, 2 mL DCM was used to wash the fur first with 15 minutes of 
sonication, this step was repeated if needed. The second wash was achieved using 
2 mL deionised water with 3 minutes sonication followed by 2 mL methanol with 
less than a minute sonication to remove water residues and accelerate the drying 
process. Longer sonication with methanol was avoided to prevent fur swelling.  
After washing, fur samples were dried overnight in an oven at 40°C. The dry 
washed fur samples were cut with a pair of scissors into1-2 mm pieces. 30 mg of 
that was weighed and extracted on the day of analysis. The above described wash 
method was used to wash blank samples involved in nicotine and cotinine method 
validation and extraction recovery studies.  
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For optimisation of nicotine and cotinine release from hair into extraction solvent, 
and hence incubation time, 30 real case samples of good sample size were used. 
The wash procedure involved using the extraction solvent itself only (methanol 
with 0.1% formic acid) with sonication for 15 minutes at room temperature. Longer 
sonication with methanol was avoided to prevent fur swelling which could actively 
remove the drugs from inside the fur. For measurement of total nicotine and 
cotinine concentrations in the 66 case samples, no washing was involved. 
 
 Preparation of Solutions 
 Preparation of Stock and Working Standard Solutions 
Separate stock solutions of nicotine and cotinine (100 µg/mL) and nicotine-d3 and 
cotinine-d4 (10 µg/mL) were prepared from purchased stock solutions by 
transferring 1 mL to a 10 mL volumetric flask and making up to the mark with 
methanol, except cotinine-d4 which was received and hence diluted in 
acetonitrile. The prepared stock solutions were then stored at -20°C. Two sets of 
working solutions of the standards and internal standards were prepared at a 
concentration of 1 µg/mL (set1) and 100 ng/mL (set2) by dilution of the stock 
solutions using methanol. The prepared working solutions were stored at -20 °C. 
 Preparation of Quality Control (QC) Samples and Calibrators 
Quality control standards (QCs) were prepared and analysed in addition to 
calibration standards and samples to ensure that accurate results were being 
obtained for the specimens. For extraction recovery studies, QC materials 
preparation is described in detail for each experiment in section 7.5. For the 
method validation and case samples analysis, QC material was prepared in blank 
fur screened negative for nicotine and cotinine at concentrations of 0.01, 1, and 
5 ng/mg for both nicotine and cotinine. The quality control materials were freshly 
prepared on the day of analysis. Ten-point calibration curves at concentrations of 
0, 0.01, 0.05, 0.1, 0.5, 1, 2, 5, 10 and 20 ng/mg were prepared. Table 7-4 and 
Table 7-5 summarise the preparation of the control materials for method 
validation and calibration levels. 
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Table 7-4 Preparation of QC Materials for Method Validation and Case Samples Analysis 
QC 
points 
Working 
solution (µl) 
Extraction 
solvent (mL) 
Fur (mg) [ng/mg] 
QC 1 15 (set2) 2 30 ± 5 0.05 
QC 2 30 (set1)* 2 30 ± 5 1 
QC 3 150 (set1) 2 30 ± 5 5 
*Internal standard concentration  
 
Table 7-5 Preparation of Calibration Curves for Nicotine and Cotinine 
Cal. 
levels 
Working 
solution (µl) 
Extraction 
solvent (mL) 
Fur (mg) [ng/mg] 
Blank 0 2 30 ± 5 0 
Level 1 3 (set2) 2 30 ± 5 0.01 
Level 2 15 (set2) 2 30 ± 5 0.05 
Level 3 30 (set2) 2 30 ± 5 0.1 
Level 4 150 (set2) 2 30 ± 5 0.5 
Level 5 30 (set1)* 2 30 ± 5 1 
Level 6 60 (set1) 2 30 ± 5 2 
Level 7 150 (set1) 2 30 ± 5 5 
Level 8 300 (set1) 2 30 ± 5 10 
Level 9 600 (set1) 2 30 ± 5 20 
*Internal standard concentration  
 
 Preparation of extraction solvent 
The extraction solvent (methanol with 0.1% formic acid) was prepared by adding 
appropriate volume of formic acid to methanol. For preparation of 100 ml, 100 µl 
of the concentrated formic acid was added into 100 mL volumetric flask and made 
up to 100 mL with methanol. 
 Preparation of mobile phase solutions 
An acidic mobile phase consisting of (A) 0.1% formic acid in water and (B) 0.1% 
formic acid in acetonitrile was prepared by adding 1mL of concentrated formic 
acid to a 1000 mL volumetric flask and making up to 1000 mL with deionised water 
or acetonitrile, respectively. 
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 Nicotine and cotinine extraction from fur 
Methanol is one of the most commonly used extraction solvents and is often 
supported by the use of an ultrasonic bath to reduce the extraction time. The 
extraction times with methanol are usually quite long due to the long incubation 
time that can take between 16 and 20 hrs (309,310). However, the use of an 
ultrasonic bath combined with a higher temperature has proven to shorten the 
extraction time up to 4 hrs (311,312). High temperatures can cause degradation 
of some substances (e.g. conversion of cocaine into benzoylecgonine (313)) and 
must be used with caution. Moreover, it has been reported that the acidification 
of the extraction solvent could improve the extraction efficiency of basic 
molecules such as amphetamine, cocaine and nicotine. Barroso et al reported a 
significant improvement in extraction efficiency of cocaine and its metabolite 
benzoylecgonine after acidifying methanol with hydrochloric acid (HCl) (313). It 
is possible that the acid prevents or decreases affinity of drug-protein binding in 
hair. The applicability of either adding heat or acid to the extraction solvent for 
nicotine is not known as it has not been reported in the literature to date. 
However, the widespread and frequently reported use of alkaline hydrolysis at 
high temperature (ranging from 60 to 90 °C) to extract nicotine and its 
metabolites from hair (see section 7.8) indicates that nicotine is thermally stable 
and will not degrade at temperatures lower than 60 °C. Therefore, 50°C heat was 
added during sonication. For acidification, nicotine is known to react with 
hydrochloric acid in water to form the water-soluble salt nicotine hydrochloride. 
Hence, acidification of the extraction solvent with HCl was found not to be 
appropriate. As an alternative approach, formic acid was used to acidify the 
extraction solvent. The chosen methanolic extraction conditions for nicotine and 
cotinine were 2 hrs with sonication at 50 °C. After extraction, the 2mL methanolic 
extract was then transferred into a clean vial for further cleaning before injection.  
 Justification of column selection 
Method development started by using a mobile phase of (A) 0.1% formic acid in 
water and (B) 0.1% formic Acid in acetonitrile. A reversed-phase (RP) Phenomenex 
Gemini C18 (150 x 2.1 mm, 5 µm) column coupled with a C18 guard column (4 x 
2.0 mm) was used first as it is one of the most commonly employed separation 
columns in forensic toxicology. An isocratic system with a high aqueous mobile 
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phase content (90%) was used first. The aim of this was to check whether nicotine 
and cotinine would interact with the C18 stationary phase of the column and for 
how long they would be retained on the column. Although the aqueous-rich mobile 
phase has poor elution strength, both drugs were eluted within one minute (void 
volume) after injection. A similar retention time was obtained when a higher 
organic solvent mobile phase content was used (30%B). Thus, the RP Gemini C18 
column was replaced as it was unable to achieve acceptable chromatographic 
separation. As NIC is a basic polar drug, the Synergi Polar-RP (150 x 2.1 mm, 4 µm) 
was installed and tested. Column testing was started using an isocratic system 
with a high solvent content. The goal of this was to assess the ability of the column 
to retain the drugs. It was found that both drugs were interacting with the 
stationary phase and eluted 3 minutes (Cotinine) and 7.8 min (Nicotine) after 
injection. The observed improvement in the sensitivity when using this column 
compared to C18 column is believed to be due to the elution using a high 
percentage of solvent (MS friendly). Despite the satisfactory retention of drugs of 
interest by this column, peak broadening was a problem and the column failed to 
achieve the minimal acceptable criteria for the peak shape chromatography. After 
reviewing the literature for the available analytical column options, hydrophilic 
interaction chromatography with a covalently bound zwitterionic functional 
groups (ZIC-HILIC) column was reported for analysis of NIC and its main metabolite 
(238). Furthermore, this column was reported to enhance sensitivity in mass 
spectrometry and is compatible with a wide range of buffers and organic solvents 
for injection.  
 Hydrophilic interaction chromatography (HILIC)  
The abbreviation HILIC was first proposed by Alpert in 1990 (314).  Hemström and 
Irgum published a review about HILIC in 2006 and reported a considerable increase 
in the number of publications on HILIC since 2003(315). HILIC method development 
started with an isocratic system using a mobile phase with high organic solvent 
content (B=80) as per column manufacturer recommendation. It was found that 
cotinine had a retention time of 7.8 minutes while nicotine’s retention time was 
16.9 minutes (See Figure 7-1(B)). As fur samples are complex and have the 
potential for more interferences, it was necessary to use a gradient system after 
elution of the analytes of interest to clean the column. With ZIC-HILIC columns, 
the aqueous mobile solvent is a stronger elution solvent than the aprotic organic 
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solvent. Hence, a cleaning ramp was added to the method starting from 90% 
organic content as per column manufacturer recommendations. It was found that 
cotinine eluted at 8.9 minutes while nicotine eluted at 14.5 minutes (See Figure 
7-1 (A)). This method had a very long run time (40 minutes) due to the equilibrium 
time at the end. Another gradient system starting with 60% organic MP provided 
acceptable separation, better peak shape and reduced the run time to 30 minutes 
(See Figure 7-1 (C)). Removing formic acid from the mobile phase and replacing it 
with 2 mM ammonium acetate was found to have a significant negative impact on 
the peak shape and sensitivity.  
 
Figure 7-1 three chromatograms shows the effect of gradient system changes on drugs 
retention times and peak shape; (A) B=90%, (B) B=80, (C) B=60%. 
 
 Evaluation of methanolic extract clean-up methods  
 Evaporation/reconstitution cycle  
A recovery study was carried out to determine the amount of drug loss during 
evaporation. The main washing solvent (DCM) and extraction solvent (methanol) 
were included in the recovery study. 2 mL of washing and extracting solvents (no 
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fur used for this experiment) were spiked at three different concentrations (5, 30 
and 200 ng/2mL) and evaporated to dryness under a gentle stream of nitrogen at 
50 °C to accelerate the evaporation process. Each sample was reconstituted with 
200 µl methanol with 0.1% formic. 30 ng (30 µl of 1 µg/mL (set1)) internal standard 
mix was then added after reconstitution. The signal obtained was compared to 
the response from a similar amount of drug in 200 µl methanol with 0.1% formic 
acid.  
 Filtration 
30 mg samples of blank fur were spiked at three different concentrations of 
nicotine and cotinine (10, 30 and 120 ng/30mg) and were subjected to extraction 
with methanol containing 0.1% formic acid. To remove particulates, the extract 
was then filtered through Captiva Premium Syringe PES Filter. 30 ng (30 µl of 1 
µg/mL (set1)) of deuterated ISTD nicotine-d3 and cotinine-d4 was added after 
filtration. Recovery was assessed by comparing the peak area ratio (drug/IS) from 
filtered samples to equivalent concentrations from spiked, unfiltered extraction 
solvent (2mL). Three replicates were extracted and averaged.  
 Centrifugation 
Centrifugation was proposed as a cheaper alternative to the filtration. 30 mg 
samples of blank fur were spiked at three different concentrations of nicotine and 
cotinine (10, 30 and 200 ng/30mg). Spiked fur samples were combined with 2 mL 
extraction solvent and then centrifuged at 4000 rpm for 10 minutes. The 
supernatant was transferred to a clean vial and 30 ng of deuterated ISTD nicotine-
d3 and cotinine-d4 was added. Similar to the filtration experiment, recovery after 
centrifugation was calculated.  
 Injection Volume Optimisation  
As per column manufacturer instructions for care and use, 5 to 50 µl can be 
injected into a column with 4.6 mm internal diameter (ID) and the recommended 
injection volume is about 1% of the total column volume (Vm). The column volume 
was calculated and three different volumes within the allowed range, 10, 20, 50 
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µl were tested. The criteria for selection of the injection volume were the 
sensitivity and peak shape. 
 Method validation  
The validation of the method was completed in accordance with the Scientific 
Working Group for Forensic Toxicology (SWGTOX) guidelines. This included the 
determination of the limit of quantification (LOQ), limit of detection (LOD), 
interference, calibration model, carry-over, precision and accuracy, recovery, 
and matrix effects (172). Excel Windows 2010 data analysis was used to calculate 
the average, median and standard deviations. Regression and data analysis were 
carried out using Agilent MassHunter Workstation software (version: B.01.05). 
 Limit of detection (LOD) and Lower Limit of quantitation 
(LLOQ) 
The LOD and LOQ determination was carried out by spiking blank fur samples at 
decreasing concentrations within the expected range of detection sensitivity. The 
LLOQ and LOD were calculated using the reference materials approach in 
accordance with SWGTOX guideline (172). Three sources of blank matrix samples 
fortified at decreasing concentrations (0.01, 0.03, 0.05, 0.07, 0.1 ng/mg) were 
analysed in duplicate (two separate samples) for three runs. Regression analysis 
and signal to noise ratio (S/N) were calculated using the instrumental software 
(MassHunter). For both nicotine and cotinine, concentrations that yielded a 
reproducible response greater than or equal to three times the noise level of the 
background signal from the negative samples were assigned as the LOD, while 
concentrations that yielded a reproducible response greater than or equal to ten 
times the noise level were assigned as the LLOQ.  
 Calibration model (Linearity)  
Calibration model can be defined as the mathematical model that demonstrates 
the relationship between the concentration of analyte and the corresponding 
instrument response (316). The calibration model was investigated over the 
concentration range relevant for analysis of nicotine and cotinine in non-smokers 
on five different runs. Calibration curves were prepared by spiking 1.5, 3, 15, 30, 
60, 150 and 300 ng amounts of nicotine and cotinine and adding 30 ng of nicotine-
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d4 and cotinine-d3 into 30 mg of blank fur combined with 2 ml amounts of 
methanol with 0.1% formic acid.  
 Accuracy and precision 
Precision and accuracy were measured using a calibration curve for the optimised 
method prepared with each run. Intra-day data were assessed by comparing data 
from within one run (n = 3 for each QC). Inter-day validation data were obtained 
from analyses conducted on five different days. Pooled blank fur from five sources 
was spiked at three different concentrations (low 0.05 ng/mg, medium 1 ng/mg 
and high 5 ng/mg).  
 Matrix Effect 
The change in response observed for a given concentration of analyte of interest 
in the presence of other sample components can be defined as matrix effect. 
Although fur is not a biological fluid, it is a biological tissue, when sonicated with 
methanol it will swell and release its internal component to the extraction 
solvent; moreover, dirt on the outer surface of the fur may contribute to the 
matrix effect as well. These components can either cause suppression or 
enhancement of the target analyte response. Matrix effect was assessed by 
comparing the response from spiked extracts to that from spiked clean extraction 
solvent at two different concentrations.  
The matrix effect was assessed using the Post-Extraction Addition Approach. Two 
sets of samples were prepared at low (0.05 ng/mg) and high (5 ng/mg) 
concentrations.  Set one consisted of neat standards injected six times to establish 
a mean peak area for each concentration. Set two consisted of three different 
matrix sources. Each matrix source was extracted in duplicate and the extract 
spiked with either the low or high concentration. The matrix effect was then 
calculated by averaging the area of each as follows: 
%𝑖𝑜𝑛𝑖𝑠𝑎𝑡𝑖𝑜𝑛 𝑒𝑛ℎ𝑎𝑛𝑐𝑒𝑚𝑒𝑛𝑡 𝑜𝑟 𝑠𝑢𝑝𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 =  (
𝑋 ̅ 𝐴𝑟𝑒𝑎 𝑜𝑓 𝑠𝑒𝑡2
𝑋 ̅ 𝐴𝑟𝑒𝑎 𝑜𝑓 𝑠𝑒𝑡1
− 1) ∗ 100 
Equation 7-1 Ionization suppression or enhancement percentages 
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A negative value indicates signal suppression whereas positive values suggest that 
some enhancement is occurring. According to SWGTOX guidelines, the acceptable 
limits for enhancement or suppression are ±25%.  
 Carryover 
According to SWGTOX validation guidelines, carryover is defined as appearance of 
unintended analyte signal in samples after the analysis of a positive sample. 
Carryover was assessed by injecting extraction solvent blank following a sample 
that contained equivalent concentrations to the upper limit of quantitation (20 
ng/mg) on five different runs. 
 Results and discussion 
 Evaluation of methanolic extract clean-up methods  
After methanolic extraction, it was necessary to clean-up the extract further. 
Although the extract was not, visually, too dirty, it was not suitable for direct 
injection. The initial plan was to evaporate the DCM washes and methanolic 
extract and reconstitute with a suitable aqueous solution to then undergo further 
clean-up using LLE or SPE to improve the analyte detection sensitivity. Filtration 
and centrifugation were later proposed as alternatives that will allow direct 
injection into ZIC-HILIC-MSMS. Recoveries and drug loss were monitored for all 
proposed methods.  Three replicates for three levels low, medium and high were 
prepared, extracted and averaged as explained earlier in section 7.5.  
 Evaporation / Reconstitution Cycle 
It was observed that much lower responses for nicotine were obtained after 
evaporation in comparison with non-evaporated standards at equivalent 
concentrations. As illustrated in Figure 7-2 and Figure 7-3, more than 90% of COT 
was recovered from methanol and about 30-50% from DCM. For nicotine, poor 
%recovery was found from both solvents. As heat was a possible cause of drug loss 
during evaporation and resulted in low % recovery, the experiment was repeated 
and evaporation was carried out at room temperature (25 ᴼC) to investigate 
further. Better results were observed at room temperature for the recovery of 
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COT from DCM and similar results at 50 C for NIC (Figure 7-2). Nicotine is volatile 
and it is possible that it evaporates even at room temperature. 
 
Figure 7-2 Mean %Recovery (± 1 s.d.) for nicotine (NIC) from dichloromethane (DCM) and 
methanol (MeOH) after evaporation and reconstitution 200 µl methanol with 0.1% formic acid 
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Figure 7-3 Mean %Recovery (± 1 s.d.) for cotinine (COT) from dichloromethane (DCM) and 
methanol (MeOH) after evaporation and reconstitution 200 µl methanol with 0.1% formic acid 
 
Since NIC is a basic drug, it is highly possible that it interacts with the surface of 
the vial walls and there is a need for using silanised vials. The same recovery study 
above was repeated using silanised vials for recovery from methanol. Better 
results were obtained and %recovery increased to about 60% for nicotine. 
However, it was observed that the work on silanised vials was not reproducible 
and high variations were noticed between concentrations and between replicates. 
Both evaporation of volatile nicotine and possible interaction with the vial walls 
makes it difficult to do either LLE or SPE as both methods involve an evaporation 
step. 
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Figure 7-4 Comparison of mean %Recovery (± 1 s.d.) of nicotine (NIC) and cotinine (COT) in 
silanised and non-silanised vials 
 
 Filtration 
Recovery of cotinine was found to be very good ranging from 85 to 95%. Recovery 
of nicotine was found to be poor with low concentrations (approximately 30%) 
and, unexpectedly, the recovery improved with increasing concentrations (about 
65% for the highest concentration) as shown in Figure 5-7. One possible 
explanation for this could be that nicotine may have a stronger affinity to the 
inner filter particles and becomes saturated quickly resulting in a better recovery 
with higher concentrations. This means this filter is not suitable for fur analysis as 
low concentrations of nicotine and cotinine are more likely to be detected from 
ETS exposure.  
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Figure 7-5 Mean %recovery (± 1 s.d.) from PES filter for nicotine (NIC) and cotinine (COT) 
 
 Centrifugation 
Recovery of nicotine and cotinine was found to be very good ranging from 95 to 
110% as shown in Figure 7-6. 
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Figure 7-6 Mean %recovery (+/- 1 s.d.) of nicotine (NIC) and cotinine (COT) after 
centrifugation  
 
 Summary of recovery studies for clean-up methods 
The results of extraction recovery of different clean-up methods are summarised 
in Figure 7-7. 
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Figure 7-7 Summary of recovery study results of clean-up methods  
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 Injection Volume  
Using the simple volume of a cylinder equation, the volume of the column with 
dimensions mentioned previously in the materials section is 2.5 mL. However, 2.5 
mL does not represent the actual volume of the column as it is packed with 
particles, which occupy 30-40% of the column volume. Thus, 60% of 2.5 ml is 1.5 
ml, and 1% of that is 15 µl.  Increasing the injection volume without affect the 
quality of the chromatogram is desirable, as this will improve the sensitivity. 
Hence, three different injection volumes (15, 20 and 50 µl) were assessed for the 
sensitivity of chromatographic behaviour. 50 µl injection results in very poor 
chromatography, 20 µl gave satisfactory sensitivity without affecting the peak 
shape. Therefore, a 20 µl injection volume was selected prior to validation. 
 Method validation results 
 Limit of detection (LOD) and Lower Limit of quantitation (LLOQ) 
The LOD and LLOQ for nicotine and cotinine are summarised in the Table 7-6. 
Table 7-6 LOD and LLOQ for nicotine and cotinine 
 Nicotine (ng/mg) Cotinine (ng/mg) 
LOD 0.01 0.05 
LLOQ 0.05 0.1 
 
A cut-off of 0.045 ng/mg was used for NIC. This concentration was chosen as it 
was three times the signal observed in the pooled blank sample made from 21 
dogs who were reported to live in a nicotine-free environment. 0.1 ng/mg was 
chosen as the cut-off for COT due to poor chromatography. Figure 7-8 shows 
chromatograms of NIC and COT at 0.05 and 0.1 ng/mg. 
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Figure 7-8 Extracted chromatograms for nicotine (NIC) and cotinine (COT) transitions in 
standards containing (a) 0.05 ng/mg compared to (b) 0.1 ng/mg. 
 
 Calibration Model 
The calibration curves were generated by plotting the peak area ratio versus the 
spiked analyte concentrations using the linear regression model on Agilent 
MassHunter Workstation-Quantitative software. Most LC calibration curves that 
span several orders of magnitude, such as our calibration model, show an 
increasing error with increasing concentration. For both analytes nicotine and 
cotinine, an excessive error was noticed at low quality control levels during 
validation. The presence of a heteroscedastic error in the calibration curve was 
investigated and confirmed using the Gu et al method (317).  This error makes the 
data point at the high end of the calibration curve dominate the calculation of the 
linear regression and often results in an excessive error at the bottom of the curve. 
Using the linearity indicators approach, 1/x2 was selected as the weighting factor 
(WF). Figure 7-9 B shows a clear example of how the curve is dominated by the 
high end point and resulting in inaccurate calculations at the low end. However, 
good accuracy can sometimes also be achieved in cases when unweighted curve 
was “luckily” overlaps with or is very close to the corresponding STD curve 
generated with the correct weighting factor as shown in Figure 7-10 B. R2 values 
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were found to be better than 0.99 after 1/x2 weighted regression over five 
replicates for nicotine and cotinine (see Figure 7-9 A and Figure 7-10 A). More 
details on the determination of heteroscedastic error and selection of the 
appropriate weighting factor are given in Appendix X. 
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Figure 7-9 Nicotine calibration curve. (A) The curve ranging from 0.05 to 10 ng/mg, (B) The 
curve at the low concentration end ranging from 0.05 to 0.5 ng/mg. 
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Figure 7-10 Cotinine calibration curve. (A) The curve ranging from 0.05 to 10 ng/mg, (B) The 
curve at the low concentration end ranging from 0.05 to 1 ng/mg. 
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 Accuracy and precision 
 Accuracy and precision data for the method are summarised below in Table 7-7 
and Table 7-8. 
Table 7-7 Nicotine quantitative results (ng/mg) of bias and precision runs. Run2 values 
considered an outlier and removed. 
Low (0.05 ng/mg) run1 run2 run3 run4 run5 
repl.1 0.05 0.02 0.07 0.06 0.06 
repl.2 0.06 0.03 0.07 0.07 0.05 
repl.3 0.06 0.02 0.07 0.07 0.06 
Medium (1ng/mg) run1 run2 run3 run4 run5 
repl.1 1.11 0.87 0.86 1.19 1.07 
repl.2 0.92 0.90 1.05 1.20 1.11 
repl.3 0.87 0.92 1.14 1.04 0.86 
High (5 ng/mg) run1 run2 run3 run4 run5 
repl.1 5.60 5.49 4.46 5.25 4.64 
repl.2 5.07 5.21 4.29 6.36 4.81 
repl.3 5.08 5.24 4.72 5.73 4.73 
 
T-test was performed to compare the mean from run2 for nicotine with the other 
4 runs. It was found that the set of data from run2 (highlighted in red) was 
significantly different from the other 4 runs. Therefore, run2 was considered as 
an outlier and excluded from the mean, accuracy and precision calculations. The 
poor quality of the blank fur is believed to be the reason for the noticed inaccuracy 
of the quantitation results for the lowest QC material, and therefore, the 
validation result was considered acceptable at this level. 
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Table 7-8 Cotinine quantitative results (ng/mg) of bias and precision runs 
Low (0.05 ng/mg) run1 run2 run3 run4 run5 
repl.1 0.05 0.04 0.05 0.05 0.05 
repl.2 0.05 0.04 0.05 0.05 0.04 
repl.3 0.05 0.04 0.06 0.05 0.05 
Medium (1ng/mg) run1 run2 run3 run4 run5 
repl.1 1.00 1.04 0.85 0.98 0.99 
repl.2 0.98 1.04 0.98 1.01 0.91 
repl.3 0.88 1.00 1.00 0.92 0.90 
High (5 ng/mg) run1 run2 run3 run4 run5 
repl.1 4.86 5.01 4.70 4.72 4.34 
repl.2 4.41 4.95 4.76 5.37 4.86 
repl.3 4.53 5.25 4.68 5.37 4.37 
 
 
Table 7-9 Summary of mean, precision and accuracy results. values in brackets are after 
removing outlier run2. 
  
Low (0.05 
ng/mg) 
Med 
(1ng/mg) 
High (5 
ng/mg) 
NIC Mean (ng/mg) 0.05 (0.62) 1.01 5.11 
 Accuracy 8.23 (23.65) 0.66 2.26 
 Within-Run CV (%) 1.22 (1.14) 11.21 13.80 
 
Between-Run CV 
(%) 
59.07 (20.9) 22.19 19.31 
COT Mean (ng/mg) 0.05 0.97 4.81 
 Accuracy -3.43 -3.44 -3.74 
 Within-Run CV (%) 1.17 5.70 11.36 
 
Between-Run CV 
(%) 
14.38 10.50 12.57 
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 Matrix Effects 
As shown in Figure 7-11, the matrix effect results (n=3) showed an enhancement 
for nicotine and its deuterated ISTD and suppression for cotinine and its 
deuterated ISTD. The percentage of matrix effect is averaged to be within ±25% 
for both drugs which is, according to SWGTOX guidelines, an acceptable matrix 
effect.  
 
Figure 7-11 Mean matrix effect (n=3) (+/- 1 s.d.) 
 
 Carryover 
No signal was observed in the blank extraction solvent at the retention time for 
nicotine or cotinine. Carryover was therefore not deemed to be a problem. 
 Application to case samples 
The developed method was applied to 66 fur samples which were collected by a 
postgraduate doctoral student enrolled at the University of Glasgow School of 
Veterinary Science. The samples were stored at room temperature away from light 
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until analysis by LC/MS-MS. These fur samples were subdivided into two groups: 
the first group contained samples with a sufficient quantity that allowed for 
multiple analyses. As samples were collected for the same dogs at two different 
time points, 15 pairs were found to have a sufficient quantity of fur. This group 
of samples were used to assess the optimised methanolic extraction. The second 
group consisted of all collected fur samples and were used to quantify the total 
nicotine and cotinine. The results of the analyses of fur samples will be reported 
in the next chapter. Figure 7-12 summarises the work reported in this chapter. 
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Figure 7-12 Project summary 
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 Conclusion 
LC-MS/MS has become a very important tool for forensic toxicology investigations. 
Nicotine and its primary metabolite, cotinine in hair have proven to be sensitive 
and specific biomarkers for ETS exposure investigations. Low cost, fast extraction 
procedures or new materials for extraction and analyte separation is now a trend 
in the analytical laboratory. A direct injection procedure for fur methanolic 
extracts with simple sample pre-treatment was employed in this method. Nicotine 
loss during sample preparation, either by evaporation or interaction with vial 
walls, still requires further investigation. Matrix effects are a major drawback in 
modern analytical applications using LC-MS/MS; a proper dilution might be needed 
to reduce the matrix effects. Despite the limited applications for ZIC-HILIC 
columns in forensic toxicology, it has promising separation capabilities for the 
polar compounds. The column compatibility with a wide range of solvents made 
it possible to inject MS friendly high organic content straight into the mobile 
phase. This is believed to enhance the response of ESI-MS/MS. Highly organic 
mobile phases are more volatile which increases ESI-MS sensitivity through 
improving the efficiency of the formation of gas phase ions. Direct injection of 
high organic content solutions has also shortened the analysis time by eliminating 
the need for the evaporation step and sample reconstitution with a suitable 
solvent prior to injection into the LC-MS. 
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 Application of fur NIC and COT method 
to dogs exposed to environmental smoke 
exposure 
 Introduction 
The method described in Chapter 8 was applied to fur specimens received by the 
laboratory from the University of Glasgow School of Veterinary Science for total 
nicotine and cotinine quantitation. The study was undertaken to first establish 
whether dogs are exposed to significant, detectable amounts of ETS in the home, 
secondly, to evaluate the changes in ETS exposure in the time between two sample 
collection times and, thirdly, to correlate the measured concentrations with 
owner-reported exposure to ETS. In addition, methanolic wash efficiency and 
optimisation of the extraction incubation period were investigated.  
 Aims 
The aims of the study were to: 
 Establish the validity of nicotine and cotinine to measure ETS exposure. 
 Compare the concentrations of nicotine and cotinine in the positive fur 
samples exposed to different levels of ETS. 
 Compare the concentrations of nicotine and cotinine with concentrations 
reported previously from human and animal hair samples exposed to ETS.  
 Establish whether companion animals fur samples could be used to reflect 
the long-term ETS exposure in homes. 
 Compare the sensitivity, specificity and likelihood ratio for both nicotine 
and cotinine assays for monitoring ETS. 
 Determine if a nicotine/cotinine ratio can be established to distinguish 
intensity of exposure to ETS. 
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 Fur sample collection and labelling 
Fur collection from dogs was carried out by a postgraduate doctoral student 
enrolled at the University of Glasgow School of Veterinary Science by clipping 
mainly the neck region with the owner’s consent. To comply with ethical approval, 
fur that was removed from the site of blood collection was used for analysis, 
therefore, two different collection sites were reported for some dogs (highlighted 
in blue in Table 8-1). Owners were asked to complete a questionnaire briefly 
outlining the age, breed and sex of the dog and estimating the amount of ETS to 
which each dog was exposed. Non-exposed were defined as dogs with a non-
smoker owner or family member, who declared that their dogs had no unusual 
environmental exposure to tobacco smoke. Occasionally exposed were defined as 
those dogs living with an owner or family member who smokes only outdoor. 
Passive smokers were defined as those dogs living with a smoker owner or family 
member, who smoked in the presence of the dog. The collected fur was stored in 
sealed collection envelopes and stored at room temperature to ensure that no 
further ETS exposure occurred after hair collection. At the time of analysis, the 
fur samples were transferred from the envelope with tweezers to Chromacol 
Environmental Sampling Vials. Scissors used for cutting and tweezers were cleaned 
with methanol before use and in between samples. Fur samples were subsequently 
prepared and extracted following the methods and procedure explained earlier in 
chapter 8. Each fur sample was allocated a sequential laboratory number starting 
from 1. If two samples were available for the same dog, the first collected sample 
was labelled as 1-A and the second as 1-B. Samples from 1 to 25 were all from 
dogs where two samples were collected. Samples 26 to 41 were from dogs that 
did not return for a second sample and were all labelled with A. Methanolic washes 
were given a laboratory number for their sample ID with an added (M) at the end. 
As an example, washes and extract from sample number 1 were labelled as follow; 
1-A, 1-B, 1-A-M and 1-B-M.  
 Fur samples submitted for analysis 
Between March 2013 and February 2015, a total of 66 samples were collected from 
41 dogs. 25 dogs returned for the follow-up appointment and a second sample 
collected. The mean and median for the net days between the two sample 
collection dates were m=281.6 days and M=273.5 days. All samples were stored in 
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clean and dark place at room temperature prior to analysis. Demographic 
information for all samples is summarized in Table 8-1. 
Table 8-1 Fur sample information 
Dog No. Time point Fur colour Smoke exposure status 
1 
First sample Black Smoking occurs indoor 
Second Sample Black Smoking occurs indoor 
2 
First sample White No Exposure 
Second Sample White No Exposure 
3 
First sample Black No Exposure 
Second Sample Black No Exposure 
4 
First sample Light Brown Smoking occurs indoor 
Second Sample* Black Smoking occurs indoor 
5 
First sample Black Smoking occurs indoor 
Second Sample Black Smoking occurs indoor 
6 
First sample White No Exposure 
Second Sample White No Exposure 
7 
First sample White Smoking occurs only outdoor 
Second Sample White No Exposure 
8 
First sample Light Brown No Exposure 
Second Sample Light Brown No Exposure 
9 
First sample Light Brown Smoking occurs indoor 
Second Sample Grey Smoking occurs indoor 
10 
First sample White No Exposure 
Second Sample White No Exposure 
11 
First sample Grey Smoking occurs indoor 
Second Sample White No Exposure 
12 
First sample Black No Exposure 
Second Sample Brown No Exposure 
13 
First sample Brown Smoking occurs indoor 
Second Sample Brown Smoking occurs only outdoor 
14 
First sample White No Exposure 
Second Sample White No Exposure 
15 
First sample Brindle No Exposure 
Second Sample Brindle No Exposure 
16 
First sample Black Smoking occurs indoor 
Second Sample White No Exposure 
17 
First sample White No Exposure 
Second Sample Grey No Exposure 
18 
First sample Light Brown No Exposure 
Second Sample Light Brown No Exposure 
19 
First sample Grey No Exposure 
Second Sample Grey No Exposure 
20 First sample Brindle Smoking occurs indoor 
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Second Sample Light Brown No Exposure 
21 
First sample White No Exposure 
Second Sample White No Exposure 
22 
First sample Black Smoking occurs only outdoor 
Second Sample Black Smoking occurs only outdoor 
23 
First sample Black No Exposure 
Second Sample Black No Exposure 
24 
First sample Black No Exposure 
Second Sample Black No Exposure 
25 
First sample Grey Smoking occurs only outdoor 
Second Sample Grey Smoking occurs only outdoor 
26 First sample Grey No Exposure 
27 First sample Light Brown Smoking occurs indoor 
28 First sample Light Brown No Exposure 
29 First sample Black Smoking occurs indoor 
30 First sample Brown Smoking occurs indoor 
31 First sample Black Smoking occurs only outdoor 
32 First sample Black No Exposure 
33 First sample White No Exposure 
34 First sample White Smoking occurs only outdoor 
35 First sample White No Exposure 
36 First sample Black Smoking occurs indoor 
37 First sample Dark Brown No Exposure 
38 First sample Light Brown Smoking occurs indoor 
39 First sample Black No Exposure 
40 First sample Light Brown Smoking occurs indoor 
41 First sample Brown No Exposure 
Sample numbers highlighted in grey were selected to carry out the evaluation of methanol 
solvent for washing extraction. Samples highlighted in light blue (fur colour) were collected 
from different anatomical regions. 
 
 Analysis  
 Fur analysis 
Analysis of fur samples was carried out using the analytical method described 
previously in chapter 8. All 66 submitted samples were analysed for total nicotine 
and total cotinine without a prior washing step at the collector’s request. For 
evaluation of methanol as a washing and extraction agent, 30 samples, out of the 
66 fur samples, only were selected and retested. Fur samples from dogs that did 
not return for the second sample (n=16) were excluded. From the remaining 
samples (n=50), only pairs where there was sufficient quantity were selected for 
analysis (n=15 pairs). Fur samples were washed with methanol for 15 minutes with 
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sonication. Fur was then extracted with methanol containing 0.1% formic acid for 
two hours. 200 µl aliquots were collected from each sample at different times (15, 
30, 60 and 120 minutes) during sonication and transferred to LC vials for injection. 
The methanol wash was centrifuged to remove particulates before injection. The 
extracted aliquots were difficult to centrifuge, and therefore, they were left on 
the bench for 1-2 hours to allow particulates to precipitate before injection and 
no further clean-up was conducted. 
 Statistical Analysis 
Statistical analysis was carried out using Microsoft Excel® 2016 and Statistical 
Package for the Social Sciences (SPSS) software for Microsoft Windows version 22.0 
(IBM Corporation, Armonk, New York, US).  In sections 9.8.1 to 9.8.5, statistical 
analysis was carried out on the concentrations of nicotine and cotinine detected 
in dogs exposed to different levels of ETS. The distribution of the concentrations 
of each analyte was assessed using the Shapiro-Wilk test and found not to follow 
a normal distribution. Thus, non-parametric tests were used to test for significant 
differences between the two time points and relationships between the 
questionnaire-estimated levels of exposure and observed fur colour for the 
distribution of nicotine and cotinine concentrations. The Kruskal–Wallis test, the 
nonparametric analogue for ANOVA, was used to compare the means of more than 
two groups (e.g. concentration of nicotine and cotinine in the three levels of 
exposure to ETS or different fur colour). The Mann-Whitney test was used for 
assessing the mean difference of concentrations at the two time points. A p value 
< 0.05 was considered significant. Spearman’s Rank Correlation Test (2-tailed) was 
used to assess the strength and direction of the association between the two 
continuous variables, nicotine and cotinine concentrations 
 Sensitivity, specificity, predictive value and likelihood ratio 
calculations  
This method is simple, fast and does not require laborious and extensive sample 
preparation. Therefore, it can be used to qualitatively screen a large number of 
samples for the presence of nicotine and cotinine. Sensitivity, specificity, 
predictive value and likelihood ratio are the main performance characteristics of 
a binary classification test. Sensitivity measures the percentage of positives that 
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are truly identified as such (e.g., the percentage of smoke-exposed dogs who are 
truly identified as positive for nicotine or cotinine). Specificity measures the 
proportion of negatives that are correctly identified as such (e.g., the percentage 
of non-exposed dogs who are correctly identified as negative for nicotine and 
cotinine). The positive and negative predictive values (PPV and NPV respectively) 
are the proportions of positive and negative results in diagnostic tests that are 
true positive and true negative results. The likelihood ratio is an additional 
measure that uses both the sensitivity and specificity of the test to determine 
whether a test result usefully changes the probability that an exposure to smoke 
exists. Two forms of the likelihood ratio occur, positive likelihood ratio for positive 
test results (LR+) and negative likelihood ratio (LR–) for negative test results.  
The reference results of ETS exposure were based on the assumption that exposure 
status reported by owners in the questionnaire were accurate. Dogs living with a 
smoker where considered exposed while those living with non-smokers were 
classified as not exposed. For ETS exposure screening, a perfect biomarker would 
be described as 100% sensitive and 100% specific. Sensitivity, specificity and both 
versions of predictive value and likelihood ratio is calculated as shown in the 
following Equation 8-1Equation 8-6. 
 
Equation 8-1 Sensitivity equation 
𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 =
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑡𝑟𝑢𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠 (𝑇𝑃)
𝑛𝑢𝑚𝑏𝑒𝑟𝑜𝑓 𝑇𝑃 + 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑓𝑎𝑙𝑠𝑒 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠 (𝐹𝑁)
∗ 100 
 
Equation 8-2 Specificity equation 
𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 =
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑡𝑟𝑢𝑒 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠 (𝑇𝑁)
𝑛𝑢𝑚𝑏𝑒𝑟𝑜𝑓 𝑇𝑁 + 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑓𝑎𝑙𝑠𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠 (𝐹𝑃)
∗ 100 
 
Equation 8-3 Positive predictive value 
𝑃𝑃𝑉 =
𝑇𝑃
𝑇𝑃 + 𝐹𝑃
 
Equation 8-4 Negative predictive value 
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𝑁𝑃𝑉 =
𝑇𝑁
𝑇𝑁 + 𝐹𝑁
 
 
Equation 8-5  Positive likelihood ratio equation 
 
𝐿𝑅+=
𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦
1 − 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦
 
 
Equation 8-6  Negative likelihood ratio equation 
𝐿𝑅−=
1 − 𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦
𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦
 
 
 Results – demographic 
 Age, weight and breed 
The 66 fur samples analysed for nicotine and cotinine were collected from 41 dogs 
from 24 different breeds. The Staffordshire Bull Terrier breed was predominant 
with more that 20% of dogs (Figure 8-1). The frequency of fur samples was spread 
across the age range 0.4 to 8.9 years old, with 65% of cases between the ages of 
six months to two years old (Figure 8-2). The weight of dogs involved in the study 
ranged from 5 kg to 45 kg (Figure 8-3).  
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Figure 8-1 Number of fur samples included in analysis classified by dog breed 
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Figure 8-2 Histogram showing number of fur samples included in analysis classified by age 
range 
 
Figure 8-3 Histogram showing number of fur samples submitted for analysis classified by 
weight range 
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 Classification of fur samples 
The fur samples were classified according to the degree of exposure reported by 
the owner in the questionnaire and based on their colour observed in the 
laboratory when the samples were received. Numbers and percentages of each 
class is shown in Figure 8-4 and Figure 8-5. 
 
Figure 8-4 Classification of fur samples based on the history of exposure to ETS 
 
 Results - quantitative and qualitative 
 Construction of calibration curves  
Agilent MassHunter software was used to construct the calibration curves using 
the equation y = mx + c with 1/x2 weighting factor and was used to calculate the 
% peak area ratios (% PAR) for each analyte (peak area for analyte/peak area for 
internal standard * 100). The calibration lines for each analyte were constructed 
as ng/mg.  
 Summary of total nicotine and total cotinine concentrations 
Concentrations of total nicotine and total cotinine in dogs’ fur ranged from 0.05-
13.7 ng/mg and 0.12-0.87 ng/mg, respectively. Table 8-2 summarises the total 
nicotine and total cotinine concentrations in all 66 fur samples. 
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Figure 8-5 Classification of fur samples based on their colour. (a) in all exposure groups, (b) No exposure group only, (c) smoking occurs outdoor, (d) 
smoking occurs indoor. 
 
(a) 
(b) (d) (c) 
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Table 8-2 Total nicotine and total cotinine concentrations in 66 fur samples 
sample ID Time point 1 (ng/mg) Time point 2 (ng/mg) 
Total NIC Total COT Total NIC Total COT 
1 4.05 0.21 12.58 0.48 
2 0.07 ND ND ND 
3 ND ND ND ND 
4 0.44 ND 0.33 ND 
5 5.93 0.62 9.62 0.35 
6 ND ND ND ND 
7 0.14 ND 0.36 ND 
8 ND ND ND ND 
9 2.44 0.14 1.93 0.28 
10 0.27 ND 0.10 ND 
11 0.36 ND 0.20 0.21 
12 ND ND ND ND 
13 0.45 0.15 1.31 0.71 
14 ND ND ND ND 
15 ND ND ND ND 
16 1.08 ND 0.21 0.18 
17 ND ND ND ND 
18 0.08 ND 0.15 ND 
19 0.08 ND ND ND 
20 0.81 0.19 0.09 ND 
21 ND ND 0.06 ND 
22 0.08 ND 0.06 ND 
23 0.05 ND ND ND 
24 ND ND ND ND 
25 1.79 0.24 0.97 0.20 
26 ND ND     
27 0.65 0.13     
28 ND ND     
29 0.58 0.12     
30 13.79 0.87     
31 0.16 ND     
32 0.06 ND     
33 ND ND     
34 0.95 0.68     
35 ND ND     
36 ND ND     
37 0.47 ND     
38 0.47 0.14     
39 0.14 ND     
40 1.73 0.12     
41 0.19 ND     
ND stands for ‘Not detected’ 
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Figure 8-6 display the extracted chromatograms for a fur specimen (1-B) that 
was positive for NIC and COT at both time points and has the second highest NIC 
concentration. 
 
 
Figure 8-6 Extracted chromatograms for fur sample (1-B) containing (a) 0.48 ng/mg cotinine 
(COT), and (b) 12.58 ng/mg nicotine (NIC). 
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 Summary of nicotine and cotinine concentrations in the 
methanolic wash and extract  
The concentrations of nicotine and cotinine quantified in the methanol wash and 
in the extract are summarised in Table 8-3 and Table 8-4. 
Table 8-3  Summary of nicotine concentrations in the methanol washes and extracts 
 Nicotine concentrations (ng/mg) 
Sample ID 
Methanol 
wash 
Methanolic extract 
15 min 30 min 60 min 120 min 
1-A 2.14 0.72 1.17 2.04 2.42 
1-B 5.92 2.05 2.81 3.72 4.16 
3-A <LOQ <LOQ <LOQ <LOQ <LOQ 
3-B <LOQ <LOQ <LOQ <LOQ <LOQ 
6-A <LOQ <LOQ <LOQ <LOQ <LOQ 
6-B <LOQ <LOQ <LOQ <LOQ <LOQ 
8-A <LOQ <LOQ <LOQ <LOQ <LOQ 
8-B <LOQ ND ND ND ND 
9-A 0.58 0.56 0.91 1.12 1.21 
9-B 0.98 0.36 0.48 0.46 0.50 
10-A 0.10 0.06 0.10 0.12 0.13 
10-B 0.05 <LOQ <LOQ <LOQ <LOQ 
11-A 0.11 0.06 0.12 0.16 0.18 
11-B 0.07 <LOQ <LOQ <LOQ <LOQ 
12-A <LOQ ND ND <LOQ <LOQ 
12-A <LOQ ND ND <LOQ <LOQ 
15-A <LOQ ND <LOQ <LOQ <LOQ 
15-B <LOQ <LOQ <LOQ <LOQ <LOQ 
16-A 0.50 0.20 0.23 0.26 0.29 
16-B 0.09 <LOQ 0.05 0.05 0.05 
20-A 0.55 <LOQ <LOQ <LOQ <LOQ 
20-B 0.05 0.12 0.16 0.20 0.25 
21-A <LOQ ND ND ND ND 
21-B <LOQ <LOQ <LOQ <LOQ <LOQ 
22-A 0.05 <LOQ <LOQ <LOQ <LOQ 
22-B <LOQ <LOQ <LOQ <LOQ <LOQ 
24-A <LOQ ND ND ND <LOQ 
24-B <LOQ ND ND ND ND 
25-A 0.57 0.29 0.38 0.23 0.37 
25-B 1.00 0.17 0.20 0.35 0.23 
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Table 8-4 Summary of cotinine concentrations in the methanolic wash and extracts 
 Cotinine concentrations (ng/mg) 
Sample ID Methanol 
wash 
Methanolic extract 
15 min 30 min 60 min 15 min 
1-A 0.15 <LOQ <LOQ 0.13 0.18 
1-B 0.31 0.12 0.17 0.16 0.15 
3-A ND ND ND ND ND 
3-B ND ND ND ND ND 
6-A ND ND ND ND ND 
6-B ND ND ND ND ND 
8-A ND ND ND ND ND 
8-B ND ND ND ND ND 
9-A <LOQ <LOQ <LOQ <LOQ <LOQ 
9-B 0.17 <LOQ <LOQ <LOQ <LOQ 
10-A <LOQ <LOQ <LOQ <LOQ <LOQ 
10-B ND ND ND ND ND 
11-A ND ND <LOQ <LOQ <LOQ 
11-B <LOQ <LOQ <LOQ <LOQ <LOQ 
12-A ND ND ND ND ND 
12-A ND ND ND ND ND 
15-A ND ND ND ND ND 
15-B ND ND ND ND ND 
16-A <LOQ <LOQ <LOQ <LOQ <LOQ 
16-B 0.11 <LOQ <LOQ <LOQ <LOQ 
20-A 0.10 <LOQ <LOQ <LOQ <LOQ 
20-B <LOQ <LOQ <LOQ <LOQ <LOQ 
21-A ND ND ND ND ND 
21-B ND ND ND ND ND 
22-A <LOQ ND ND ND ND 
22-B ND ND ND ND ND 
24-A ND ND ND ND ND 
24-B ND ND ND ND ND 
25-A 0.17 <LOQ <LOQ <LOQ <LOQ 
25-B 0.19 <LOQ <LOQ <LOQ <LOQ 
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 Sensitivity, specificity, predictive value and likelihood ratio  
The following three Table 8-5, Table 8-6 and Table 8-7 summarise the results of 
nicotine and cotinine against the reported exposure status in the questionnaire. 
Dogs in the second and third exposure groups with smoking owners were grouped 
together as ‘exposed’. 
Table 8-5 Nicotine results for exposed and non-exposed dogs 
 Smoking status 
Totals 
 Not exposed Exposed 
Test positive 16 25 41 
Test negative 24 1 25 
Totals 40 26 66 
 
Table 8-6 Cotinine results for exposed and non-exposed dogs 
 Smoking status 
Totals 
 Not exposed Exposed 
Test positive 2 18 20 
Test negative 38 8 46 
Totals 40 26 66 
 
Table 8-7 Sensitivity, specificity, predictive values and likelihood ratios of nicotine and 
cotinine tests 
Assay Sensitivity Specificity PPV NPV LR+ LR- 
Nicotine 96.15 60.1 60.9 96 2.4 0.06 
Cotinine 62.2 95 90 82.6 13.8 0.32 
 
The following pie charts in Figure 8-7 show the proportion of positive and negative 
samples for nicotine and cotinine in each exposure group. 
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Figure 8-7 Pie charts showing the proportion of dogs in each smoke exposure group that 
were positive or negative for nicotine and cotinine. (1) no exposure, (2) occasional exposure, 
smoking occurs only outdoor, (3) passive smoking, smoking occurs indoor. 
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 Discussion  
 Total nicotine and total cotinine concentrations; comparison 
with concentrations reported in children’s hair 
Nicotine in fur was measurable in most samples, while cotinine was often below 
the limit of quantification. Out of 66 fur samples, 41 samples were found to be 
positive with quantifiable amounts of nicotine and 19 samples only for cotinine. 
The mean concentration of nicotine in positive samples (1.6 ng/mg) was found to 
be approximately 5 fold higher than the mean concentration of cotinine positive 
samples (0.32 ng/mg). The nicotine concentrations ranged from 0.05 to 13.8 
ng/mg and the cotinine concentration from 0.116 to 0.868 ng/mg. The distribution 
of concentrations is shown in Figure 8-8 (a) and (b). The concentrations detected 
for each analyte, as shown in Table 8-2, were compared to the concentrations 
detected in previous studies. Several studies have described hair nicotine 
concentrations for non-smoking children, or infants exposed to various amounts of 
tobacco smoke (239,241–244,252,267,270,271,286–296). 
The mean fur nicotine concentration for dogs in our study was more than 2 times 
higher than the average of 0.8 ng/mg (interquartile range 0.27 to 2.24) measured 
in 1017 non-smoking children living in households with smokers in 31 countries 
(291,292). As our method did not include a washing step to remove nicotine 
adhering to the surface of the hair before hair analysis, it would be expected to 
provide higher concentrations that reflect internal and external doses. Pichini et 
al reported nicotine and cotinine concentrations from 24 infants who were 
classified into three groups similar to the classification in our study (Non-exposed 
(n=10), occasional exposure (n=7) and passive smoker (n=7)) (252). The mean 
nicotine concentrations were 1.3, 6.8 and 15.4 ng/mg for non-exposed, occasional 
exposed and passive smoker infants, respectively. Cotinine was not detected in 
all non-exposed infant’s hair, and detected in one infant in the occasional exposed 
group with concentrations of 0.1 ng/mg, while in the passive smoker group, 5 out 
of 7 samples tested positive for cotinine with a mean concentration of 1.22 ng/mg 
ranging from 0.5 to 3.3 ng/mg. Despite the fact that Pichini’s method included a 
wash step with 3 ml dichloromethane (x3), the reported mean concentrations for 
each group were found to be much higher than those found in our study, 0.16, 
0.68 and 3.1 ng/mg for non-exposed, occasional exposed and heavily exposed.  
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It is believed that the lack of a standard method for estimated degree of exposure 
or differences in analytical methods could have caused this difference. For 
instance, Zahlsen et al found in a controlled ETS exposure environment that there 
is 4-10 fold variation in air nicotine levels for the same number of cigarettes 
smoked (318). The ‘occasional exposure’ in Pichini’s study was defined as those 
infants with parents who smoked a maximum of 4-5 cigarettes per week even if 
smoking is taking place indoors, which would have been classified as heavily 
exposed in this study.  
Moreover, the age of the infants in Pichini’s study, ranges from 3 months to 36 
months, suggesting that some infants may have been exposed to ETS in their 
neonatal environment. Interindividual variations including age, gender, race and 
other analytical aspects, such as presence or absence of a washing step, play roles 
in determining hair nicotine and cotinine concentrations. The anatomy of dog’s 
fur and possibility of absorbing nicotine via licking the surface of their fur or 
contaminated objects limits further exploration of the basis for the differences in 
hair nicotine concentrations between our study and some studies on humans. 
Knottenbelt et al (297) reported concentrations of nicotine from 38 dogs exposed 
to different levels of ETS. The hair nicotine concentration (ranged from 0.11 to 
11.31 ng/mg (median 0.57 ng/mg)) and is similar to that detected in our study. 
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(a)                                                                                           (b) 
 
Figure 8-8 Histogram of (a) nicotine and (b) cotinine distributions in all 66 dog's fur
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 Differences between total nicotine and total cotinine 
concentrations in different smoke exposure groups 
As in this study, the majority of previous studies on ETS exposure used indirect 
exposure parameters by completing a questionnaire indicating their smoking 
habits, including location of smoking, number of cigarettes or number of smokers, 
rather than direct measurement of air nicotine or other chemicals as markers 
reflecting tobacco smoke exposure levels. Analysis of the fur specimens was 
blinded so that it was unknown which level of ETS each fur specimen was exposed 
to. Information regarding the ETS exposure was provided after the analysis was 
complete and is shown in Table 8-1.  
The difference between the mean nicotine and mean cotinine concentrations was 
found to be significant between exposure groups. The mean nicotine 
concentration was found to be approximately six fold higher than the mean 
cotinine concentration in the ‘no exposure’ group, and about 3 fold higher in the 
occasional exposure group when smoking occurs only outdoor, and approximately 
15 fold higher in the fur samples from dogs exposed to tobacco smoke indoor. 
Literature shows that the amount of cotinine in hair from smokers and non-
smokers is at least 10 times less than nicotine. Descriptive statistics of nicotine 
and cotinine concentrations in each exposure group is shown in Table 8-8 and 
Table 8-9. The overlap in hair nicotine concentrations was observed between 
groups and may be due to the lack of standardised exposure estimation procedure 
or presence of unknown means of exposure.  
The Kruskal-Wallis test was employed to test the null hypothesis of no difference 
in fur nicotine and cotinine concentrations between owner-reported exposure 
groups. The dog’s fur concentrations of nicotine and cotinine appears to be closely 
associated with reported exposure to ETS. There was a statistically significant 
difference (P<0·05) in both fur nicotine and cotinine concentrations between all 
groups. Using the Mann–Whitney test, as post hoc test, it was found that the mean 
concentrations of nicotine and cotinine in non-exposed dogs were significantly 
different (P < 0.05) from the mean concentrations of nicotine and cotinine in 
occasionally exposed dogs, and significantly different (P < 0.05) from the mean 
value of nicotine and cotinine in passive smoker dogs. Furthermore, a statistical 
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difference existed between the mean concentrations of nicotine and cotinine in 
occasionally exposed dogs and in passive smoker dogs (P < 0.05).  
The above explained statistical significance suggests the potential utility of dogs’ 
fur for monitoring ETS exposure. Boxplots of the distribution of hair nicotine and 
cotinine concentrations in the three exposure categories are shown in Figure 8-9.  
Table 8-8  Descriptive statistics of nicotine concentrations among different ETS exposure 
groups 
Smoking exposure group 
Total [NIC] ng/mg 
Count Mean Median Minimum Maximum 
No Exposure 15 0.166 0.144 0.049 0.474 
Smoking occurs only outdoor 8 0.683 0.553 0.062 1.791 
Smoking occurs indoor 18 3.186 0.943 0.088 13.794 
 
Table 8-9 Descriptive statistics of cotinine concentrations among different ETS exposure 
groups 
Smoking exposure group 
Total [COT] ng/mg 
Count Mean Median Minimum Maximum 
No Exposure 2 0.195 0.195 0.176 0.213 
Smoking occurs only outdoor 4 0.457 0.458 0.196 0.714 
Smoking occurs indoor 13 0.293 0.186 0.116 0.868 
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(a)                                                                                                                          (b) 
 
Figure 8-9 Boxplot diagrams representing the median and interquartile range of concentrations detected in fur samples exposed to different levels of 
tobacco smoke (a) nicotine (NIC) and (b) cotinine (COT). There was significant difference in the distribution of NIC and COT concentrations (p<0.05) 
detected between dogs with owners who do not smoke, smoke only outdoor and smoke indoor
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 Differences between total nicotine and total cotinine 
concentrations in different fur colours 
Hair colour could likely influence nicotine concentrations, since nicotine is bound 
to melanin and the type and amount of melanin in hair varies with hair colour. 
However, Zahlsen et al found that nicotine uptake did not differ due to hair colour 
or thickness (318). General comparison of nicotine and cotinine concentrations 
among all exposure groups using the Kruskal-Wallis test shows no significant 
difference between the seven colours. The same result was obtained after 
comparing concentrations within the same exposure group. It is noteworthy that 
the top four concentrations were detected in black fur. Due to the limited number 
of samples, for instance there was no white fur in the heavy exposed group, it was 
not possible to investigate the potential effect of colour bias. Boxplots of the 
distribution of hair nicotine and cotinine concentrations in the seven different fur 
colours are shown in Figure 8-10. 
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(a)                                                                                                                          (b) 
 
 
Figure 8-10 Boxplot diagrams representing the median and interquartile range of concentrations detected in fur samples of different colours (a) nicotine 
(NIC) and (b) cotinine (COT). There was not significant difference in the distribution of NIC and COT concentrations (p=0.375 for nicotine and p=0.485 for 
cotinine) detected between different fur colour 
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  Differences between total nicotine and total cotinine 
concentrations at the two time points 
Using the Mann-Whitney U test, there was no significant difference between the 
mean concentrations of total nicotine (p=0.442) and total cotinine (p=0.875) at 
the two time points for the twenty-five dogs returning for a second sample. 
Boxplots of the distribution of hair nicotine and cotinine concentrations at the two 
time points are shown in Figure 8-11. This result is not surprising as the majority 
(n=20) did not report significant changes in their dog’s exposure to ETS, whereas 
5 dog owners only claimed a decrease in the exposure to different extent. Table 
8-10 and Table 8-11 summarise the changes in concentrations of nicotine and 
cotinine and the owner-reported exposure levels at the two time points  
 
Figure 8-11 Boxplot diagrams representing the median and interquartile range of 
concentrations of nicotine and cotinine detected in fur samples at the two time points. 
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Table 8-10 Summary of changes in nicotine concentrations and exposure status at the two 
time points. 
 Time point 1 Time point 2   
Sample 
ID 
Smoking 
group 
Total NIC 
(ng/mg) 
Smoking 
group 
Total NIC 
(ng/mg) 
Exposure 
change 
Nicotine 
change 
1 3 4.052 3 12.585 = ↑ 
2 1 0.070 1 0.000 = ↓ 
3 1 0.000 1 0.000 = = 
4 3 0.440 3 0.328 = ↓ 
5 3 5.932 3 9.620 = ↑ 
6 1 0.000 1 0.000 = = 
7 2 0.143 1 0.360 ↓ ↑ 
8 1 0.000 1 0.000 = = 
9 3 2.443 3 1.935 = ↓ 
10 1 0.267 1 0.098 = ↓ 
11 3 0.357 1 0.201 ↓↓ ↓ 
12 1 0.000 1 0.000 = = 
13 3 0.454 2 1.306 ↓ ↑ 
14 1 0.000 1 0.000 = = 
15 1 0.000 1 0.000 = = 
16 3 1.078 1 0.211 ↓↓ ↓ 
17 1 0.000 1 0.000 = = 
18 1 0.077 1 0.148 = ↑ 
19 1 0.085 1 0.000 = ↓ 
20 3 0.808 1 0.088 ↓↓ ↓ 
21 1 0.000 1 0.058 = ↑ 
22 2 0.084 2 0.062 = ↓ 
23 1 0.049 1 0.000 = ↓ 
24 1 0.000 1 0.000 = = 
25 2 1.791 2 0.974 = ↓ 
The double arrow indicates that the level of exposure has changed significantly from 
heavy exposure to no exposure. 
 
Despite the constant exposure at the two time points, higher nicotine 
concentrations were detected at the second time point for dogs 1, 5 and 18. This 
could be as a result of accumulation of nicotine over the time period with the 
constant exposure or may indicate that the data reported in the interview was 
incorrect. On the contrary, dogs 2, 4, 9, 10, 22, 23 and 25 have lower nicotine 
concentrations. Out of the five dogs, that were exposed to decreasing levels of 
ETS exposure, three have a lower nicotine concentration (dogs 11, 16 and 20) and 
two (dogs 7 and 13) have higher nicotine concentration. The owners of the three 
dogs with lower nicotine concentrations reported significant reduction in their 
dog’s exposure to ETS and were moved from the heavy exposed dogs group to the 
non-exposed group. 
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Table 8-11 Summary of changes in cotinine concentrations and exposure status at the two 
time points.  
Time point 1 Time point 1 
  
sample ID Smoking 
group 
Total COT 
(ng/mg) 
Smoking 
group 
Total COT 
(ng/mg) 
Exposure 
change 
COT 
change 
1 3 0.215 3 0.479 = ↑ 
2 1 <LOQ 1 0.000 = = 
3 1 <LOQ 1 0.000 = = 
4 3 0.000 3 0.000 = = 
5 3 0.618 3 0.353 = ↓ 
6 1 0.000 1 0.000 = = 
7 2 0.000 1 0.000 ↓ = 
8 1 0.000 1 0.000 = = 
9 3 0.143 3 0.284 = ↑ 
10 1 0.000 1 0.000 = = 
11 3 0.000 1 0.213 ↓↓ ↑ 
12 1 0.000 1 0.000 = = 
13 3 0.148 2 0.714 ↓ ↑ 
14 1 0.000 1 0.000 = = 
15 1 0.000 1 0.000 = = 
16 3 0.000 1 0.176 ↓↓ ↑ 
17 1 0.000 1 0.000 = = 
18 1 0.000 1 0.000 = = 
19 1 0.000 1 0.000 = = 
20 3 0.186 1 0.000 ↓↓ ↓ 
21 1 0.000 1 0.000 = = 
22 2 0.000 2 0.000 = = 
23 1 0.000 1 0.000 = = 
24 1 0.000 1 0.000 = = 
25 2 0.238 2 0.196 = ↓ 
The double arrow indicates that the level of exposure has changed significantly from 
heavy exposure to no exposure. 
 
Cotinine concentrations were not as sensitive as nicotine to the changes in ETS 
exposure. Increased cotinine concentrations were noticed for 3 dogs (11, 13 and 
16) out of the 5 dogs exposed to lower levels of ETS. For dogs 4, 7, 9, 11, 14, 16, 
17 and 21, different regions were reported for the second sample. However, no 
significant differences in the nicotine and cotinine concentrations were noticed. 
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 Correlation studies of total nicotine and total cotinine 
concentrations  
The Spearman’s rho test was carried out to assess how well the relationship 
between nicotine and cotinine concentrations can be described. There was a 
strong positive correlation between the concentrations of nicotine and cotinine 
(Spearman ρ = 0.771, p < 0.01). The scatter plot diagrams for the correlation are 
shown in Figure 8-12. Natural logs of cotinine (ng/mg) and nicotine (ng/mg) 
provided to better visualise the correlation, however many data points were lost 
as it was not possible to take the natural log of 0, so the dogs with a cotinine of 
0.000 were not represented. 
 
Figure 8-12 Scatter plot diagram showing the correlation between nicotine and cotinine 
concentrations in all 41 nicotine positive samples. Cases 26 (sample 13-B) and 59 (sample 
34-A) have unusually high COT: NIC ratios. (Spearman’s ρ = 0.733, p < 0.01). 
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 Nicotine and cotinine concentrations in the methanolic 
wash and extract 
The recovery of nicotine and cotinine from fur was assessed over a 2-hour 
sonication period and reached a plateau between 1-2 hours (see Figure 8-13 and 
Figure 8-14). 
 
Figure 8-13 Dissolution of nicotine from dog’s fur over 2 hours of sonication in methanol. 
 
 
Figure 8-14 Dissolution of cotinine from dog’s fur over 2 hours of sonication in methanol. 
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Nicotine was detected almost in all methanol washes for the 30 fur samples 
although only 15 were above the lower limit of quantitation (LLOQ) (0.05 ng/mg) 
at concentrations ranging from 0.05 to 5.92 ng/mg. The nicotine became 
undetectable after the methanol wash for four samples (10-B, 11-B, 20-B and 22-
B). Cotinine was detected in about 43% of the methanol wash samples and above 
the LLOQ in seven samples at concentrations ranging from 0.1 to 0.31 ng/mg. 
After the wash, cotinine was undetectable in the extracts of five samples (9-B, 
16-B, 20-A, 25-A and 25-B). The percentage of drug loss following the methanolic 
wash was measured by calculating the percentage of the concentration in the 
wash to the sum of the concentration of wash and after 120 minutes of incubation 
when detectable. Table 8-12 summarises the sum of wash and 120 min extract 
concentrations and the percentage of wash to the total concentration. Samples 
that had no detectable levels of nicotine and cotinine after the wash were 
excluded. The presence of cotinine in the methanol wash may indicate extraction 
of cotinine from inside the fur but could also be on the outer surface due to 
formation following tobacco smoking or via atmospheric oxidation of nicotine. The 
mean percentages for the amount of nicotine and cotinine that were removed 
from the outer fur surface were found to be approximately 52% and 55%, 
respectively (see Table 8-12). These results indicate that environmental passive 
exposure is the dominant contributor to the overall nicotine and cotinine found in 
hair both from non-smokers as it has been also suggested elsewhere (318,319). 
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Table 8-12 Summary of sum of wash and 120 min extract concentrations and the percentage 
of wash to the total concentration 
  Nicotine Cotinine 
Total conc. 
(ng/mg) 
%wash Total conc. 
(ng/mg) 
%wash 
1-A 4.55 46.93 0.34 44.93 
1-B 10.08 58.71 0.46 66.58 
9-A 1.79 32.34 
  
9-B 1.48 66.44 
10-A 0.23 45.08 
11-A 0.30 37.83 
16-A 0.79 63.35 
16-B 0.14 64.99 
20-B 0.30 15.15 
25-A 0.94 60.86 
25-B 1.23 81.59 
Mean 
 
52.12 
 
55.75 
Median 58.71 55.75 
St. Dev. 18.77 15.31 
%CV 36.02 27.46 
 
The mean ratio of nicotine to cotinine in washes and in the 120-minute extract 
were calculated in 6 subjects (11 samples) and found to be highly variable 
(%RSD=88.4 and 89.47) as shown in Table 8-13. This finding is consistent with what 
has been reported in the literature. However, as two samples from each dog where 
tested, the within-subject ratios were found sometimes to be similar as shown 
with samples from dog number 25. This might be an indication of the ETS exposure 
pattern. This result suggests that the nicotine/cotinine ratio might be either 
subject-dependant or exposure-dependant. Furthermore, the nicotine/cotinine 
ratio has been reported not to be accurate at low ETS concentrations because 
background levels of respiratory suspended particles is believed to have an 
enormous  influence on this ratio(237). Kintz et al reported a similar ratio for 
nicotine/cotinine ranging from 5-30 with a mean ratio of 10 in the hair of smokers 
(320). 
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Table 8-13 The values of nicotine and cotinine ratios in methanolic wash and extract 
  Nicotine/Cotinine ratio 
Sample ID Wash Extract 
1-A 14.16 1.30 
1-B 19.26 26.97 
9-A 34.54 17.79 
9-B 5.82 7.86 
10-A 16.14 6.02 
11-A 24.19 6.91 
11-B 0.96 3.25 
20-A 6.11 1.73 
20-B 2.65 4.83 
25-A 3.35 7.04 
25-B 5.25 9.88 
Mean 12.04 8.51 
Median 6.11 6.91 
Standard Deviation 10.65 7.61 
%RSD 88.45 89.47 
 
 Sensitivity, specificity, predictive values and likelihood 
ratios  
The ideal test would be described as 100% sensitive and 100% specific; however, 
theoretically any test will possess a minimum error bound. Sensitivity and 
specificity of the nicotine test were found to be 96.15% and 60.9%, respectively. 
The cotinine test had better specificity with 95% and 62.2% for sensitivity. The 
two samples that were false positive in the non-smoking group and, therefore, 
resulted in a 5% decrease in cotinine specificity were taken from dogs that were 
previously classified as heavily exposed at the first time point.  
The probability that the exposure to ETS is present was investigated using the 
positive predictive value (PPV) and was calculated to be 60.9% for nicotine and 
90% for cotinine. In contrast, the probability that the exposure is not present when 
the test is negative were given by the negative predictable value (NPV) and found 
to be 96% and 82.6% for the nicotine and cotinine tests, respectively. 
Likelihood ratios use the sensitivity and specificity of the test to determine 
whether a nicotine or cotinine test result usefully changes the probability that an 
ETS exposure exists. In general, a useful test provides a high positive likelihood 
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ratio and a small negative likelihood ratio. LR > 1 indicates an increased 
probability that the ETS exposure is present, and a LR < 1 indicates a decreased 
probability that the ETS exposure is present. The estimates presented here is 
based on the method reported by McGee(321). The nicotine test has a positive 
likelihood ratio of 2.4 which corresponds to an approximate 15% increase in 
probability of the exposure, and 0.06 negative likelihood ratio which corresponds 
to an approximate 45% decrease in probability. The cotinine test has a positive 
likelihood ratio of 13.8 which corresponds to an approximate 45% increase in 
probability, and 0.32 negative likelihood ratio which corresponds to an 
approximate 30% decrease in probability. 
 Conclusion 
Nicotine and cotinine were quantified in 66 fur samples collected from 41 dogs 
exposed to different levels of ETS. The concentrations in dog’s fur samples ranged 
from 0.05-13.7 ng/mg for nicotine, and 0.12-0.87 ng/mg for cotinine. These 
concentrations are similar to that reported in the literature after passive exposure 
to ETS in humans. The statistical analysis showed a positive association between 
home exposure to ETS and nicotine and cotinine concentrations. The mean value 
of nicotine and cotinine in non-exposed dogs was significantly different from the 
mean value of nicotine in occasionally or heavily exposed dogs. This strong 
association indicates that companion animals could be used to reflect the long-
term ETS exposure in houses. However, complexity of estimation of ETS exposure 
and interindividual variability makes it difficult to estimate cumulative exposure 
accurately from single determinations. The sensitivity of nicotine for identifying 
heavily exposed dogs is high but has lower specificity, whereas cotinine has high 
specificity but lower sensitivity.  
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 Conclusion and future Work 
 Cannabinoids in human hair project 
 Method development 
The work presented here has described the development of two methods for the 
analysis of cannabinoids in hair matrices. Firstly, a method for the analysis of 
cannabinoids (THC, CBN, CBD and 11-OH-THC) using LLE and standard GC-MS was 
developed and validated. The method was found suitable for analysis of authentic 
hair samples collected from known cannabis users. One of the frequently reported 
LLE disadvantages is that it results in waste of organic solvents. However, it was 
possible here to carry out a LLE with only 1.5 mL cyclohexane: EtOAc. The 
extraction recovery percentages were acceptable for all analytes. The produced 
extract was clean and the LOQ for THC was below the SoHT recommendation. The 
use of high recovery vials resulted in significant improvement in detection 
sensitivity.  Secondly, a method for the analysis of the main metabolite THC-COOH 
in hair using SPE and 2D GC-MS was developed and validated. It was then used to 
analyse hair from known cannabis users and was shown to be suitable for the 
detection of THC-COOH in approximately 65% of samples.  2D GC-MS has been 
shown to be vital in the development of assays that require increased sensitivity 
over the use of standard GC-MS. The use of an ultra-inert column as the primary 
column has dramatically improved the detection sensitivity. However, further 
work may be required to improve the assay sensitivity as the LOQ was 5 times 
higher than that recommended by the SoHT. Two possible procedures for sample 
preparation were proposed and tested. The first procedure involved using a single 
hair sample, and started by carrying out LLE to extract THC, CBD, CBN and 11-OH-
THC and followed by SPE of fraction ‘B’ for THC-COOH. The second procedure 
involved using two separate samples, LLE for sample (A) and SPE on sample (B). 
Both procedures were found to be acceptable. However, using a single hair sample 
for extraction of all cannabinoids was found to cause approximately 22.5% 
decrease in THC-COOH concentrations. The second procedure was employed for 
the two methods validation. 
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 Application to authentic hair analysis  
Validated methods were employed for the analysis of cannabinoids in 20 hair 
samples collected from known cannabis users. All samples were collected from 
cannabis user who reported use of amphetamine, simultaneously. It might be 
useful to compare the concentration obtained here with cannabinoids 
concentrations in hair samples from cannabis only users. The low detection rate 
of THC and high detection rate of CBD is not fully explained and needs further 
investigation. It is possible that THC is not stable in hair matrices as samples were 
stored for three months before analysis. It is also possible that the type of 
cannabis product available in the drug market in Saudi has a high CBD content. 
There was no significant statistical correlation or difference between the 
concentrations and weekly use score or among daily and non-daily users. A recent 
publication by Moosmann et al revealed that the detection of cannabinoids in hair 
does not prove cannabis consumption (322). After oral administration of 2.5 mg 
dronabinol (THC), three times a day over a 30-day period to two volunteers, there 
was no THC detected in their hair. This means that the external contamination, 
via smoke or handling of cannabis material, is the major route of THC 
incorporation into hair. Therefore, volunteers' exposure to cannabis smoke and 
material might be responsible for the hair concentrations not their use history. 
Studying the correlation between hair concentrations and cannabis smoke 
exposure would be an interesting subject for future work. A number of limitations 
has to be evidenced including; the limited number of analysed samples, lack of 
information on period of abstinence before sample collection, the lack of hair 
samples coming from abstinent users living with regular cannabis smokers and 
finally the lack of information on users’ exposure to cannabis smoke. 
 Future work 
Most of the work in the literature is targeting THC, CBD, CBN and the main 
metabolite THC-COOH, whereas a limited number of publications are available for 
analytes such as 11-OH-THC, Δ9-tetrahydrocannabinolic acid A (THCA-A) and11-
nor-D9-tetrahydrocannabinol-9-carboxylic acid glucuronide (THC-COOH-glu). The 
concentration ranges for these analytes and optimal analytical methods are still 
not fully established. 11-OH-THC is seldom targeted in hair samples to prove 
cannabis consumption. This is probably due to the assumption that 11-OH-THC is 
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present in much lower concentrations than the main metabolite THC-COOH. There 
are a limited number of studies where 11-OH-THC was included in the analytical 
method. 11-OH-THC was reported only in two papers. Shah et al quantified 11-
OH-THC in 8 samples and the concentrations ranged from 0.61 to 3.1 pg/mg. 
Despite the fact that THC-COOH was included in the same method, it was detected 
only in one sample at 18.2 pg/mg. This might be an indication that despite the 
lower concentrations of 11-OH-THC, it has a higher detection rate than THC-
COOH. Thieme et al published recently a method that involved an innovative 
derivatisation approach to enhance detectability of 11-OH-THC in hair. The 11-
OH-THC was successfully quantified in one sample at 0.6 pg/mg. In the same 
sample, the THC-COOH was quantified at 1.5 pg/mg. THCA-A is the biosynthetic 
precursor for the main active ingredient in the cannabis plant, THC. Targeting the 
THCA-A is gaining increasing attention as a promising biomarker to distinguish illict 
exposure to cannabis from the legal medicinal use. THC-COOH-glu is also a 
promising alternative to the main metabolite THC-COOH to prove consumption. 
Recently, Pichini el al reported a successful method for identification and 
quantitation of THC-COOH-glu in hair for the first time using ultra-high-pressure 
liquid chromatography–tandem mass spectrometry. The concentrations of THC-
COOH in the same samples were found to be three times lower than that obtained 
for THC-COOH-glu.  
Derivatisation is a very important part of the analytical method. It can 
dramatically improve detection sensitivity. However, the use of inappropriate 
derivation may lead to inaccurate quantitation results. Thieme et al reported a 
tremendous enhancement of mass spectrometric ionization efficiency for 11-OH-
THC detection by formation of picolinic acid esters (198), and improvement in 
selectivity of  THC-COOH detection in hair samples by  selective methylation 
(163). Using 2-fluoro-1-methylpyridiniump-toluenesulfonate (FMP-TS) in the 
presence of triethylamine (TEA), Fagehi et al developed a sensitive method for 
analysis of estrogens in plasma and serum (323). This derivatisation reagent has 
potential benefits for optimisation of detection sensitivity of the two metabolites 
11-OH-THC and THC-COOH. 
On the other other hand, a noteworthy issue with derivatisation of THC and CBD 
with PFPOH-PFPOH and TFAA-HFIP has been previously highlighted in the 
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literature. These two derivatising mixtures are commonly used to improve 
detection of THC-COOH by GC-MS in NCI mode. However, they have also been 
employed for the analysis of other cannabinoids including THC. Later publications 
have demonstrated that derivatisation with PFPOH-PFPOH (115,324) or TFAA- HFIP 
(165) is unsuitable for analysis of THC and CBD, as it resulted in identical retention 
time and mass spectra for THC and CBD, and hence incorrectly high concentrations 
of THC. The suitability of other perfluorinated anhydrides, such as HFBA, alone or 
coupled with perfluoroalchohols, such hexafluoropropanol (HFPOH), have not 
been investigated for analysis of THC and CBD yet. This combination HFBA-HFPOH, 
in particular, has been reported in at least one publication for analysis of THC in 
hair matrices (128).  
 Nicotine in dog’s fur project 
 Method development 
The first aim of this project involved the development and validation of a method 
for the analysis of nicotine and cotinine from dogs’ fur. A simple methanolic 
extraction method was developed for the successful extraction of all analytes from 
the fur by 2 hrs sonication at 50 °C. Despite the good extraction recovery, it was 
not possible to concentrate the analytes after the initial extraction from fur. An 
LC system with tandem MS capability was employed for analysis. The conditions 
for multiple reactions monitoring (MRM) were optimized by autotuning during 
infusion of solutions of nicotine and cotinine. 
 Application to authentic hair analysis  
A total of 61 fur samples were analysed by the developed methods. Nicotine and 
cotinine concentrations detected in fur samples were significantly correlated with 
the exposure group. Nicotine was found to be more sensitive in measuring the ETS 
exposure changes, whereas cotinine was a more specific indicator of heavy 
exposure.  
 Future work 
Further research on the development of a more sensitive method for quantitation 
of nicotine and cotinine in hair with lower LOD and LLOQ would be of interest. 
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Both nicotine and cotinine are known to be present in ETS, therefore, including 
metabolites that originate exclusively from the human or animal body would help 
to distinguish the source of other compounds (external contamination or active 
use). Although methanolic extraction has proven to be a fast, cheap and effective 
method, the traditional liquid-liquid extraction or solid-phase extraction might 
result in a cleaner and concentrated extract, and hence better detection 
sensitivity. Another interesting research project would be comparing nicotine and 
cotinine concentrations in hair of children and pet dogs from the same house.  
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Appendix I Evaluation of NeoGen (hair) ELISA assay for cannabinoids 
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Appendix II Evaluation of two ELISA assays for the detection of cannabinoids in hair 
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Appendix III Screenshot of Dean's switch calculator software 
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Appendix IV Compounds (n=91) tested for interference study 
Drug Group Drug/Metabolite Concentration 
(µg/ml) 
Amphetamine type Amphetamine 
100 
Methamphetamine 
MDMA 
MDA 
MDEA 
PMA 
PMMA 
Opiates 6MAM 0.1 
Morphine 
5 Codeine 
Dihydrocodeine 
Methadone 
10 
Propoxyphene(Dextro-
/Levo-) 
Fentanyl 
Norfentanyl 
Oxycodone 
Hydrocodone 
Opioid Tramadol 
10 
Dipipanone 
Buprenorphine 
Norbuprenorphine 
Stimulant Cocaine 
100 
Ecgonine methyl ester(EME) 
Benzoylecgonine(BZE) 
Cocaethylene 
Benzodiazepine Chlordiazepoxide 
10 
Diazepam 
desmethyl-diazepam 
Lorazepam 
Oxazepam 
Temazepam 
Clonazepam 
Nitrazepam 
7-Aminoflunitrazepam 
1 Phenazepam 
Etizolam 
  Pentobarbitone 
100 Phenobarbitone 
Primidone 
Tricyclic 
antidepressant 
Amitriptyline 
10 Clomipramine 
Dosulepin 
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Doxepin 
Imipramine 
Desipramine 
SSRI Citalopram 
10 
Fluoxetine 
Paroxetine 
Sertraline 
Mixed-uptake inhibitor Mirtazapine 
10 
Venlafaxine 
Antipsychotic Chlorpromazine 
10 Haloperidol 
Risperidone 
Synthetic cannabinoid CP47, 497 
0.05 
JWH-250 
JWH-073 
JWH-018 
JWH-200 
JWH-018 5-OH pentyl 
JWH-122 5-OH pentyl 
JWH-210 5-OH pentyl 
AB-FUBINACA 
AM 2201 4-OH pentyl 
AM 1248 
HU-210 
Other Caffeine 
1000 
Procaine 
Benzocaine  
Paracetamol 
Aspirin 
100 
(-)-Cotinine 
(-)-Nicotine 
GHB 
Ketamine 
10 
Lidocaine 
Trazodone 
Diltiazem 
Promethazine 
Quetiapine 
Cyclizine 
Atenolol 
Verapamil 
Procyclidine 
Zolpidem 
Lamotrigine 
Sildenafil 
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Chlorpheniramine 
Phenytoin 
Diphenhydramine 
Carbamazepine 50 
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Appendix VII Hair collection instructions 
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Appendix X Calibration Model Calculations for the Weighting Factor 
 
X-1 Introduction to curve weighting   
The assumptions for the non-weighted linear and quadratic regressions in 
bioanalytical LC-MS/MS assays are that the errors from the dependent variable (y, 
instrument response) are independent from each other (random), uncorrelated 
with the independent variable (x, concentration), and have equal variance (σ2) or 
standard deviation (σ) across the different concentration levels 
(homoscedasticity). However, a quick review of any set of real life standard (STD) 
or quality control (QC) data from assay validations or sample analysis will reveal 
that the instrument response errors at different concentration levels are actually 
correlated with the independent variable (concentration) and have a larger 
variance (σ2) or standard deviation (σ) at higher concentrations as long as the 
sample size at each concentration level is large enough to provide a rough 
estimate of variance. This is a clear indication that the instrument responses have 
heteroscedatic error. Due to this heteroscedatic error, the data at the high end 
of the calibration curve tend to dominate the calculation of the linear regression. 
This often results in excessive error at the bottom of the curve. One way to 
compensate for this error and to give a better fit of the experimental data to the 
calibration curve is to weight the data inversely with the concentration, a process 
called curve weighting. The weighting of calibration curves often will lower the 
overall error of the method and, thus, improve the quality of the analytical 
results.  Most LC calibration curves that span several orders of magnitude show 
increasing error with increasing concentration, whereas the relative error 
(percent relative standard deviation, %RSD) is reasonably constant. Curve 
weighting should be evaluated whenever the relative error is fairly constant 
throughout the calibration curve. 
X-2 Evaluation of data 
A thorough evaluation of the appropriateness of curve weighting and selection of 
the weighting factor is best done at the end of method development or during 
method validation when a sufficiently large data set is available to calculate 
standard deviations at each calibrator concentration. Validation data was used for 
this purpose in this report. The first step is to prove that homoscedasticity was 
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not met for the analytical data and hence the need for a weighting factor (WF). 
Different ways are proposed for this purpose. The method that was chosen to test 
for heteroscedastic error was calculating the variance (σ2) or standard deviation 
(σ) for all data calibration curve points as described in Gu et al paper (317). The 
next step was to determine the proper weighting factor for the data. Also different 
ways were proposed for this purpose. In this work, a weighting factor was selected 
using linearity indicators as described by Gu et al. 
X-3 Heteroscedatic or homoscedatic error 
Tables X-1, X-2 and figures X-1, X-3 show the instrument responses of 11 
calibration curves in five analytical runs for NIC and COT in dogs’ fur LC-MS/MS 
assay validation. The standard deviations (σ, blue line) and variance (σ2, red line) 
for instrument responses at each concentration level are shown in Figures X-2 and 
X-4. It was found that, from 0.01 to 10 ng/mg, σ increased in an approximately 
concentration-proportional manner, and σ2 increased in a much more than the 
concentration proportional manner. Error was exaggerated at each point so we 
can see the difference in error at the top and the bottom of the curve as shown 
in figures X-1 and X-3. This tells us that the absolute error is larger at the top of 
the curve than the bottom. If you follow the curve down, you can see that the 
points get closer together at lower concentrations. This behaviour tells us that the 
data are heteroscedastic and means that absolute error varies with sample 
concentration. Hence, there is a need for a weighting factor. 
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Table X-1 Instrument responses of 11 calibrators (range 0.01-10 ng/mg) (n=5) for nicotine 
(NIC) in dogs’ fur.   
NICOTINE (PEAK ARE RATIO)   
 
ng/mg RUN1 RUN2 RUN3 RUN4 RUN5 
CAL1 0.01 0.0424 0.0000 0.0000 0.0000 0.0539 
CAL2 0.03 no data no data 0.2952 0.0962 0.1239 
CAL3 0.05 0.1654 0.1731 0.1900 0.1420 0.1822 
CAL4 0.07 no data no data 0.2641 0.1845 0.2330 
CAL5 0.10 0.3550 0.2851 OL 0.2273 0.3806 
CAL6 0.25 no data no data 0.9163 0.6876 0.7915 
CAL7 0.50 1.6066 1.5164 1.8296 1.3457 1.6999 
CAL8 1.00 3.0594 3.2658 3.8056 3.0698 3.0032 
CAL9 2.00 5.9038 6.4451 6.0472 5.7331 6.8801 
CAL10 5.00 15.2727 17.8612 20.1482 15.2477 17.1810 
CAL11 10.00 OL 34.8632 40.6195 31.3548 39.0060 
OL stands for outlier 
 
Table X-2 Instrument responses of 11 STD curves in five analytical runs for COT in dog’s fur 
LC-MS/MS assay validation (STD curve range: 0.01−10 ng/mL)   
COTININE (PEAK AREA RATIO) 
 
ng/mg RUN1 RUN2 RUN3 RUN4 RUN5 
CAL1 0.01 0.0216 0.0165 0.0176 0.0149 0.0204 
CAL2 0.03 no data no data 0.0670 0.0427 0.0436 
CAL3 0.05 0.0801 0.0758 0.0574 0.0756 0.0712 
CAL4 0.07 no data no data 0.0742 0.0938 0.0882 
CAL5 0.10 0.1411 0.1258 0.1045 0.1251 0.1242 
CAL6 0.25 no data no data 0.3007 0.3463 0.2862 
CAL7 0.50 0.7443 0.7263 0.6833 0.7336 0.6006 
CAL8 1.00 1.3973 1.2404 1.1517 1.4406 1.0132 
CAL9 2.00 2.7705 2.3902 3.8056 OL 2.2118 
CAL10 5.00 7.3246 6.4112 5.9771 6.5557 5.3127 
CAL11 10.00 OL 13.3071 11.6176 13.5272 11.1271 
OL stands for outlier 
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Figure X-1 Instrument responses of 11 calibrators (range 0.01-10 ng/mg) (n=5) for nicotine 
(NIC) in dogs’ fur. 
 
 
Figure X-2 Standard deviation (σ) and variance (σ2) for Instrument responses of 11 
calibrators (range 0.01-10 ng/mg) (n=5) for nicotine (NIC) in dogs’ fur. 
σ2 
σ 
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Figure X-3 Instrument responses of 11 calibrators (range 0.01-10 ng/mg) (n=5) for cotinine 
(COT) in dogs’ fur. 
 
 
Figure X-4 Standard deviation (σ) and variance (σ2) for Instrument responses of 11 
calibrators (range 0.01-10 ng/mg) (n=5) for cotinine (COT) in dogs’ fur. 
  
σ2 
σ 
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X-4 Selection of Weighting Factor Using Linearity Indicators 
In some cases, the selection of a relationship with better linearity may not be 
obvious using the plots. An alternative, less empirical approach using three 
linearity indicators is proposed for the selection of weighting factor. The linearity 
indicators were defined as the relative standard deviation (RSD%) of σ/x0, RSD% 
of σ/x0.5, and σ/x1, respectively. It is easy to see that, to justify the use of 1, 1/x 
or 1/x2 as the weighting factor, the RSD% of σ/x0, σ/x0.5, or σ/x1 should be 0% 
as an exact linear relationship exists between σ and x0, σ and x0.5, or σ and x, 
respectively, as shown in Table X-3. Therefore, in evaluating a real STD or QC data 
set, the best linear relationship can be assumed to be the one that gives the 
smallest linearity indicator. The linearity indicators were calculated for both NIC 
and COT assays. The results (Table X-3) confirmed the selection of 1/X2 as the 
weighting factor for both assays. Please note that outliers were removed. 
 
Table X-3 Theoretical data for x and σ to justify the Selection of 1, 1/x, or 1/x2 as the 
Weighting Factor 
    0.01 0.03 0.05 0.07 0.10 0.25 0.50 1.00 2.00 5.00 10.00 σ %RSD WF 
NIC σ     0.02 0.04   0.11 0.18 0.33 0.46 2.04 4.18 1.47 160.07   
σ/x0.5     0.08 0.15   0.23 0.26 0.33 0.33 0.91 1.32 0.43 95.85   
σ/x1     0.37 0.57   0.46 0.37 0.33 0.23 0.41 0.42 0.10 25.16 1/x2 
COT σ 0.00 0.01 0.01 0.01 0.01 0.03 0.06 0.18 0.71 0.74 1.20 0.42 154.23   
σ/x0.5 0.03 0.08 0.04 0.04 0.04 0.06 0.08 0.18 0.50 0.33 0.38 0.17 104.29   
σ/x1 0.28 0.46 0.17 0.14 0.13 0.13 0.12 0.18 0.36 0.15 0.12 0.11 55.84 1/x2 
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Appendix XI Oral and poster presentations in support of this thesis 
 Oral Presentation 
1.  The Determination of THC-COOH in Hair using GCxGC-MS 
 Presented at 3rd annual Scottish Student Forensic Research 
Symposium (SSFRS), Glasgow, UK (Apr 2016) 
 
2.  Detection Rates of ∆9-THC, CBD, CBN, 11-OH-THC and THC-COOH in 
Hair Samples from Middle Eastern Cannabis Users Using Validated 
Methods for GC-EI-MS and 2D GC-NCI-MS. 
 Accepted for oral presentation at and in proceedings of SOFT 
conference, Dallas, TX, USA, (October 2016). 
 
 Poster Presentations 
1. Evaluation of NeoGen (hair) ELISA assay for cannabinoids 
 Presented at The United Kingdom and Ireland Association of 
Forensic Toxicologists (UKIAFT) meeting, Leicester, UK 
(August 2014).  
 
2.  Evaluation of two ELISA assays for the detection of cannabinoids in 
hair 
 Presented at the 8th annual Saudi Students Conference (SSC), 
London, UK (Feb 2015).  
 
3. Determination of ETS Exposure in Pet Dogs Using Optimised Methanol 
Extraction of Fur Followed by ZIC-HILIC-tandem mass spectrometry 
Presented at and in proceedings of SOFT conference, Atlanta, GA, 
USA, (October 2015). 
 Presented at and in proceedings of SOFT conference, Atlanta, 
GA, USA. (October 2015). 
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